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Although smoking is the main cause of lung cancer, lung cancer among never-smokers is not 
uncommon and is the 7th leading cause of cancer deaths worldwide. There is recent evidence 
that lung cancer in never-smokers may be a distinct clinical entity from smoking-related lung 
cancer. Lung cancer incidence in Singaporean Chinese women is relatively high given the low 
prevalence of smoking, and etiologic studies conducted in this population would be particularly 
useful in identifying risk factors for never-smoker lung cancer.  
 This thesis examines three potential etiologic pathways which we hypothesise to play a role in 
never-smoker lung cancer, based on mechanistic considerations and existing epidemiologic 
studies – chronic inflammation resulting in uncontrolled cell proliferation, direct damage arising 
from exposure to carcinogens, and pro-carcinogenic estrogen pathway signaling in lung tissue. 
The factors that we investigated included chronic airway inflammation and genetic 
polymorphisms in the inflammatory pathway (examining 6 polymorphisms in 5 genes), previous 
Non-Steroidal Anti-Inflammatory Drug (NSAID) use, exposure to domestic inhalants, dietary 
factors, and reproductive factors and polymorphisms in the estrogen signaling pathways 
(examining 5 polymorphisms in 4 genes).  
Data from two hospital-based case-control studies (conducted from 1996 to 1998 and from 2005 
to 2008) of Chinese female incident lung cancer patients, and controls frequency-matched by 
age and date of admission, were used. A standardized questionnaire was administered on all 
participants by trained interviewers, and, where permitted, blood and saliva samples were 
obtained. In total, 702 cases and 1578 controls were recruited, of whom 433 cases (61.7%) and 
1375 controls (87.1%) were never-smokers.  
Tuberculosis was positively associated with lung cancer, although this association was not 
statistically significant. There was no effect of asthma, atopy or chronic productive cough 
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individually, but the presence of one or more of these conditions was positively associated with 
lung cancer in individuals possessing specific genotypes in the IL1-ß-31T/C and IL1RN genes. 
The IL6-634 G allele was positively associated with lung cancer. A positive association with lung 
cancer was observed with the number of polymorphism sites where at least 1 “risk” allele was 
present [the “risk” alleles being evaluated were IL1-ß-31T/C (T allele), IL1RN (*2 allele), and 
IL6-634C/G (G allele)] among those with asthma, cough or atopy, but not in those without. 
Regular use of aspirin, an NSAID, was inversely associated with lung cancer, and this inverse 
association was strongest for those starting use 1 to 5 years prior to admission, and those 
whose duration of use was 12 to 60 months. These data together suggest that inflammation and 
inflammatory processes are important in never-smoker lung carcinogenesis.  
Inhalants in the domestic environment contain compounds that may cause direct genetic 
damage at the cellular level, and can also provoke chronic inflammation. Contrary to our 
expectation, a positive relationship with daily exposure to incense or mosquito coils and to 
cooking fumes was observed only among smokers, with no relationship seen among never-
smokers. These interactions were statistically significant. Our data suggest that smokers are 
more susceptible to the risk-enhancing effects of other inhalants. We postulate that these 
results may in part be explained by the chronic airway inflammation induced by chronic 
smoking.  
Our study of diet focusing on meat consumption showed that meat and, in particular, fish 
consumption was inversely associated with lung cancer in never-smokers, but null effects were 
seen for processed meats and dietary heterocyclic amines. The inverse association of fish 
consumption with lung cancer could be due to omega-3 fatty acids (a prominent nutrient found 
in fish) and their effects, among others, in reducing inflammation in the local tissue milieu.   
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Our study of reproductive factors found that parity and menstrual cycle length were inversely 
associated with lung cancer, while age at first birth, age at menopause and reproductive period 
were positively associated. The COMT rs4680 A allele was positively associated with lung 
cancer, but null effects were seen with other polymorphisms. These data suggest that high 
circulating estrogen levels over the lifetime are associated with lung cancer risk, especially in 
never-smokers, and that this effect could be at least partially mediated through direct catechol 
estrogen damage to genetic material.   
Collectively, the research studies in this thesis implicate both the inflammatory and estrogen 
pathways in lung carcinogenesis. Perhaps the most significant aspect of this set of findings is 
that chronic inflammation may play a bigger role in never-smoker lung cancer than has been 
previously recognized. Further research is needed to confirm these epidemiologic findings, and 
to delineate the precise role played by inflammation and reproductive factors in the etiology of 
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CHAPTER 1  LUNG CANCER: AN INTRODUCTION 
Lung Cancer 
A hundred years ago, lung cancer was a rare medical condition. The celebrated 
American surgeon Alton Ochsner noted in an article in 1973 that he remembered as a 
student in 1910 being asked to witness an autopsy of a patient with lung cancer because 
it was an unusual case. Indeed, he saw his next lung cancer case only 17 years later, in 
1927. Yet in that same year, he saw eight cases within six months (1). This early cluster 
of lung cancer heralded a major epidemiologic shift in lung cancer incidence worldwide: 
today, eighty years later, lung cancer is the leading cause of cancer mortality in the 
world, killing an estimated 1.3 million people every year, nearly half a million more a year 
than from stomach cancer, the next greatest cause of cancer deaths worldwide (2).  
The histology of lung cancer is fairly heterogeneous, suggesting that lung cancer may be 
a “collection of diseases” rather than a single disease. The main division used in clinical 
practice is between small cell lung cancer (SCLC) and non-small cell lung cancer 
(NSCLC). This differentiation has prognostic and treatment significance, as SCLCs have 
different biological and molecular characteristics and appear to be more chemo-and 
radio-sensitive (3,4). Among NSCLCs, tumours are broadly classified into 
adenocarcinomas, squamous cell carcinomas, and large cell carcinomas. Rare tumours 
including carcinoid tumours are also found. Tumours tend to be heterogeneous, and 
tumours with mixed features have been recognized – for example: adenosquamous 
carcinomas (having malignant cells of both adenocarcinoma and squamous cell 
carcinoma histology), and combined small cell carcinoma (tumours with cells of both the 
small cell and the non-small cell histology) (5). The majority of tumours are NSCLC, with 
SCLC comprising only about 10-30% in most reported series (6). Among NSCLC, 
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squamous cell carcinomas were the most common in the mid to late 20th century (7), but 
adenocarcinomas have increased in overall incidence and now comprise the majority of 
tumours in most countries.   
Lung cancer remains highly lethal with very low 5-year survival of about 10-20% even in 
the countries with the best treatment for the condition (8). Survival for both SCLC and 
NSCLC are equally dismal, without significant differences in survival by histologic 
classification. Screening for lung cancer is still investigational. Screening X-rays do not 
appear to be effective, although a large trial is ongoing and results from this trial will only 
be reported in 2015 at the earliest (9). In recent years, attention has focused on the 
utility of spiral Computerised Tomography screening. There is some evidence that CT 
screening may be useful in high-risk groups (10) and definitive trials are underway. 
Nevertheless, the universally dismal survival rates for lung cancer even for relatively 
early stage disease suggest that the best way to reduce the public health burden of lung 
cancers is through prevention. Identification of risk factors for lung cancer and translating 
this epidemiologic knowledge into public health practice to control these risk factors 
remain the most effective methods to reduce the burden of lung cancer. 
This understanding of the importance of prevention has led to intensive investigations 
into risk factors for lung cancer. However, few risk (or protective) factors have been 
identified with certainty. These include smoking, environmental tobacco exposure (ETS) 
and some occupational toxins. High consumption of fruits and vegetables also appear to 
be protective. 
The most well-known risk factor, and perhaps the most prevalent worldwide, is that of 
tobacco smoke. The relationship between smoking and lung cancer was gradually 
recognized, first by individual physicians in the 1930s and 1940s, then in 2 sets of 
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landmark studies by Doll and Hill in the United Kingdom and Hammond and Wynder in 
the United States (11). Since then, this relationship has been definitively established as 
the main cause of lung cancer through a wide variety of case control and cohort studies 
throughout the world. Relative risk estimates for cigarette smoking on lung cancer risk 
range from 20-40 (12), and both intensity in terms of number of cigarettes smoked and 
duration of smoking appear to influence risk (13). Biochemical and cellular biologic 
evidence supports this association. Tobacco smoke is a complex mixture of organic 
compounds, many of which (such as nitrosamines including NNK, polycyclic aromatic 
hydrocarbons, acroleins and aryl amines) are clearly carcinogenic in both in vitro and in 
vivo models (14-16). This carcinogenicity is mediated through a variety of biological 
pathways, including direct genotoxic damage to DNA, activation of growth and 
proliferation pathways and suppression of apoptosis, and chronic inflammation with 
subsequent cellular proliferative response to inflammatory injury (14-16). 
Environmental tobacco smoke (ETS) exposure is now known to increase risk among 
never-smokers who work and live with cigarette-smokers. Relative risk estimates for 
ETS exposure is much lower than those for smoking, of about 1.2-1.3 in cohort studies 
(17-19). In some countries, because of the widespread prevalence of smoking in 
enclosed environments and hence exposure to ETS, this small relative risk can translate 
to exceedingly large population attributable risks. In the US alone, estimates suggest 
that 3000 to 5000 lung cancer deaths annually may be due to ETS exposure (20).  
Occupational causes of lung cancer have also been identified, including radon (21), 
asbestos (22), arsenic (22, 23), silica (24), cadmium (25), nickel (26), and chromium 
exposure (26) in miners, construction workers, and heavy industry factory workers. The 
mechanisms of action are varied. Radon decays into radon progeny, which then emits 
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alpha particles that cause direct genotoxic damage to respiratory epithelial cells (21).  
Asbestos and silica deposit within the lungs and induce inflammation and cellular 
proliferation (22-24). Cadmium, nickel and chromium may both directly, and indirectly, 
through the generation of reactive oxygen species, damage DNA (25, 26). Coal smoke 
emission is also well-established as a risk factor, both in occupational and domestic 
settings (27), with robust supportive evidence derived from both in vitro and in vivo 
mechanistic and human epidemiologic studies (27).  
Multiple studies have suggested that fruit and vegetable consumption are protective 
against lung cancer (28). A relatively recent review of the current evidence by the World 
Cancer Research Fund and the American Institute for Cancer Research concluded that 
carotenoid-containing foods are likely protective, and non-starchy vegetables, selenium-
containing foods and quercetin (a flavonoid compound)-containing foods might also be 
protective, based on limited evidence (29). A local study has highlighted the protective 
effect of cruciferous vegetables, in particular in smokers (30); the putative protective 
compounds appear to be isothiocyanates. 
Other risk factors have also been explored. Using the model of smoking-related lung 
carcinogenesis, where the effect of smoking is mediated through both direct 
carcinogenic damage and chronic inflammation, investigators have also considered the 
role of other possible carcinogens, such as cooking fumes (27, 31, 32), smoke 
emissions from incense (33), mosquito coils (34) and wood smoke (27,35). Meat-derived 
carcinogens as a result of cooking or food-processing methods have also been studied 
(36, 37). Other investigators have considered the role of chronic inflammation and 
immune system dysfunction by studying the risks imposed by pre-existing chronic lung 
disease (38, 39), chronic infection by the bacterium chlamydiae pneumonia (40), the 
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Human Papilloma Virus (41) and the Human Immunodeficiency Virus (42), and atopic 
conditions such as allergic rhinitis, atopic dermatitis, and allergies (43, 44).  
Because of the relatively higher proportion of women among never-smoker lung cancer 
cases, and of some data (although disputed) suggesting higher incidence of lung cancer 
in never-smoking women compared to men (45), the role of estrogen-related factors and 
reproductive history has also been examined (46, 47). 
The evidence for these putative risk factors has not been consistent, and interpretation 
of the results has been complicated by methodological limitations and differences in 
study populations.  Recent evidence for some of these factors is examined and 
evaluated later in the relevant chapters. 
Variation in personal risk of a disease outcome may be due to both differing levels of 
exposure to environmental factors, with subsequent epigenetic effects on gene 
expression, and to genetic variation among individuals. It is likely that genetic 
susceptibility in lung cancer, similar to genetic susceptibility seen for other complex non-
communicable diseases, is a result of the combined effect of many genes, each of which 
exerts only a small effect. It is also probable that genetic and environmental risks interact 
such that it is the joint effect that is important rather than the separate individual effects 
(48).  
There is indeed some evidence both that genetic susceptibility is important (although the 
risk estimates are low), and that joint effects may be more important than individual 
effects separately. Genome-Wide Association Studies have identified a susceptibility 
locus at position 15q25 (49-51), mapping to a gene for the nicotinic acetylcholine. While 
two of the studies were conducted solely in smokers (49, 50), the third showed that the 
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locus conferred risks in both never smokers and smokers (51). Two additional loci at 
6p21.33 (mapping to the BAT3-MSH5 gene locus) and 5p15.33 (the TeRT-CLPTM1L 
locus) were identified subsequently (52, 53). In 2010, an additional locus at 13q31.3, 
mapping to the GPC5 gene was found to associate with lung cancer in never smokers 
(54). More recently, additional risk loci at 3q28, 13q12.12 and 22q12.2 were also 
identified in a study conducted on Han Chinese subjects (55).   
Other studies have used a candidate gene approach to identify genetic susceptibility 
loci. These have focused on genes involved in the metabolism of products of cigarette 
smoke, including both Phase 1 (CYP1A1) and Phase 2 (GST and UDP) enzymes. 
Phase 1 enzymes (cytochrome P450s such as CYP1A1) activate carcinogens in tobacco 
smoke such as PAH, while Phase 2 enzymes (such as glutathione- S transferases 
([GSTs] and UDP Glucuronosyltransferases [UGTs]) detoxify phase 1 products into 
soluble metabolites which are then excreted (56, 57). A pooled analysis identified a 
polymorphism in exon 7 of the CYP1A1 gene as risk conferring in lung cancer (58). 
Other studies have identified the GSTM1 null genotype as risk-conferring, particularly 
among smokers and those with strong ETS exposure (30, 59, 60), providing an example 
of the importance of the joint effect of genes and environmental factors in conferring risk 
in diseases.  
While smoking is the leading cause of lung cancer by virtue both of its high prevalence 
and its large causal effect, and smoking control is a key pillar in lung cancer prevention 
worldwide, never-smoker lung cancer is nonetheless not uncommon (45). The relative 
paucity of well-established common risk factors for lung cancer other than smoking and 
ETS suggests that additional investigations using well-designed studies are necessary. 
Further, in order to remove a potential masking effect of smoking, studies that are 
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conducted in sufficiently large numbers of never-smokers would be particularly valuable. 
Moreover, as I will discuss in Chapter 2, there is growing evidence that lung cancer in 
never-smokers is biologically different from that in smokers. This further emphasizes the 
importance of studying never-smoker lung cancer as a separate disease entity. 
Format of thesis 
The aims of this research thesis are to identify genetic and environmental risk factors for 
lung cancer in Chinese women, focusing specifically on never-smokers, through the 
analysis of data obtained from the Gene and Environment in Lung Cancer (GEL) 
studies. The GEL studies are two hospital-based case-control studies conducted in 
Singapore between 1996-1998, and 2005-2008. This thesis examines the separate and 
joint effects of environmental and genetic risk factors in two broad areas – inflammation 
and inflammatory pathways, and reproductive factors and estrogen pathways. In 
addition, it will examine two other possible risk factors for never-smoker lung cancer: 
exposure to domestic inhalants, and dietary factors. This thesis hence comprises five 
studies, including two for the research area on inflammation.  
The first three chapters of this thesis explain the rationale for conducting the GEL 
studies. In this chapter, I have noted that few risk factors have been established for lung 
cancer, and that additional investigations into risk factors are important, as prevention of 
lung cancer remains the most appropriate method of control at this time. In Chapter 2, 
evidence for lung cancer in never-smokers as a distinct entity from smoking-related lung 
cancer is presented. The chapter will make the case that it is necessary to consider 
never-smokers separately from smokers, rather than opting for the usual practice of 
adjusting for smoking. Further, understanding risk factors in never-smokers is 
particularly important in populations with low prevalence of smoking, such as the 
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Singaporean Chinese women. In Chapter 3, local lung cancer data from the Singapore 
Cancer Registry is presented. I will argue that the ethnic variation in lung cancer rates do 
not appear to be explained by differences in smoking prevalence rates alone. Further, 
Chinese women have a disproportionately high lung cancer rate despite low smoking 
prevalence, suggesting that this group would be a useful study population to elucidate 
risk factors for never-smoking lung cancer. Results from an Age-Period-Cohort analyses 
of this group (Chinese women) are presented, which suggest that the relevant risk 
factors for Chinese women include those factors whose prevalence changed 
substantially during the 1970s and 1980s. These may include factors such as diet, 
exposure to chronic inflammation, exposure to inhalants in the domestic environments, 
and female reproduction. These potential factors are examined in detail in the remaining 
6 chapters, which form the body of this thesis.   
In Chapter 4, the design of the GEL studies and general methodology including the 
statistical methods used are described in detail. Chapters 5 to 9 present findings and the 
discussion of the association of these potential factors to lung cancer. In each of the 5 
chapters, an introduction considers the current state of knowledge with regard to the 
factor of interest. Additional methodological issues specific to that analysis are 
discussed. Results are then presented, and a detailed discussion follows, during which 
possible limitations in interpretation of findings are also mentioned. In each case, the 
analysis is performed either exclusively in never-smokers, or else compares the effects 
of the risk factor under investigation between smokers and never-smokers.   
In Chapter 5, the role of previous inflammatory events in the lung and airways and gene 
polymorphisms in the inflammation pathways is examined. Chapter 6 looks at the effect 
of chronic Non-Steroidal Anti-Inflammatory Drug (NSAID) use. Chapter 7 presents 
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findings of an analysis of the effect of female reproductive factors and gene 
polymorphisms in the estrogen metabolism pathways. Chapter 8 explores exposure to 
inhalants in the domestic environment, and notes that the effect of inhalants may be in 
part mediated through inflammation. Chapter 9 studies the effect of meat consumption 
on lung cancer, and raises the possibility that the protective effect of fish consumption 
observed could be due to omega-3 fatty acids and their anti-inflammatory activity. 
Collectively, this series of studies described in Chapters 5 to 9 constitute an 
epidemiologic investigation into risk factors for never-smoker lung cancer, focusing on 2 
key areas – the role of inflammation, and the role of female reproductive factors. Finally, 




CHAPTER 2  LUNG CANCER IN NEVER-SMOKERS: EVIDENCE FOR A DISTINCT 
CLINICAL ENTITY FROM SMOKING –RELATED LUNG CANCER  
Several different lines of recent evidence suggest that lung cancer in never-smokers is a 
distinct entity from smoking-related lung cancer. 
Epidemiologic evidence 
Worldwide, never-smokers represent only about 10% of all lung cancer patients in men, 
but from 15% to 75% of lung cancer patients in women, with higher proportions in Asia 
(45, 61, 62). The relatively small proportion in males is due largely to the extremely high 
numbers of smoking-related lung cancer in this group. Never-smoker lung cancer is not 
an uncommon entity. If separated out from smoking-related lung cancers, it would still be 
the 7th most common cause of cancer death worldwide, on par with the global mortality 
of cervical cancer, pancreatic cancer and prostatic cancer (45). It has a substantial 
reported global mortality of about 15-20 per 100000 annually (45). 
Various descriptive studies have pointed out that never-smokers with lung cancer are 
more likely to be females (although the lung cancer incidence in never-smokers appears 
similar in both males and females) (45, 61, 62), and the most common tumour histology 
among never-smokers is adenocarcinomas (45). In Asian countries, never-smoker cases 
are on average younger than smokers (63), and the stage at diagnosis tends to be more 
advanced among never-smokers than smokers (63). Despite that, never-smokers have 
better overall survival, after adjustment for known prognostic factors such as pre-morbid 





Evidence from cancer biology 
Molecular differences in lung cancer tissue between smokers and never-smokers have 
been observed. The frequency of TP53 mutation frequency is higher among smokers. 
There is also evidence that among TP53 mutations, the proportion of G:C to T:A 
transversions occur more frequently in smoking–related cancers (64).  
EGFR and KRAS mutations tend to occur in lung adenocarcinomas (30% and 20% of all 
lung adenocarcinomas, respectively), but both are rare in other histologic subtypes (65). 
The mutations in EGFR are mostly point mutations and deletion in the tyrosine kinase 
domain, leading to a constitutively active and ligand-independent receptor state (66, 67). 
Tumours with these “activating” mutations are dependent on continued EGFR signaling 
for proliferation and survival (61, 67). Activating mutations in EGFR appear to occur 
more frequently among never-smokers (45% vs 7%), women, and in patients of east 
Asian ethnicity (61, 63, 66, 67). 
KRAS mutations mostly occur on codons 12, 13 and 61, and affect GTP-ase activity of 
the molecule (68). Mutations result in a constitutively active KRAS molecule, which then 
induces downstream signaling molecules RAF1 and MAPK. Axctivated MAPK 
phosphorylates and activates transcription factors (eg c-Jun, c-Myc and c-Fos) that 
induce cell proliferation (68). Evidence for the association between KRAS mutations and 
smoking status is inconsistent. A study using data from an Asian population reported 
that KRAS mutations were associated with ever smoking, males and poor histologic 
differentiation (69). Two smaller studies in populations of Caucasian origin did not find a 
significant association, although there was a trend towards lower KRAS mutation 
frequencies in never-smokers (66, 67). A larger study in an American population of 
mostly whites also failed to show an association between KRAS mutations and smoking 
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status, although the transversion mutations were strongly associated with ever smokers 
(68). It is not yet clear if these differences in findings represent true differences between 
Asian and European populations. 
Differences in HER2 mutations have also been reported; HER2 mutations are reported 
in 2% of non-small cell lung cancers, and all involved deletions in exon 20 (70). HER2 
mutations, EGFR mutations and KRAS mutations were mutually exclusive (70). Similar 
to EGFR mutations, HER2 mutations appear to be more common in females and never-
smokers (70).  
Recently, a group of Chinese researchers reported that an EML4-ALK fusion gene was 
detected in the tumours of 12 of a cohort of 103 lung cancer patients (71). This fusion 
protein was associated with never-smokers, younger age of onset, and 
adenocarcinomas without EGFR or KRAS mutations, and was also correlated with ALK 
protein expression but not EML-5. ALK inhibits apoptosis and promotes growth and 
proliferation through activation downstream of the PI3K/Akt and the MAPK pathways. 
Gene expression microarray profile studies suggest that the gene expression profile in 
lung tumours of smokers differed from those of never-smokers (72). Although there were 
similarities in gene expression in the two groups, it was possible to differentiate the two 
groups based on expression profiles. Notably, one study found that four times as many 
genes changed expression in never-smokers compared to smokers. This was 
interpreted to suggest that adenocarcinomas in never-smokers developed locally, while 





Evidence from clinical trials 
EGRF- Tyrosine Kinase inhibitors such as erlotinib and gefitinib were first used in the 
early 2000s to treat patients with advanced non-small cell lung cancer (61, 74). Re-
analysis of data from several large clinical trials suggested that EGFR TKIs benefited 
never-smokers more than ever-smokers, and this was primarily due to the higher 
proportion of tumours with activating EGFR mutations among never-smokers (61). A 
phase III trial conducted in Asia of EGFR-TK inhibitors as first-line treatment compared 
to the standard of carboplatin/paclitaxel in never or light smokers showed better 
progression-free survival but no improvement in overall survival (75, 76), but the authors 
noted that about two-thirds of patients with EGFR mutation-positive tumours and 
assigned to standard therapy crossed over to TKIs, and this high cross-over rate could 
have confounded the overall survival results (76). 
Summary  
The available data therefore suggests that never-smoker lung cancer is a distinct 
biological entity from smoking–related lung cancer. Never-smoker lung cancer has a 
different epidemiologic profile in terms of patient age and survival. Gene expression 
patterns are different, and the main genes that drive cell proliferation in the tumours also 
differ (EGFR mutations in never-smoker lung cancers, KRAS and TP53 in smoking-
related lung cancer). Consequently, tumour response to a class of anticancer agents, 
the EGFR-TK inhibitors, also differed by smoking status.  
The carcinogenic processes in smoking –related and never-smoker lung cancers may be 
different as well, with different environmental and genetic risk factors. It is important at 
this juncture to determine if risk factors indeed do differ for never-smokers, and if so, to 
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establish the etiologic factors in never-smoker lung cancer. Study designs for etiologic 
research would need to consider smoking–related lung cancer and never-smoker lung 
cancer separately, instead of continuing with the current practice of treating lung cancer 
as a homogenous group and adjusting for smoking behavior in the analysis. 
Unfortunately, because of the much higher smoking prevalence in many populations, 
most studies of lung cancer, especially cohort studies, have not been able to accrue 
sufficient numbers of never-smokers to achieve sufficient power to investigate risk 
factors in this group separately. Singapore is one of a few populations around the world 
where sufficient numbers of never-smoker lung cancer can be accrued with relative 
ease, because of the extremely low smoking prevalence and unexpectedly high lung 




CHAPTER 3  LUNG CANCER IN SINGAPORE 
I) Incidence 
Lung cancer was the cancer with the highest incidence in men and the third highest 
incidence in women (excluding skin cancers) in Singapore for the years 2003 to 2007 
(77).  
Introduction 
In this chapter, I explore epidemiologic trends for lung cancer in Singapore and look at 
ethnic and gender differences in these trends. These data offer clues to the possible risk 
factors that may be important in lung carcinogenesis in Singapore.  
For this analysis, aggregate data for cancer numbers and estimated person-years were 
obtained from the Singapore Cancer Registry, by 5-year age bands, 5-year periods and 
5–year birth cohort groups, and stratified by ethnicity. Information about incident cancers 
comes from notifications made by medical professionals, pathology reports, hospital 
records, and death certificates. To improve the comprehensiveness of notifications, the 
Registry checks all pathology reports, death reports and records of public sector 
hospitals and matches these against notifications. The Registry believes that cancer 
registration is essentially complete, since all cases diagnosed histologically, and all 
cases with mention of cancer in public hospital discharge forms and death certificates 
are included. Prior to 2002, notifications were verified through review of pathology 
results. After 2002, additional data from medical records were used. From 2007, cancer 
notifications have been made compulsory under the National Registry of Diseases Act 




population estimates made by the Department of Statistics Singapore from 1968 through 
to 2007. Data were truncated below 30 years of age, as numbers of cases were small in 
those age-groups. For comparison between population groups, a Standard Population 
was created using the World Standard Population, but with truncation at 30 years of age. 
Figure 3.1 shows the Age-Standardised Rates for men and women for the period 1968-
2007. (Because the Standard Population used is the World Standard Population from 
ages 30 to 79, the ASRs differ from those calculated by the Singapore Cancer Registry, 
although the trends observed are similar. Comparisons with other estimates should be 
made with care because of the different standard population used.) The rates show a 
clear gender-specific difference in lung cancer rates, with much higher rates in men than 
women. In addition, the rates in men show rapidly rising rates that appear to have 
peaked in the early 1980s, before showing a gradual decline. The rates for females have 
not changed so substantially, but they also show a peak in the early 1980s, with a very 
gradual decline subsequently.  
Results 
In Figure 3.1, there is a plateau and decline in lung cancer incidence in men. 
Conversely, women experience a slower decline in lung cancer incidence. There is also 
substantial ethnic variation in lung cancer incidence. Lung cancer incidence is highest 
amongst the Chinese in both males and females, with significantly lower rates in Malays, 
and, particularly, in Indians (Figures 3.2 and 3.3).   
In order to interpret the trends in lung cancer observed, smoking prevalence rates need 




Figure 3.1 Lung cancer incidence in Singaporean men and women, 1968-2007 
 
Rates/100, 
000 1970 1975 1980 1985 1990 1995 2000 2005 
Males 95.91 126.04 134.93 124.35 107.60 97.17 89.83 81.16 
Females 34.63 41.87 44.08 41.90 36.03 36.13 30.89 30.73 




































Age-Standardised Lung Cancer Incidence 










000 1970 1975 1980 1985 1990 1995 2000 2005 
Chinese 110.58 155.27 177.17 163.98 140.52 130.64 120.81 105.65 
Malays 28.66 64.77 61.42 80.73 81.19 76.17 87.21 81.97 
Indians 21.07 44.05 43.14 50.91 35.16 26.67 28.29 37.67 






































Age-standardised Lung Cancer Incidence 











000 1970 1975 1980 1985 1990 1995 2000 2005 
Chinese 36.23 49.97 55.23 51.44 45.35 46.39 39.58 38.48 
Malays 15.18 13.27 20.23 29.32 26.16 22.43 27.57 27.00 
Indians 14.87 20.89 12.91 13.35 8.85 11.92 18.45 6.53 




























Age-standardised Lung Cancer Incidence 
































Males 51.4 42 44.3 34.9 25.3 33.2 27.1 24.3 21.8 23.7 24.7 
Females 8.3 4.5 6.3 3.4 2.0 3.0 3.2 3.6 3.5 3.7 4.2 





Table 3.2 Estimated smoking prevalence (% current smokers) in Singaporean men 
and women, by ethnicity. 


















All Chinese 21.5 18.1 12.8 16.5 13.8  11.7  12.8 
 Malays 28.3 24.4 18.7 30.8 23.4  18.6  26.5 
 Indians 24.0 17.6 13.1 15.3 16.4  12.1  10.1 
           
Males Chinese  32.9 23.4  24.0 22.5 20.5 21.2 22.2 
 Malays  46.3 36.7  43.3 39.5 29.9 41.3 45.5 
 Indians  31.8 23.8  29.9 18.2 22.4 20.6 17.3 
           
Females Chinese  3.6 2.3  3.2 3.7 3.1 3.6 3.8 
 Malays  2.1 0.9  3.4 4.9 7.4 5.5 8.1 











community-based studies (79-88).  The studies conducted in 1992, 1998, 2001, 2004, 
2007 and 2010 were nationally representative surveys by the Ministry of Health, while 
earlier studies were community-based studies that were not representative. Caution 
must be taken when interpreting these findings, since some results were not taken from 
nationally representative populations, the definition of a smoker differed between 
studies, and no standardization for age was performed. Further, smoking prevalence 
data prior to the 1970s were not available.  
Nevertheless, the results are striking in demonstrating a significant gender difference in 
smoking prevalence. The smoking prevalence in women never reached 10% in any of 
the studies, and was consistently lower than 5% in studies of the last 20 years. The 
smoking prevalence in men was about 50% in the 1970s, and appears to have declined 
since. Recent surveys suggest that between a quarter and a fifth of men are current 
smokers. These results suggest that smoking may largely account for the significantly 
higher lung cancer incidence in men compared to women, and the decline in lung cancer 
incidence in men in recent years may be a result of the decline in smoking prevalence 
from the late 80s onwards.   
The attributable risk of smoking is likely to be lower for women, given the traditionally low 
rates of smoking, and indeed data suggest that only about half of Chinese women with 
lung cancer had ever smoked (89). Nevertheless, recent data suggest an increasing 
prevalence of smoking among young women (for example, smoking prevalence among 
18-19 year old females was 3.7% in 1998 (84), 6.6% in 2004 (86) and 7.3% in 2010 (88) 
from the National Health Survey, which used similar sampling techniques and a similar 
questionnaire between the 2 surveys, and 9.1% in 2007 from the National Health 
Surveillance Survey (87), which had a different design and sampling from the National 
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Health Surveys.)  If this rising trend reflects a true increase in smoking prevalence in 
young women, and persists, it is likely that the very gradual decline in lung cancer 
incidence rates in women will reverse itself in the next 20-25 years.  
Smoking prevalence rates have been consistently highest in the Malays, with lower rates 
in the Chinese and Indians, particularly among men (81-88), see Table 3.2. While it is 
possible that differences in smoking behavior in terms of frequency and duration of 
smoking, and in biological susceptibility to cigarette smoke could explain why smoking 
prevalence rates do not appear to correlate with lung cancer incidence among the 
different ethnic groups, it is more probable that other factors account for these 
differences. Notably, the lung cancer incidence rates among Chinese women seem 
disproportionately high compared to other groups given the relatively low rates of 
smoking. Nevertheless, the lung cancer incidence in both Malay males and Malay 
females are rising, while those for Chinese males and to a lesser extent, Chinese 
females are dropping. This may be a consequence of the higher smoking prevalence in 
the Malay community observed since the 90s. If current trends persist over the next 15-
20 years, incidence rates in Malays will overtake those of the Chinese for both males 
and females.    
In 2003-2007, the most common histologic type was adenocarcinoma, comprising 43% 
of all cases with histology. 18% were squamous cell carcinomas, and about 10% were 
small cell carcinomas (77). Other registries have also reported rising incidence rates for 
adenocarcinomas (90, 91), and this is consistent too with the reported increase in the 
proportion of lung adenocarcinomas among all lung cancers (92). The data are also 
consistent with Seow et al’s review of epidemiologic trends in 1998 (89), which noted a 
three-fold increase in the incidence rate of adenocarcinomas among Chinese women, 
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with adenocarcinomas being the most common histological type in 1988-1992, 
comprising 51.3% of all histologically-confirmed cancers.  
The relatively high lung cancer incidence seen in Singaporean Chinese women are 
consistent with rates reported in Chinese women in other communities around the world, 
in particular from findings reported in the US which have highlighted relatively high lung 
cancer incidence in women of Asian, in particular Chinese, ethnicity compared to other 
ethnic groups (93). These results highlight the need for further detailed study of lung 
cancer risk factors in this high-risk group, the results of which may suggest appropriate 
preventive and public health measures, and also elucidate etiologic mechanisms for 
never-smoker lung cancer, a disease entity that is difficult to study epidemiologically 
because of the preponderance of smokers among lung cancer cases in most 
populations around the world.  
II) Mortality and survival 
Lung cancer had the highest mortality rate in men and the second highest in women of 
all cancers in 2003-2007 (77).  What drives the high mortality is not simply the high 
incidence, but also poor survival associated with lung cancer. Improvements in lung 
cancer treatment have resulted in at-best survival benefits measured in months rather 
than years, and the 5 year survival rate remains dismal.  
Relative survival data from the Singapore Cancer Registry suggest that 5-year Age-
Standardised Relative Survival (ASRS) has increased from about 4% in the 70s to about 
10% in the late 90s and early 2000s in men, and from about 6% in the 70s to about 14% 
in the early 2000s in women (77). This very marginal improvement in survival reflects the 
very high case-fatality and the lack of substantial improvements in lung cancer 
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treatment.  In recent years, attention has focused on the use of Tyrosine Kinase 
Inhibitors (TKIs) such as erlotinib and gefitinib. Although use of these TKIs have not 
been shown to improve survival overall, their use appears advantageous in a subgroup 
of EGFR mutation-positive cancers, with some improvements in survival. These EGFR 
mutation-positive cancers appear to be more frequent among never-smokers, Asians, 
and females (as discussed in Chapter 1). Although these TKIs do not appear to be a 
magic bullet offering a definitive breakthrough in lung cancer treatment, if early results 
hold out, more widespread use of TKIs in EGFR mutation positive cancers may result in 
improvements in relative survival, particularly among women, for whom such cancers 
comprise a larger proportion.   
Lung cancer in Chinese women 
The previous section highlighted the relatively high rates of lung cancer despite 
consistently low prevalence of smoking among Chinese women. To understand the 
epidemiologic trends in this population group better, this section makes a more detailed 
examination of the lung cancer incidence trends in Chinese women, and includes Age-
Period-Cohort (APC) modeling to allow an assessment of the relative contribution of 
period and cohort effects in lung cancer incidence trends among Chinese women.   
Introduction 
The APC model is a Poisson regression model, where the number of events in any age 
group, period and birth cohort is modeled as a Poisson random variable (94). This 
estimate provides a quantitative method of assessing trends over time, and of evaluating 




groups equally, for example changes in the way lung cancer is detected and diagnosed, 
through screening practices) from effects that vary from generation to generation (birth 
cohort effects affecting age groups unequally, for example changes in lifestyle and 
behavioural factors, such as smoking, for example).   
The linear relationship between age at diagnosis, birth cohort and period of cancer 
diagnosis does not allow simultaneous estimation of all three effects unless further 
assumptions are made to the model. Different assumptions imposed can result in widely 
varying parameter estimates. For this brief analysis therefore, the full Age-Period-Cohort 
model was not used. Instead, three models were compared: a model with age as the 
only explanatory variable, one with age and period as explanatory variables, and a third 
with age and cohort as explanatory variables. To compare between these models, the 
goodness of fit of the models was determined using the deviance statistic; a non-
significant value indicates a good fit. To compare between models, the Akaike 
Information Criterion (AIC) was used; smaller AIC values indicate better fit. Where 
appropriate, Incidence Rate Ratios (IRRs) obtained from the APC models are used to 
summarize the effects of age, period or cohorts.  
Figure 3.4 shows the age-specific incidence rates by time period of diagnosis, and 
Figure 3.5 shows the age-specific incidence rates by birth cohort. Age-specific rates 
from the age-group 50-54 and older are presented; rates for younger age-groups are 
very low. The data show a strong effect of age, with much higher age-specific rates in 
older age-groups than younger ones. Age-specific rates are lower in later periods 
(Figure 3.4). This is seen for all age-groups, but is particularly prominent in older age-




decrease by cohort is particularly prominent for incidence rates in older age-groups (age 
60-64 and above) and is not seen in younger age-groups. 
Table 3.3 shows overall results of the APC analysis. Table 3.4 reports the IRRs for age 
and cohort from the model with age and cohort as explanatory variables. Table 3.3 
suggests that models with age alone and age and period did not fit the data well. In 
contrast, the age and cohort model had a good fit. The Akaike Information Criterion test 
similarly shows that the model containing age and cohort was superior to both a model 
containing age alone, and one containing age and period.   
The results therefore suggest that in Chinese females, differences in lifestyle factors 
between different cohorts of women (resulting in the strong cohort effect observed) may 
be important in explaining secular changes in lung cancer incidence rates. The IRR for 
lung cancer increases with increasing age, consistent with Figures 3.4 and 3.5. Lung 
cancer incidence is extremely low in those younger than 45, and rates increase rapidly 
beyond that. The IRRs for cohort effects suggest that, compared to the 1933-1937 
cohort, older cohorts were at higher risks for lung cancer. However, the decrease in risks 
appears to have stabilized, and younger cohorts do not appear to be at significantly 
lower risks of lung cancer. In other words, the highest risks for lung cancer occur among 
birth cohorts who entered adulthood before or during the Second World War, while lower 
risks were seen in cohorts that entered adulthood in the post-war period, and who 





Figure 3.4 Age-specific lung cancer incidence by period of diagnosis in 













































































Table 3.3 Age-Period-Cohort modeling of the lung cancer incidence in 





P  AIC 
Age 343.2 70 <0.001 824.3 
Age and period 165.5 69 <0.001 718.1 
Age and cohort 61.3 54 0.23 572.5 
 
 
Table 3.4 Incidence rate ratio estimates of lung cancer for age-groups and cohorts 
of Singaporean Chinese females from APC model of age and cohort 








30-34 0.06 (0.05-0.09) 1898-1902 1.17 (0.98-1.40) 
35-39 0.13 (0.10-0.16) 1903-1907 1.54 (1.35-1.75) 
40-44 0.28 (0.23-0.33) 1908-1912 1.38 (1.24-1.55) 
45-49 0.54 (0.47-0.62) 1913-1917 1.31 (1.18-1.44) 
50-54 1.0 1918-1922 1.36 (1.23-1.50) 
55-59 1.52 (1.36-1.71) 1923-1927 1.30 (1.18-1.44) 
60-64 2.48 (2.22-2.77) 1928-1932 1.14 (1.04-1.26) 
65-69 3.74 (3.35-4.17) 1933-1937 1.0 
70-74 4.86 (4.35-5.43) 1938-1942 0.90 (0.81-1.05) 
75-79 6.17 (5.50-6.92) 1943-1947 0.84 (0.74-0.96) 
  1948-1952 0.92 (0.80-1.05) 
  1953-1957 0.85 (0.73-1.00) 
  1958-1962 0.85 (0.69-1.04) 
  1963-1967 0.81 (0.60-1.08) 
  1968-1972 0.90 (0.59-1.37) 
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Assuming that the induction period between exposure and cancer incidence is on 
average about 20-25 years (the induction period for cigarette smoke on lung cancer is 
believed to be at least 20 years and likely longer; this period will vary for other 
exposures), and since lung cancer incidence increases sharply after the age of 50, the 
relevant age of exposure to factors conferring lung cancer risks in these women is in 
their 30s to 40s. If these assumptions are true, then the sources of exposure that 
conferred a higher risk of lung cancer for Chinese women would have been common in 
the post-World War Two years, and then became less common, with the critical period 
during which the prevalence of these exposures shifted being the 1970s and 1980s. 
This in turn suggests that environmental factors that might have changed substantially in 
the 1970s and 1980s should be investigated as possible risk factors for lung cancer in 
Chinese women. It is possible that changes in smoking practice may explain some of 
this cohort effect. The national survey conducted in Singapore in 1984 suggests that 
smoking was more prevalent among older women than younger ones (82), with a 
prevalence of about 8-9% among those aged 50-59, and 10-12% in women above the 
age of 60. Although these data were of all Singaporean women, Chinese women would 
have represented about three-quarters of the women studied and the results therefore 
likely reflected the prevalence in Chinese women. In contrast, in 2010, the smoking 
prevalence rates in Chinese women 50 to 59 years and older than 60 years were both 
1.4% (88). These data offer some indirect evidence that smoking practice may have 
been more common among women entering adulthood in the post-war period, with a 
lower prevalence of smoking in women entering adulthood in the 70s and 80s, thus 
accounting for the lower cancer rates in Chinese women that have been observed. 
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However, smoking alone probably does not explain all of the effect seen. The available 
smoking prevalence data, although incomplete, suggest that while smoking prevalence 
might have been higher in Chinese women entering adulthood before or during World 
War compared to women entering adulthood in the post-war period, these prevalence 
rates (of about 9-12%) were still substantially lower (on the order of three-to-four fold 
lower) than those seen in men, and would not fully explain the relatively high lung cancer 
incidence unless we assume that women have a particularly high susceptibility to the 
carcinogenic effects of cigarettes. Further, Seow et al (89) reported that even as early as 
the 70s, only about half of Chinese female patients with lung cancers in Singapore had 
smoked. Our data from the GEL studies show that only 60% of the women with lung 
cancer that we recruited had smoked (see Chapter 4). These data suggest that factors 
other than smoking have a high attributable risk in this group of women. Finally, the late 
60s to early 80s were a period of great social change in Singapore, marked by strong 
economic development and major lifestyle changes for the population as Singapore 
underwent industrialization and modernization. It is possible therefore that other 
environmental factors whose prevalence changed during the socio-economic transition 
in Singapore could account for some of the cohort effect observed.  
The population of Singapore experienced major changes in living conditions in the late 
1960s and 70s. The incidence rates of infectious lung diseases such as tuberculosis and 
pneumonia declined as Singapore became more developed (95). Cooking practices 
including change in stove type and fuel type also altered substantially in the 70s and 
80s. Cooking practices prior to the 1960s, where a larger proportion of people lived in 
cramped crowded urban conditions or in kampongs, may differ substantially from 
cooking practices of the 70s and 80s, when Singaporeans were moved into public high-
rise housing with better ventilation and modern fuel systems (96). Dietary practices 
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would have changed as well, as people started eating proportionately more meat and 
less vegetable as they became more affluent (97). Reproductive factors could also be 
investigated, since the economic transitions of the 70s and 80s in Singapore were also 
accompanied by very marked changes in reproductive behavior among Singaporeans – 
including delay in child-birth, decline in parity, and earlier menarche (98) (although the 
decline in lung cancer rates is seen starting from birth cohorts who entered their 
reproductive years prior to the 1970s and 1980s and who would not have experienced 
some of the changes in reproductive behavior seen during this period such as declines 
in parity.)  
Genetic factors are not likely to explain the cohort effects seen, since the time frame is 
too short for changes in the prevalence of genetic risk factors to account for changes in 
lung cancer rates. However, it is possible that changes in the environment could have 
affected the phenotypic expression of specific genetic risk factors. A genetic factor that 
increases risk only in the presence of a specific environmental exposure may confer risk 
over and above the effect of the exposure alone. However, in the absence of the 
environmental exposure, the genetic factor may not increase risk. This form of gene-
environment interaction will amplify the effects of “environmental” exposures. 
Summary 
Lung cancer is the most common cancer in men and the third most in women. There is 
strong variation in lung cancer incidence rates in different ethnic groups, and these 
cannot be explained by smoking alone. In particular, the rates in Chinese women appear 
disproportionately high despite low smoking prevalence. A detailed examination of lung 
cancer incidence in Chinese women suggests that both age and cohort effects are 
important explanatory variables. Older birth cohorts appear to be at higher risk of lung 
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cancers compared to the cohort born in 1933-1937, although younger cohorts did not 
appear to show further decreases in risk.  Cohorts entering adulthood after World War 
Two, and who entered their 40s after the 1970s and 1980s were at lower risk of lung 
cancer compared to cohorts who came of age earlier. This suggests that relevant risk 
factors that should be investigated for this group of women include environmental factors 
in which the prevalence changed substantially during the 70s and 80s. While changes in 
smoking behavior may partly explain the cohort effects seen, the relatively low overall 
smoking prevalence in Chinese women, the high proportion of never-smokers among 
Chinese female lung cancer cases, and the great social and economic transitions that 
the population of Singapore underwent in the 70s and 80s suggest that it would be 
prudent to investigate other possible risk factors for lung cancer in this group of women.  
The Genes and Environment in Lung Cancer (GEL) studies were designed and 
implemented in Singapore in order to study risk factors for lung cancer in Chinese 
women, focusing on potentially relevant factors such as diet, exposure to inhalants in the 
domestic environment, reproductive history, history of chronic inflammatory and atopic 
conditions of the respiratory system, and genetic factors such as polymorphisms in the 




CHAPTER 4  THE GENE AND ENVIRONMENT IN LUNG CANCER (GEL) STUDIES: 
DESIGN AND METHODS 
Data from 2 case-control studies (Gene and Environment in Lung cancer studies [GEL]) 
conducted in Singapore were used for this thesis. 
The Genes and Environment in Lung Cancer (GEL) studies 
The Genes and Environment in Lung Cancer (GEL) studies are two hospital-based 
case-control studies conducted in 1996-1998 and 2005-2008 from the five major public 
sector hospitals in Singapore. These studies were designed to investigate possible risk 
factors associated with lung cancer in Chinese women, a population group marked by 
low smoking prevalence and relatively high lung cancer rates, suggesting susceptibility 
to never-smoker lung cancer. These factors include previous history of inflammatory 
disease, anti-inflammatory drug use, exposure to inhalants other than smoking or ETS in 
the domestic environment, meat and meat constituents, and reproductive factors. The 
study aimed to interrogate two pathways: the inflammatory pathway and associated 
inflammatory gene polymorphisms, and the estrogen pathway and associated estrogen 
pathway gene polymorphisms. 
Both studies used similar study designs and questionnaires. Eligible cases were 
Chinese females with incident primary carcinoma of the lung (all histological types) 
identified within 3 months of diagnosis. 787 eligible lung cancer patients were identified 
in the five hospitals, of whom 702 (89.2%) agreed to participate. The response rate for 
cases was 95.0% in the first study, and 84.6% in the second. Histological or cytological 
reports were reviewed and confirmed the diagnosis of primary lung carcinoma in 673 
cases; 29 cases were confirmed on the basis of radiological investigations, in which 
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metastatic cancer to the lung from other sites was deemed to be unlikely on clinical 
grounds.  
Controls were selected from Chinese female patients admitted to the same hospitals and 
frequency matched for age (within ten years) and date of admission. Patients admitted 
for a diagnosis and treatment of cancer or chronic respiratory disease were excluded, 
and no more than 10% of controls were recruited within a single diagnostic category.  
The response rate among controls was 91% (96.9% in the 1st study and 85.4% in the 
2nd), and data from a total of 1578 controls were available for analysis. Control patients 
were admitted for a wide range of conditions: 27% had diseases of skin, bones, joints 
and connective tissue, 11% were admitted for gastrointestinal or hepatobiliary system 
complaints, 14% were admitted for acute trauma, 8% were admitted for neurological or 
psychiatric conditions, 12% had diseases of the cardiovascular system. 
Both cases and controls gave written, informed consent for the interview and the tracing 
of their medical records. As the studies aimed to investigate genetic susceptibility, and 
the possible interaction of these genetic risk loci with environmental factors, blood 
samples were also obtained where consent was given. The study was approved by the 
Institutional Review Board of the National University of Singapore and participating 
healthcare institutions. In total, 702 cases and 1578 controls were recruited in the 2 
studies.  433 cases (61.7%) and 1375 controls (87.1%) in the study were never-
smokers, defined as individuals who had not smoke at least 1 cigarette a day for a year. 
Of these, 298 cases and 718 controls provided blood samples, and 88 cases and 168 
controls provided saliva samples. 
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There were minimal differences between cases and controls that provided blood 
samples and those who did not (data not shown). The exception to this was in 
Environmental Tobacco Smoke (ETS) exposure amongst controls: 52% of those who 
provided blood specimens reported ETS exposure compared to 44% in the study 
population as a whole (P<0.05). 
 A structured questionnaire was administered in-person by trained interviewers. 
Interviewers were not blinded to case or control status, but possible observer bias was 
monitored by recording and reviewing at random a sample of interviews conducted. The 
structured questionnaire elicited information of participants’ demographic characteristics, 
occupational history, smoking history, family history of cancer, personal medical history 
(self-reported history of tuberculosis, chronic productive cough, asthma, allergic rhinitis 
and atopic eczema), diet (including intake of fruit and vegetable), childhood living 
conditions, reproductive history, exogenous hormone use and use of other medications, 
and indoor environmental exposures such as passive tobacco exposure, cooking, stove 
and oil use,  and exposure to kitchen fumes and inhalants such as incense and mosquito 
coils. The questionnaire used is enclosed as Appendix A. 
Genomic DNA was extracted from the buffy coat of 5 ml of whole blood samples using 
the FlexiGene DNA kit (Qiagen Inc.), in accordance with the manufacturer’s protocol. 
Saliva DNA was extracted from 2 ml of saliva with the Oragene DNA Self-Collection Kit 
(DNA Genotek Inc., Ontario, Canada) and DNA concentration measured with Quantifiler 
Human DNA Quantification kit (Applied Biosystems, Life Technologies Inc, California, 
USA).  
In general, the selection of sequence polymorphisms for genotyping was based on (a) 
their location in the promoter, untranslated region (UTR), or exons of the gene, or 
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published evidence showing possible effects of the polymorphism on the level and 
activity of the gene products; (b) a minor allele frequency ≥ 5% in Chinese population 
from the NCBI database; (c) associations with lung cancer reported previously by other 
researchers.  
All Single Nucleotide Polymorphisms (SNP) were genotyped using a high-throughput 
genotyping platform base on a 5’ nuclease allelic discrimination assay in a 96-well 
format on the ABI StepPlusOne real-time Polymerase Chain Reaction (PCR) System 
(Applied Biosystems). The Taqman universal PCR master mix and predesigned SNP 
genotyping assay mix containing PCR primers and probes were purchased from ABI. To 
ensure the accuracy of genotyping results, three positive controls and two negative 
controls were included in each 96-well plate, and 10% of DNA samples were genotyped 
in duplicate for each polymorphism.  
Based on biologic considerations, as well as results from reverse stepwise analyses, the 
following variables were used for adjustment: age at diagnosis, country of origin, housing 
type, number of years in school, environmental tobacco exposure at home, history of 
cancer in a first degree relative, mean intake of fruit and of vegetable (in servings/week), 
and smoking status (current, ex-smokers, defined as smokers who have not smoked in 
the last 30 days, and never-smokers) as well as a study set variable (in analyses where 
data from both studies were combined) to indicate which case-control study the 
participant belonged to. Among smokers, smoking duration (in years), the logarithm of 
the average number of cigarettes smoked per day, and the time (in years) an individual 
stopped smoking prior to diagnosis (set at 0 for current smokers) were independent risk 




variables showed that smoking duration alone adequately explained the variation in risk 
attributable to smoking, and this was added as an adjustment variable for smokers.   
Unconditional logistic regression was used, and odds ratios (ORs) and 95% confidence 
intervals (CIs) calculated. Tests for linear trend were performed by entering the factor of 
interest into the logistic regression model as an ordinal variable, where each 
successively higher category in that factor was assigned a higher numeric value in the 
variable. The likelihood ratio test was used to test for multiplicative interaction between 
two variables of interest by constructing a multiplicative interaction term of the 2 
variables of interest, and then comparing two regression models, one without interaction 
term (null model), and the other with the interaction term (alternative model).  No 
adjustments for multiple comparisons were made for tests of main effects of variables of 
interest. Adjustment for multiple comparisons was made for all tests of statistical 
interactions using the method of Benjamini and Hochberg (99), in which the P value is 
adjusted by taking into account the False Discovery Rate (ie the number of null 
hypotheses erroneously rejected) based on the number of statistical comparisons made.  
The χ2 test was used to test for Hardy-Weinberg equilibrium by looking for a statistically-
significant difference between the expected and observed values of the genotype 
counts. All P values calculated are two-tailed, and significance was set at P< 0.05. We 
used STATA statistical software, version SE 10.1 (StataCorp LP, Texas, USA) and R 
statistical package version 2.13.0 (R Development Core Team, Austria, Vienna) for data 
analyses. All SNPs studied were in Hardy-Weinberg equilibrium in the control 
population. 
Table 4.1 summarises key baseline variables between cases and controls in the two 
case control studies. Cases were significantly younger and also consumed less fruit and 
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vegetables. They were more likely to have been born in China, live in private housing, 
smoke, report daily environmental tobacco exposure, and have a positive family history 
of lung cancer in a first-degree relative. Among smokers, cases reported longer smoking 
duration. Half of the cases (51.7%) had lung adenocarcinomas, and the proportion of 
adenocarcinomas was higher among never-smokers (62.6%) than smokers (34.2%).  
The proportion of adenocarcinomas also appears slightly higher than the proportions 
reported by the Singapore Cancer Registry (43% adenocarcinomas, 18% squamous cell 
carcinomas, 10% small cell carcinomas) (77). This may reflect the higher proportion of 
adenocarcinomas in women, especially amongst never-smokers.  
Mitigating limitations of the case-control design 
This section discusses the general limitations of the case-control design and the steps 
that have been taken to mitigate these limitations. Issues about the effect of the design 
and conduct of this study on the interpretation of specific research findings are 
discussed in the relevant sections in subsequent chapters. 
Study design issues associated with case-control studies are well-known (100, 101). 
These include problems of information bias, reverse causation, selection bias, and 
random misclassification due to problems with recall. 
Because outcomes are known prior to obtaining information about exposure, it is 
possible that systematic misclassification (information obtained from cases differ 
systematically from that obtained from controls that do not reflect true differences in 
exposure) can occur. This could be due to interviewer bias or recall bias among 
participants. Reverse causation can result when the disease process give rise to 
differences in the reporting of exposure. This can occur even though participants are 
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asked to recall exposures in the past if the development of the condition spans over a 
long period of time. Selection bias can occur when cases and controls are not chosen 
from the same underlying sample population. For example, this may happen when 
controls could not have become cases if they had developed the disease because they 
would have attended a different hospital and not have come to the attention of 
researchers. Hospital-based studies can run a higher risk of selection bias, as hospital 
controls may differ systematically from the population from which they are drawn. (The 
effect of this potential selection bias on the interpretation of findings with regard to Non-
Steroidal Anti-Inflammatory Drug Use is discussed in Chapter 7.) Random 
misclassification can also occur as a result of inaccuracy of recall of events in the distant 
past by both cases and controls, resulting in biases of odds ratios estimates towards the 
null. The GEL studies tried to minimize these design limitations in a few ways. These are 
summarized in Table 4.2. The hospital-based design was felt to be preferable to a 
population-based design for two reasons: it was not possible to obtain a population list 
from which to sample, and it would be difficult to obtain high response rates from a 
population-based study. To minimize the risk of selection bias, controls were chosen 
from a wide variety of hospital departments and diagnoses groups, thereby minimizing 
the bias that may result from any unusual characteristics of a particular group of 
patients. Each specific admission diagnosis represented less than 5% of all controls. 
Controls were chosen from the same hospitals as the cases. This increased the 
likelihood that cases and controls were being drawn from the same study population, 
since it is likely that the controls would have attended the same hospitals if they had 
developed the outcome of interest (ie lung cancer). For exposures that are known a 
priori to associate with a specific group of diagnoses, controls with that group of 
diagnoses were excluded from analyses, in accordance with the proposal
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Table 4.1 Baseline characteristics of female Chinese lung cancer patients and controls, Singapore, 1996-1998, 2005-2008 














Age in yrs <0.001   0.42   0.001 
mean +/-SD 65.9+/-
11.8 
64.1+/-12.3  63.0+/-12.5 63.6+/-12.2  70.5+/-8.9 67.3+/-12.6  
Average weekly fruit consumption 
(servings) 
<0.001   <0.001   0.11 
mean +/-SD 6.8+/-8.5 9.0+/-8.6  7.5+/-7.1 9.3+/-8.5  5.7+/-10.2 7.2+/-8.8  
Average weekly vegetable consumption 
(servings) 
<0.001   <0.001   0.08 
mean +/-SD 21.4+/-
19.3 
25.6+/-21.3  22.3+/-19.4 25.9+/-21.3  20.0+/-19.0 23.3+/121.5  
Years of education 0.06   0.02   0.02 
mean +/-SD 3.6+/-4.5 4.0+/-4.4  4.8+/-4.9 4.2+/-4.5  1.7+/-2.9 2.4+/-3.7  
 
 n % n % P n % n % P n % n % P 
Dialect Group 0.03     0.008     0.01 
Hokkien 290 41.7 673 43.5  151 35.2 577 42.8  139 52.1 96 48.5  
Teochew 157 22.6 307 19.9  109 25.4 265 19.7  48 18.0 42 21.2  
Cantonese 151 21.7 286 18.5  85 19.8 252 18.7  66 24.7 34 17.2  
Hainanese 40 5.8 89 5.8  38 8.9 80 5.9  2 0.8 9 4.6  
Hakka 38 5.5 138 8.9  31 7.2 125 9.3  7 2.6 13 6.6  
Others 20 2.9 53 3.4  15 3.5 49 3.6  5 1.9 4 2.0  
Country of Birth 0.001     0.012     0.59 
Singapore 442 63.0 1031 65.3  274 63.3 900 65.5  168 62.5 131 64.5  
Malaysia 92 13.1 271 17.2  57 13.2 239 17.4  35 13.0 32 15.8  
China 145 20.7 234 14.8  85 19.6 198 14.4  60 22.3 36 17.7  
Other 23 3.3 42 2.7  17 3.9 38 2.8  6 2.2 4 2.0  
Current housing 0.019     0.001     0.17 




4 room or larger 
public flat 
332 47.6 775 49.3  202 47.0 682 49.8  130 48.7 93 46.0  
Private apt or 
house 
111 15.9 183 11.7  83 19.3 170 12.4  28 10.5 13 6.4  
Marital status 0.03     0.81     0.57 
Currently or 
previously married 
654 93.2 1467 93.0  403 93.1 1275 92.7  251 93.3 192 94.6  
Never married 48 6.8 111 7.0  30 6.9 100 7.3  18 6.7 11 5.4  
Ever worked outside the home 0.017     0.56     0.01 
Yes 513 73.1 1224 77.7  330 76.2 1065 77.6  183 68.0 159 78.3  
No 189 26.9 352 22.3  103 23.8 308 22.4  86 32.0 44 21.7  
Smoking status <0.001          0.45 
Never smokera 433 61.7 1375 87.1            
Ex-smokerb 143 20.4 115 7.3       143 53.2 115 56.7  
Current smoker 126 18.0 88 5.6       126 46.8 88 43.3  
Smoking duration (years)c           <0.001 
Mean +/- SD       43.7+/-17.8 33.4+/-20.3  
Average no of sticks smoked           0.06 
Mean +/- SD       11.5+/-11.3 9.6+/-10.9  
Years since stopped smokingd           <0.001 
Mean +/- SD         7.0+/-12.8 12.8+/-17.8  
Environmental Tobacco Smoke exposure 
at home 
0.008     0.30     0.75 
< Daily 334 48.1 848 54.1  226 53.1 764 55.9  108 40.2 84 41.6  
Every day 361 51.9 720 45.9  200 46.9 602 44.1  161 59.9 118 58.4  
Family history of 
cancere 
    0.003     <0.001     0.45 
No 531 75.6 1286 81.5  309 71.4 1112 80.9  222 82.5 174 85.7  
Yes, other sites 126 18.0 229 14.5  88 20.3 208 15.1  38 14.1 21 10.3  
Yes, lung cancer 45 6.4 63 4.0  36 8.3 55 4.0  9 3.4 8 3.9  
Histologic type                
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Adenocarcinomasf 363 51.7    271 62.6    92 34.2    
Squamous cell 
carcinomasg 
84 12    25 5.8    59 21.9    
Small cell 
carcinomash 
38 5.4    5 1.2    33 12.3    
Other histologyi 188 26.8    115 26.6    73 27.1    
No 
histology/cytology 
29 4.1    17 3.9    12 4.5    
Abbreviation: SD, standard deviation. 
a Defined as have never smoked at least 1 cigarette a day for a year 
b Have not smoked any cigarette in the 30 days prior to admission 
c Defined as the difference between the age at which the participant stopped smoking (taken as age at diagnosis for participants who are currently smoking), and 
that at which she started.  
d Defined as the difference between age at diagnosis and age at which participant stopped smoking; set as 0 for current smokers.  
e First degree relatives 
f Histology codes  (ICD-O-3) 8140/3 – adenocarcinoma NOS, 8260/3 – papillary adenocarcinoma, NOS, 8480/3 – mucinous adenocarcinomas 
g Histology code (ICD-O-3) 8070/3 squamous cell carcinoma, NOS 
h Histology code (ICD O-3) 8041/3 small cell carcinoma, NOS 








by Wacholder et al. (102). As Wacholder noted, controls with a previous history of a 
disease associated with the exposure need not be excluded unless cases were also 
similarly excluded. Failure to also exclude cases introduces a selection bias. In this 
study, we have not excluded cases or controls with a previous history of a disease 
associated with an exposure of interest, since our aim in participant selection was not in 
obtaining cases and controls that were “healthy”, simply that the exposure distribution in 
controls should be similar to that in the source population (See Chapter 7 for a 
discussion of this issue in relation to the study on NSAID use and lung cancer risk).  In 
this study, high response rates above 85% were obtained for both cases and controls, 
suggesting that response bias is unlikely. Controls were also frequency-matched for age, 
thus minimizing selection bias in exposure levels that could occur due to age 
differences. We further restricted both cases and controls to Chinese females. This 
homogeneity in gender and ethnicity increases the power of the study and reduces the 
risk of population stratification (a type of selection bias) arising from differences in 
ethnicity. This also permitted exploration of risk factors for lung cancer in a population 
group with relatively high rates of lung cancer despite consistently low prevalence rates 
of smoking. 
 
To reduce information bias, research nurses who performed interviews were trained, and 
a structured questionnaire was used to standardize the way in which information was 
collected. Nurses interviewed both cases and controls, and proxy interviews were not 
used. Interviews were recorded, and a small proportion (about 10%) of these recordings 
was played back to check on that the interviews were performed appropriately and 





Table 4.2 Limitations of hospital-based case-control study design, and mitigation 
of these limitations in the Genes and Environment in Lung Cancer studies 
Limitations Mitigation 
Information bias  
Cases report exposures differently 
from controls because knowledge 
of outcomes affect recall and 
reporting 
Recall bias • Participants not informed of specific 
hypotheses under investigation 
• Questions pertaining to exposures for 
these hypotheses embedded in an 
extensive questionnaire  
• No use of proxy interviews 
• Recall bias unlikely with genetic 
polymorphisms 
Interviewer knows the disease 
outcome status of their interviewees 
and probes cases and controls 
differently about exposures  
Interviewer bias • Research nurses were carefully trained 
• A structured questionnaire was used to 
standardize data collection 
• Interviews were recorded and a portion 
reviewed for quality checks 
Selection bias  
Controls not picked from same 
study population as cases; controls 
could not become cases if they had 
developed the disease 
• High response rates achieved 
• Controls, although hospital-based, 
were selected from a wide variety of 
departments and with different 
admitting diagnoses. Each diagnosis 
represented less than 5% of the total, 
number of controls 
• Controls picked from same hospitals 
as cases 
• Controls frequency-matched for age 
• Cases and controls restricted by 
gender and ethnicity (Chinese 
females) 
• Controls further restricted to exclude 
admission diagnoses that a priori are 
known to be associated with the 




Disease causes changes in level of 
exposure  
• Some exposures ascertained for the 
time point of 25 years prior to 





• Reverse causation not possible with 
genetic polymorphisms  
• Some exposures of interest (eg 
reproductive factors) occur either early 
in life-course or through life-cycle, and 
are not expected to be subject to 
reverse causation  
Confounding  
Known risk factors for lung cancer may 
also be associated with the factors under 
investigation  
• Data collected for these known risk 
factors, such as smoking, 
environmental tobacco smoke 
exposure, family history of lung cancer, 
and fruit and vegetable intake 
• Adjustment was performed in 
multivariate analyses to take these 





Participants were not informed about the specific hypotheses (especially regarding 
reproductive and inflammatory factors) of this study, other than that this was a study 
looking at risk factors for lung cancer. The questionnaire used was extensive, and 
questions about these groups of hypotheses were embedded within the questionnaire. 
The hypotheses are also not common knowledge among members of the public as they 
have not been widely discussed in the mass media. It is unlikely therefore that recall bias 
would have played a prominent role.    
To minimize reverse causation, for some exposures such as cooking or fumes, we 
asked participants about exposure 25 years prior to admission or diagnoses, although 
this could increase random misclassification. Most reproductive and inflammatory factors 
are not likely to be subject to reverse causation since they occur early in the life course 
or throughout the life-cycle. We used biological samples to study polymorphisms in the 
somatic genome, and these are also not subject to reverse causation. Further 
advantages of studying genetic polymorphisms is that “Mendelian randomization” or 
random assortment of these polymorphisms reduces confounding, and reduces 
information bias in studies of gene-environment interaction since participants would not 
be aware of their genetic polymorphism status (103).  
We collected a broad range of data, including factors that are known to be associated 
with lung cancer risk, such as smoking practice, fruit and vegetable consumption, and 
family history. This allowed us to include these variables for adjustment, thereby 







CHAPTER 5  STUDY 1 - POLYMORPHISMS IN INFLAMMATORY PATHWAY 
GENES, HOST FACTORS AND LUNG CANCER 
Introduction 
Inflammation is implicated in the pathogenesis of other cancers such as hepatocellular 
carcinoma (104), and disruptions in inflammatory signaling due to chronic inflammation 
of altered immune response may be a common pathway in carcinogenesis (105). One of 
the etiologic mechanisms by which tobacco use confers risk in lung cancer may be 
through its effects on the immune response in the lung and the resultant excess of pro-
inflammatory molecules in the lung tissue milieu (106). Previous studies implicate a past 
history of chronic inflammatory lung disease such as tuberculosis (107, 108), chronic 
bronchitis and emphysema (38, 39, 109), pulmonary fibrosis (110), and chronic 
rhinosinusitis (111), as risk factors for increased lung cancer risk in never-smokers. 
Asthma, allergic rhinitis and atopic dermatitis/eczema are related conditions that appear 
to be manifestations of an underlying systemic atopic disorder characterized by acute 
and chronic inflammation in target organs (lower respiratory tract, upper respiratory tract 
and skin, respectively). While asthma has been reported previously to be associated 
with an increase in lung cancer risk (112-114), the effect of atopy is uncertain, with 
reports of null or inverse associations (43, 44, 115). Other studies have identified genetic 
polymorphisms in key molecules in the inflammatory pathway, such as the interleukins 
(in particular interleukin 1-ß [IL1-ß) (116-121) and interleukin 6 [IL6]) (122, 123), the 
interleukin receptor antagonist (interleukin 1-ß receptor antagonist [IL1RN]) (124, 125), 
cyclo-oxygenase 2 (COX2) (126, 127), and Peroxisome Proliferator-Activated Receptor-





It is likely that the role of inflammation in lung cancer is mediated through interplay 
between host susceptibility (as reflected through polymorphisms in key inflammatory 
genes) and environmental exposures that either cause inflammatory insult to the lung, or 
confer protection in the lung from these insults. Therefore, a rational approach to 
identifying and quantifying lung cancer risks should consider both gene and environment 
factors in tandem. Such analyses may offer insights into the major biological pathways 
that drive carcinogenesis in lung cancer tissue. By identifying population groups at high 
risk of lung cancer, these findings may also have public health implications.  
In Study 1, we hypothesise that previous inflammatory medical conditions (chronic lung 
disease, chronic cough and atopy) increase lung cancer risk in never-smokers, and 
predict that these risks would be modulated by polymorphisms in inflammatory genes 
that have been identified as risk factors in previous studies, in line with the concept of 
interplay between host genetic and acquired environmental factors.  
Methods  
For this analysis, data from never-smokers in both GEL studies were used. In total 433 
cases (61.7%) and 1375 controls (87.1%) in the study were never-smokers, defined as 
individuals who had not smoke at least 1 cigarette a day for a year. Of these, 298 cases 
and 718 controls provided blood samples, for which genetic analyses could be 
performed.  
Personal medical history of tuberculosis, asthma, allergic rhinitis, atopic eczema and 
prolonged chronic cough were obtained from the questionnaires. Six polymorphisms in 5 
inflammatory genes [-31 C/T (rs 1143627) and -511 C/T (rs16944) in the IL1-ß gene, -





exon 2 (rs1801282) of the PPAR- γ gene, and the 86 base-pair Variable Number of 
Tandem Repeats (VNTR) polymorphism in intron 2 of the IL-1ß receptor antagonist gene 
(IL-1RN)] were genotyped in 298 never-smoking cases and 718 never-smoking controls 
who provided blood samples. These genes were selected because they play essential 
roles within the inflammatory pathway, and have previously been reported to be 
associated with lung cancer (116-128).  
The intron 2 VNTR in the IL1RN gene was determined as previously described (124): 
Primers (5’- CCCCTCAGCAACACTCC -3’ and 5’- GGTCAGAAGGGCAGAGA -3’) 
flanking the 86-bp tandem repeat region were used to amplify a DNA fragment 
containing the polymorphic region. PCR conditions comprised an initial denaturing step 
at 95°C for 5 minutes, followed by 35 cycles of 95°C for 30 seconds, 56 °C for 40 
seconds, and 72°C for 45 seconds, with a final extension at 72 °C for 10 minutes.  The 
PCR products were then analysed on 2% agarose gel electrophoresis along with a 
100bp DNA marker. The wild-type allele designated allele I (IL1RN*1) (129) contains 
four 86-bp repeats and generated a 410-bp PCR product. The minor alleles were 
designated allele II to allele V (129) and corresponded to 240-bp (two repeats), 325-bp 
(three repeats), 500-bp (five repeats), and 959-bp (six repeats) PCR products. 10% of 
DNA samples were also genotyped in duplicate to ensure genotyping accuracy, and the 
concordance rate for the duplicates was 100%. The call rate for the VNTR analysis was 
99.7%. The concordance rate for duplicate analyses of the other 5 SNPs that were 








Table 5.1 summarises the effect of past history of lung disease or atopy on risk of lung 
cancer. Tuberculosis (OR 1.58, 95%CI 0.95-2.62) appeared to be associated with an 
increased risk of lung cancer, although this was not statistically significant. Asthma (OR 
1.01, 95%CI 0.66-1.56), chronic cough (OR 1.73, 95%CI 0.65-4.60) and allergic 
rhinitis/atopic eczema (OR 0.93, 95% CI 0.69-1.26) were not associated with an 
increased risk of lung cancer in our study population. The composite measure of chronic 
cough, asthma, or allergic rhinitis/atopic eczema was also not associated with an 
increased risk of lung cancer (OR 0.97, 95%CI 0.74-1.27). 
When stratified by -31T/C polymorphism genotype in IL-1β, a history of chronic cough, 
asthma or atopy was positively associated with lung cancer only among participants with 
the T/T genotype (OR 2.24, 95%CI 1.15-4.38) but not in participants with the T/C or C/C 
genotype (Table 5.2). The P for interaction, after adjustment for multiple testing, was 
0.051. Because the polymorphism at the -511 position was in tight linkage disequilibrium 
with this polymorphism (R2=0.97), similar results (not shown) were obtained for the SNP 
at the -511 position and a history of asthma, atopy or chronic cough. 
When stratified by genotype at the VNTR polymorphism in the IL1RN gene, a history of 
chronic cough, asthma or atopy was positively associated with lung cancer in 
participants with the *2 allele (OR 5.09, 95% CI 1.39-18.67), but not in those with the *1 
allele. The P for interaction, adjusting for multiple testing, was 0.058. Compared to 





Table 5.1 Effect of past medical history of lung disease or atopy on risk of lung cancer in Singaporean Chinese women 
never-smokers 




OR1 (95% CI) P value 
Tuberculosis Yes 27 (6.2) 53 (3.8) 1.58 (0.95-2.62) 0.080 
No 406 (93.8) 1322 (96.2) 1.0  
Chronic productive 
cough2 
Yes 7 (1.6) 12 (0.9) 1.73 (0.65-4.60) 0.27 
No 425 (98.4) 1361 (99.1) 1.0  
Asthma Yes 34 (7.8) 97 (7.1) 1.01 (0.66-1.56) 0.96 
No 399 (92.2) 1278 (92.9) 1.0  
Allergic rhinitis/atopic 
eczema 
Yes 79 (18.2) 244 (17.8) 0.93 (0.69-1.26) 0.64 
No 354 (81.8) 1131 (82.2) 1.0  
Asthma or allergic 
rhinitis/atopic eczema 
Yes 101 (23.3) 311 (22.6) 0.93 (0.70-1.22) 0.59 
No 332 (76.7) 1064 (77.4) 1.0  
Chronic productive 
cough, asthma, or 
allergic rhinitis/atopic 
eczema 
Yes 106 (24.5) 315 (22.9) 0.97 (0.74-1.27) 0.84 
No 327 (75.5) 1060 (77.1) 1.0  
 
1 Adjusted for age, history of cancer in 1st degree relative, fruit and vegetable consumption, country of origin, dialect group, housing type, number of years in school, environmental 
tobacco exposure at home, environmental tobacco exposure at work and study set 
 





Table 5.2 Odds ratios and 95% Confidence Intervals for the interaction between IL1β and IL1RN genotypes and a history of 

































IL1β -31T/C        
C/C No 49 (16.4) 119 (16.6) 1.0  1.0  







T/C No 121 (40.6) 292 (40.8) 0.90 
(0.59-
1.38) 
0.64 1.0  







T/T No 51 (17.1) 158 (22.1) 0.62 
(0.38-
1.01) 












  LR test for interaction P value2= 0.051 
(Unadjusted P = 0.011) 
 
IL-1RN        
*1/*1 No 187 (63.6) 486 (68.5) 1.0  1.0  







*1/*2 or *2/*2 No 31 (10.5) 78 (11.0) 1.00 
(0.62-
1.62) 
0.98 1.0  
Yes 12 (4.1) 11 (1.6) 2.96 
(1.23-
7.12) 




  LR test for interaction P value2= 0.058 
(Unadjusted P = 0.029) 
 
 
1 Adjusted for age, history of cancer in 1st degree relative, fruit and vegetable consumption, country of origin, dialect group, housing type, number of years in school, environmental 
tobacco exposure at home, environmental tobacco exposure at work and study set 
 







atopy, the presence of at least 1 *2 allele and a positive history of chronic cough, asthma 
or atopy, but not either factor alone, was positively associated with lung cancer (OR 
2.96, 95% CI 1.23-7.12). There was no modification of the effect of chronic cough, 
asthma or atopy by the other 3 genotypes studied (data not presented).  
Of the 6 sequence variations studied, the -634 C/G polymorphism in IL- 6 exhibited a 
main effect (Table 5.3). Using a co-dominant model, compared to the C/C genotype, the 
C/G genotype was positively associated with lung cancer (OR 1.51, 95% CI 1.11-2.05). 
The G/G genotype was not associated with lung cancer (OR 1.00, 95%CI 0.49-2.05), 
although there were relatively small numbers in this group. Using a dominant model, the 
presence of the G allele was positively associated with lung cancer (OR 1.44, 95%CI 
1.07-1.94) compared to not having a G allele. This effect was not modulated by a history 
of tuberculosis, asthma, chronic cough or atopy.   
Table 5.4 shows the additive effects of possessing 1 or more “risk” alleles at the 3 gene 
polymorphism sites for which an association with lung cancer was found in our study 
(the T allele at IL-1β -31T/C SNP site, the G allele at IL6-634C/G CNP site and *2 allele 
at IL1RN 86bp VNTR site). Compared to those without any alleles at these 3 sites, those 
persons having “risk” alleles at 1 site had an OR of 1.20, those with alleles at 2 sites, an 
OR of 1.57, and those with alleles at all 3 sites, an OR of 1.89. Although none of the 
individual ORs were statistically significant, the P value for trend was 0.026. The additive 
effect was seen only in those with a positive history of chronic cough, asthma or atopy 
(ORs 2.87, 6.76 for those with “risk” alleles at 1 or 2 and 3 sites respectively, P for trend 
0.001) but not in those without (ORs 0.98, 1.14 for those with ‘risk alleles at 1 and 2 or 3 















OR1 (95%CI) P 
value 
OR(95%CI)2 
IL1β -31 T/C (rs 1143627)3   
T/T 81 (27.2) 196 (27.4) 1.0   
C/T 152 (51.0) 358 (50.0) 1.14 (0.80-1.61) 0.47  
C/C 65 (21.8) 162 (22.6) 1.13 (0.74-1.71) 0.57  
-511 C/T (rs16944)3   
C/C 83 (27.9) 200 (27.9) 1.0   
C/T 155 (52.0) 359 (50.1) 1.14 (0.81-1.60) 0.46  
T/T 61 (20.1) 157 (21.9) 1.07 (0.70-1.63) 0.75  
IL6 -634 C/G (rs1800796)   
C/C 163 (54.7) 449 (62.5) 1.0  1.0 
C/G 123 (41.3) 231 (32.2) 1.51 (1.11-2.05) 0.008 1.44 (1.07-1.94) 
P value= 0.015 G/G 12 (4.0) 38 (5.3) 1.00 (0.49-2.05) 0.99 
PPAR -γ Pro12Ala (rs1801282)   
C/C 274 (92.0) 653 (91.0) 1.0   
C/G 23 (7.7) 64 (8.9) 1.04 (0.62-1.76) 0.87  
G/G 1 (0.3) 1 (0.1)   
COX-2 -8973 T/C (rs5275)3   
T/T 182 (61.3) 462 (64.4) 1.0   





C/C 15 (5.0) 28 (3.9) 1.32 (0.66-2.64) 0.44  
IL1-RN 86bp VNTR in intron 23,4   
*1/*1 251(85.4) 621 (87.5) 1.0   
*1/*2 40 (13.6) 89 (12.5) 1.26 (0.83-1.92) 0.28  
*2/*2 3 (1.0) 0 (0)   
 
 
1 Adjusted for age, history of cancer in 1st degree relative, fruit and vegetable consumption, country of origin, dialect group, housing type, number of years in school, environmental 
tobacco exposure at home, environmental tobacco exposure at work and study set 
 
2 Adjusted odds ratios, comparing participants with a genotype of C/G or G/G at IL6 -634C/G versus those with a C/C genotype 
 
3 Excludes samples with no-calls - 2 samples for IL1β -31 T/C (rs 1143627) and -511 C/T (rs16944), 1 sample for COX2 -8973 T/C (rs5275) and 3 samples for 86bp VNTR in intron 2 in 
IL1RN  
 
4 Further excludes 7 participants with *1/*4 and 2 participants with *1/*5 genotypes 
 






Table 5.4 Additive effect of “risk” alleles at 3 gene polymorphism sites [IL1β-31TC (T allele), IL1RN 86bp VNTR (*2 allele), 
and IL6-634CG (G allele)] on lung cancer risk 
 All No history of chronic cough, 
asthma or allergic rhinitis/atopic 
eczema 
History of chronic cough, 























0 25/91  
 
1.0  21/68 1.0  4/23 1.0  




0.50 105/279 0.98 (0.55-
1.75) 
0.99 38/83 2.87 (0.71-
11.53) 
0.14 















0.18 8/20 3/2 
  P for trend 
0.026 
  P for trend 
0.47 
  P for trend 
0.001 
 
    P value for interaction 0.035 
 
1 Excludes 5 samples with no-calls in at least 1 of the 3 polymorphisms sites  
 
2 Counts were made for each individual based on the number of polymorphism sites in which there was at least 1 “risk” allele: [IL1β-31TC (T allele), IL1RN 86bp VNTR (*2 allele), and 
IL6-634CG (G allele)] 
 
3 Adjusted for age, history of cancer in 1st degree relative, fruit and vegetable consumption, country of origin, dialect group, housing type, number of years in school, environmental 






Table 5.5 shows the Likelihood Ratio test P values for the interaction between the 5 
SNPs with, separately, a history of tuberculosis, history of chronic cough, history of 
asthma, and history of atopic eczema/allergic rhinitis. As IL1β511C/T and IL1β31T/C are 
in strong linkage disequilibrium, only the results for IL1β31T/C are shown. The P values 
for interaction for history of asthma with IL1β31T/C and IL1RN, and for history of allergic 
rhinitis/atopic eczema with IL1RN are significant. 
Table 5.6 shows the results for the joint effect of the composite variable of chronic 
cough, asthma and allergic rhinitis/atopic eczema and the remaining 3 SNPs (IL6-
634C/G, PPAR Pro12Ala and COX2 8973T/C). No statistical interactions were observed 
for the composite variable of chronic cough, asthma and allergic rhinitis/atopic eczema. 
Table 5.7 shows the odds ratios and 95% confidence intervals for the joint effect of the 2 
SNPs of interest (ie IL1β31T/C and IL1RN) with, separately, a history of chronic cough, 
asthma and allergic rhinitis/atopic eczema. The joint effects for each of these 3 variables 
are similar for both polymorphisms, and support our use of a composite variable 
comprising these 3 variables of chronic cough, asthma and allergic rhinitis/atopic 
eczema.   
Discussion 
Our results suggest that among inflammatory conditions of the lung, a history of 
tuberculosis (but not asthma, allergic rhinitis and atopic eczema and chronic cough, 
individually or in combination) may be associated with an increased risk of lung cancer, 
although the odds ratios did not reach statistical significance. A positive association of 
chronic cough, asthma or atopy with lung cancer risk was evident in the presence of the 





Table 5.5 Likelihood Ratio P values for interaction1,2 between 5 genetic polymorphisms and history of tuberculosis, asthma, 
chronic cough, allergic rhinitis/atopic eczema 
 
 Genetic polymorphisms 





0.79 0.64 0.38 No result3 0.51 
History of 
asthma 









0.081 0.045 0.49 0.37 0.47 
 
1 The Likelihood Ratio (LR) Test was used to test for interactions  
2 Adjusted for age, history of cancer in 1st degree relative, fruit and vegetable consumption, country of origin, dialect group, housing type, number of years in school, environmental 
tobacco exposure at home, environmental tobacco exposure at work, and study set 





Table 5.6 Odds Ratios and 95% Confidence Intervals of the interaction between PPAR, COX and IL6 genotypes and history 

































IL6 -634 C/G (rs1800796) 



































  LR test for interaction2 P= 0.86 (unadjusted P = 0.58)  
COX2 -8973 T/C (rs5275) 



























0.33 1.0  











  LR test for interaction2 P=0.86 (unadjusted P = 0.76)  
PPAR -γ Pro12Ala (rs1801282) 




1.0  1.0  











C/G or G/G No 18 (6.0) 54 (7.5) 1.02 
(0.57-
1.83) 
0.94 1.00  
 







  LR test for interaction2 P=0.86 (Unadjusted P = 0.86)  
1 Adjusted for age, history of cancer in 1st degree relative, fruit and vegetable consumption, country of origin, dialect group, housing type, number of years in school, environmental 
tobacco exposure at home, environmental tobacco exposure at work, and study set 
2 P value adjusted for multiple testing using the method of Benjamini and Hochberg (1995) [99]. 
Note:  IL1β-511C/T polymorphism is in tight linkage disequilibrium with Il1β31T/C (R2=0.97), and hence the interaction of this polymorphism with chronic cough, asthma or allergic 





Table 5.7 Odds ratios and 95% Confidence Intervals for the joint effect of IL1β31T/C and Il1RN genotypes and history of 
chronic cough, history of asthma, and history of allergic rhinitis/atopic eczema 
  IL1β31T/C IL1RN 
  C/C T/C T/T *1/*1 *1/*2 or *2/*2 
  Cases/ 
Controls 
OR* P Cases/ 
Controls 
OR* P Cases/ 
Controls 
OR* P Cases/ 
Controls 







Yes 1/1 2.52 
(0.14-
46.63) 
0.51 1/1 2.18 
(0.12-
40.92) 
0.60 1/2 1.81 
(0.16-
20.72) 
0.64 2/3 1.60 
(0.24-
10.50) 




No 63/161 1.11 
(0.73-
1.69) 
0.62 151/356 1.15 
(0.81-
1.62) 








Yes 12/12 1.00 
(0.29-
3.34) 
0.99 9/26 0.79 
(0.34-
1.86) 
0.59 5/13 2.93 
(1.18-
7.29) 
0.02 20/49 0.83 
(0.46-
1.50) 




No 69/184 1.28 
(0.83-
1.99) 
0.27 143/332 1.32 
(0.91-
1.90) 








Yes 21/27 0.93 
(0.43-
1.98) 
0.85 24/51 1.21 
(0.65-
2.24) 
0.55 13/33 2.05 
(1.01-
4.19) 
0.048 47/100 0.91 
(0.59-
1.38) 











No 60/169 1.41 
(0.88-
2.26) 
0.15 128/307 1.32 
(0.89-
1.94) 





* Adjusted for age, history of cancer in 1st degree relative, fruit and vegetable consumption, country of origin, dialect group, housing type, number of years in school, environmental 








independent effect of IL6-634 C to G polymorphism in conferring risk.  We found 
increasing odds ratios for lung cancer with increasing number of polymorphism sites 
where there was at least 1 “risk” allele in those with a history of chronic cough, asthma 
and atopy, but not in those without such a history. Taken collectively, these data support 
the hypothesis that inflammation plays a role in lung carcinogenesis among never-
smokers.  
In our study, the number of cases with a history of tuberculosis was relatively small, and 
the study was inadequately powered to detect a true association of this magnitude. Our 
finding of an increased, although non-significant, risk is consistent with other studies that 
have also reported increased risks associated with tuberculosis (130-132). Asthma was 
associated with a 1.8 fold increased odds of lung cancer in a meta-analysis of 5 case-
control studies that studied the association in never-smokers (114), and other cohort 
studies support this finding (112, 113). On the other hand, studies of the relationship of 
systemic atopic conditions such as food allergies, allergic rhinitis or atopic eczema with 
lung cancer have mainly reported null or negative associations (43, 44, 115). Some 
authors (111) have proposed that local lung effects such as mucosal inflammation are 
the reason for the increased risk seen in asthma, rather than the shift of T lymphocyte 
response to a Th2-dominated activity in the hyperreactive state of the immune system, 
which is found also in systemic atopic conditions. If so, mild and infrequent asthmatic 
attacks and the use of local medications such as inhaled cortico-steroids may mitigate 
the risk association and may explain our null findings. Chronic cough has been identified 
as an independent risk factor for lung cancer (133, 134), especially among smokers. In 
our population of never-smokers, chronic productive cough are likely due to either 





known risk factor for COPD in non-smokers (135), and eczema, allergic rhinitis and 
asthma are known to occur in the same patient in sequence, an effect known as the 
atopic march (136). We believe therefore that the cluster of symptoms or diagnoses of 
chronic cough, asthma, allergic rhinitis and atopic eczema are related and point to 
persons with an underlying atopic phenotype and a predisposition to chronic 
inflammation in the lungs.  
We observed a main effect with the IL6-634 polymorphism in our study population. 
There is biological plausibility for the role of the IL6-634 G allele in increasing lung 
cancer risk. The -634 SNP is in the promoter region of the IL6 gene, and in vitro studies 
have indicated that the G allele is associated with an increased production and secretion 
of IL-6 by peripheral blood mononuclear cells (137).  Our group had previously reported 
(122), using data from the first case-control study conducted between 1996-1998, that 
although a history of asthma or atopy and the G allele of IL6-634 were not associated 
with lung cancer on their own, the combined effect of the G allele and a history of 
asthma or atopy resulted in an odds ratio of 3.1 (95% confidence intervals 1.2 – 8.3) 
compared to the group with the C/C genotype and no history of asthma. We did not find 
any other studies investigating the IL6-634 SNP with lung cancer. Other groups have 
primarily investigated another SNP in the IL6 gene –IL6-174G/C (rs1800795), and most 
of these studies have reported null findings with this SNP (118-120, 138). 
Our study implicates the C allele in IL1β511C/T and/or the T allele in at IL1β 31T/C and 
the *2 allele of IL1RN as alleles that confer risk to lung cancer in the presence of a 
background of atopy (allergic rhinitis or atopic eczema), chronic cough or asthma. The -
31T/C polymorphism is a TATA-box polymorphism; the C allele disrupts this box and 





inflammatory (139). Zienolddiny et al previously reported an increased risk of lung 
cancer with the T allele at IL1β 31T/C (116), and Wu et al also reported that the T allele 
was associated with increased risk in a Chinese population (140), although other groups 
have reported null effects (118, 120), and results from one other study implicated, in 
contrast, the C allele of -31T/C as the risk allele (121). These studies were conducted in 
study populations of smokers or mixed populations with high proportions of smokers 
(ranging from 84-96%). Results for C3954T (rs1143634), the other SNP in the IL1β gene 
that has been commonly studied, have been similarly inconsistent, with reports both of 
an increased risk associated with the T allele (120, 141), and null effects (142). The 
inconsistencies in results could have been due to the different ethnic populations that 
were studied, as well as to the different distribution of relevant host factors such as 
exposure to environmental pollutants and pre-existing health conditions such as asthma.  
The 86-bp VNTR polymorphism of the IL1RN gene contains potential regulatory protein 
binding sites (129), and likely has functional significance in the regulation of IL1-Ra 
production. In opposition to our findings, Hu et al reported reduced risks of lung cancer 
with the *2 allele in ethnic Chinese (124), but the study population in that report was 
predominantly (70%) male and smokers (60% of cases and 48% of controls), with 
relatively fewer adenocarcinomas among the lung cancer cases (38% of cancers). 
Further epidemiologic studies to delineate the main effect and possible interactions of 
IL1RN alleles are needed, as are functional studies to clearly describe the effect of the 
*2 allele in biological systems. 
Our analysis of the summed effect of alleles at these 3 polymorphism sites suggests that 
there is an additive effect in lung cancer risk with increasing number of polymorphism 





cough, asthma and atopy, but not among those without. Although this analysis was 
based on relatively small numbers of cases and controls with chronic cough, asthma and 
atopy, this finding, if replicated, would suggest that the effects of inflammatory gene 
polymorphisms are important only in the presence of relevant host factors such as 
previous medical history. 
The gene-environment interactions observed in our study suggest that failure to take into 
account environmental and personal risk factors may explain the inconsistency of results 
obtained thus far with studies looking at the association of inflammation with lung cancer 
risk. Rothman & Greenland (100) conceptualised a causal pie where combinations of 
risk factors explain the occurrence of non-communicable diseases with multiple 
etiologies such as cancer. Most of these factors are neither necessary nor sufficient in 
themselves to cause illness, and it is the combination of factors that determine the risk to 
any individual. Some risk factors (for example smoking) may have such strong biological 
effects that, regardless of the underlying host genetic susceptibility or the presence of 
other risk factors, these factors invariably confer risk. Other factors may have weaker 
effects, and the risk associated with these factors may manifest only in hosts with 
underlying predisposition. Applying this concept to the role of inflammation in lung 
carcinogenesis, and in the light of our findings, the development of inflammatory 
pathway perturbations that result in lung carcinogenesis may depend on both the 
presence of ‘environmental’ risks that predispose to inflammatory pathway disruptions 
such as personal medical history, as well as on underlying host genetic susceptibility to 
such perturbations.  
This study represents, to our knowledge, the first study of inflammatory genotypes and 





investigate weak associations in this subgroup, which may be overshadowed by 
smoking–related effects in other populations.  
Previous studies of genetic polymorphisms have used study populations of smokers, or, 
when mixed populations where smokers comprised a heavy majority. Despite the 
inconsistencies in findings, the evidence overall appears to suggest that both a medical 
history of lung or inflammatory conditions and genetic variation in the inflammatory gene 
pathways are associated with lung cancer risk in smokers. This study adds to this body 
of knowledge by suggesting that similar associations are seen in never-smokers.  
On the other hand, the retrospective nature of this study and the use of hospital controls 
may complicate the interpretation of the results. We excluded patients admitted for 
cancers or chronic respiratory conditions. Even if there were a selection bias in our study 
(with enrichment of persons with chronic diseases in the control group), the direction of 
this bias would have resulted in an underestimate of the true risk. We depended on 
participant reports of their medical history, and there may have been reporting bias with 
cases being more likely to report a positive medical history than controls. Because of the 
similarity of symptoms, some cases might have been misdiagnosed as asthma prior to 
the diagnosis of lung cancer being made. As we had not asked the age of onset of their 
pre-existing medical condition, we were not able to exclude reports of medical conditions 
of recent onset that could have been misdiagnosed lung cancer. However, we do not 
believe that this was a major source of bias because diagnostic chest imaging is readily 
available to family practitioners in Singapore, and this would have correctly identified 





Further, these results, especially with regard to those showing gene-environment 
interactions, should be considered to be exploratory in nature. Only a subset of 
participants provided blood samples. Our analysis suggested that there were minimal 
differences between cases and controls that provided blood samples and those who did 
not (data not shown). The exception to this was in Environmental Tobacco Smoke (ETS) 
exposure amongst controls: 52% of those who provided blood specimens reported ETS 
exposure compared to 44% in the study population as a whole (P<0.05). ETS exposure 
has been linked to asthma, and the higher proportion of asthma among controls 
providing blood samples may have resulted in an attenuation of the actual effect of the 
composite variables of cough, asthma and atopy in analyses stratified by genotype.  
Mechanistic or biological effect is plausible for these interactions, but the Likelihood 
Ratio tests for interaction, although significant without adjustment for multiple testing at 
P<0.05, gave borderline significant p values after adjustment, and confirmation of these 
findings in other well-designed studies of lung cancer in never-smokers is needed. 
In summary, these results suggest that acquired inflammatory medical conditions and 
inherited polymorphisms of genes in the inflammatory response pathway may interact 
to confer risk in lung carcinogenesis among never-smokers. The finding that the 
cluster of conditions of chronic cough, asthma and atopy was associated with lung 
cancer only in the presence of pro-inflammatory genotypes linked to the IL-1 cytokine 
emphasizes the need to consider host genetic susceptibility when investigating 
putative environmental or acquired risk factors in etiologic studies.   
 
This study has been published (Lim WY, et al. Carcinogenesis 2011;32(4):522-9, 





CHAPTER 6  STUDY 2 – NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID) 
USE AND LUNG CANCER 
Introduction 
Aspirin and non-aspirin Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are widely-
used analgesic and anti-inflammatory agents. In recent years, low-dose aspirin have 
also been prescribed as prophylaxis against ischaemic cardiac and neurological events.  
The biological effect of aspirin and NSAIDs appears to be mediated mainly through the 
inhibition of cyclooxygenase (COX) enzyme. COX converts arachidonic acid to 
prostaglandin G and H2, which are further converted to a variety of eicosanoids with 
biological activity (143). Activities of these eicosanoids include anti-apoptosis, promotion 
of angiogenesis, and stimulation of estrogen synthesis (144, 145). There are 2 isoforms 
of COX: COX-1, which is constitutively expressed, and COX-2, which is inducible (143). 
While aspirin and earlier NSAIDs are non-selective, a new class of COX-2 specific 
inhibitors such as celecoxib was developed and marketed in the early 2000s. Aspirin 
and other NSAIDs differ from each other both in terms of relative affinity for the 2 
isoforms of COX, and in their mechanism of inhibition of COX. Notably, aspirin causes 
irreversible inhibition through covalent bonding of the COX molecule while most other 
NSAIDs exhibit competitive reversible inhibition (145).  
In vitro and animal studies support a protective effect of aspirin and non-aspirin Non-
Steroidal Anti-Inflammatory Drugs (NSAIDs) on cancer risk. Initial studies focused on 
colorectal cancer, where increased cyclo-oxygenase-2 (COX-2) expression in colorectal 
tumour tissue was observed, in comparison with non-tumour tissue (146). In mice 





Polyposis Coli gene induces intestinal polyposis) mice showed decreased intestinal 
polyp formation compared to COX-2 positive mice; polyp formation was reduced in 
COX-2 positive mice fed a novel COX-2 inhibitor (147).  Epidemiologic evidence also 
supports the role of aspirin in protecting against colorectal cancer, with risk reduction 
estimates of 20-50% (148, 149). 
There is growing evidence that aspirin and non-aspirin NSAIDs may also play a 
protective role in lung cancer. COX-2 enzymes are constitutively expressed in lung 
neoplastic tissue at higher levels than in non-tumour tissue (150). Animal studies show 
that these drugs protect against experimentally induced lung cancer (151). Clinical 
evidence in human patients also suggests that COX-2 expression is associated with 
poorer lung cancer survival (152). Further, experimental studies suggest that COX-2 
regulate the activity and expression of Epithelial Growth Factor Receptor (EGFR), and is 
itself regulated by EGFR in complex ways that appear to depend on cell-type specificity 
and cell environment (66, 153). This interaction could be important in the light of recent 
findings that EGFR mutations are common in lung adenocarcinomas among non-
smokers, women, and Asians (66). The role of inflammation (and the effect of anti-
inflammatory agents such as NSAIDs) in lung carcinogenesis may therefore be subject 
to effect modification by factors such as ethnicity, gender and smoking status.   
Epidemiologic studies of the role of NSAIDs and aspirin on lung cancer risk have been 
suggestive but not conclusive (154-179), with both protective and null effects being 
reported. Three meta-analyses have been performed on the available data, with 
contrasting results: one (158) reported a non-statistically significant reduced pooled OR 
for non-aspirin NSAID, but no effect for aspirin, a second (174) reported significant 





association may not be causal, while the third (175) reported a borderline significant 
reduction in risk, with significant differences in results of pooled analysis of case-control 
studies (significant protective effect) compared to cohort studies (null effect).  
In Study 2, we hypothesise that regular aspirin and non-aspirin NSAID use decreases 
lung cancer risk, and that smoking status and lung cancer tumour type modify this 
association. 
Methods 
Data for this analysis were taken from the second case-control study, comprising 399 
cases and 815 controls. In accordance with Wacholder et al’s proposal (102), controls 
whose admitting diagnoses were linked to NSAID use (patients with either disease 
conditions whose management involve use of long-term NSAIDs, or whose admission 
were for conditions directly related to NSAID use) were excluded from analysis. Of the 
815 controls, 85 were admitted for a diagnosis of chest pain, acute myocardial infarction, 
or heart failure, 11 were admitted for a stroke or a transient ischaemic attack, and 73 
were admitted for management of musculoskeletal pain, including knee, hip and back 
pain. A further 5 were admitted for conditions directly related to NSAID use (2 persons 
with ulcers due to NSAID use, 1 person with migraine and rebound headache secondary 
to analgesia use, 1 person with non-ulcer dyspepsia secondary to NSAID use, and 1 
person with nephropathy secondary to NSAID use). These were excluded for this 
analysis, leaving 641 controls for this analysis.  
History of regular use (defined as use at least twice a week for a period of a month or 





cream and steroid pills were obtained from the questionnaire. For each, the age at which 
use was started and the duration of use (in months) were also elicited. 
Results 
Comparing long-term aspirin users to non-users in cases and controls, aspirin users 
were older than non-users in both cases and controls, and also had fewer years of 
education than non-users. Among cases, aspirin users were less likely to report a 
positive family history of lung cancer. (Table 6.1) 
Table 6.2 summarises the overall results of self-reported regular intake of 6 medication 
groups on lung cancer risk. Previous regular intake of aspirin was associated with a 
statistically significant lower risk of lung cancer in both never-smokers (OR 0.50, 95%CI 
0.31-0.81) and smokers (OR 0.38, 95%CI 0.16-0.93 in smokers). No associations were 
seen with non-aspirin NSAID, paracetamol and COX-2 inhibitors, although the actual 
numbers reporting regular use were very small. No significant associations were seen 
with regular use of steroid pills or cream. 
Table 6.3 summarises the association between onset of aspirin use and duration of use 
on lung cancer risk in non-smokers. The numbers of ever-smoker users in our study 
were too small for meaningful interpretation. The lowest risks of lung cancer occurred in 
non-smokers who started using aspirin between 1-5 years before admission/diagnosis, 
and whose duration of aspirin use was between 12 and 60 months (OR 0.35, 95%CI 
0.14-1.85, and OR 0.37, 95% CI 0.16-0.85 respectively). Duration of use and onset of 
use appeared to be correlated (data not shown), so it was not possible to study the 





Restricting cases to non-smokers with lung adenocarcinomas (n=165), an OR of 0.43, 
95% CI 0.24-0.78 was obtained for the association between aspirin use and lung 
cancer. A pattern similar to that in Table 6.3 was observed when we investigated the 
onset of aspirin use and the duration of use in this subgroup, with lowest ORs achieved 
in persons starting use 1-5 years prior to admission, and in those who had used aspirin 
for 12-60 months. (Data not shown) 
To assess the impact of controls with specific diagnoses on the estimation of the effect 
of aspirin use on lung cancer risk, we systematically excluded groups of controls based 
on their admission diagnoses (in broad groupings of accidents and injuries, orthopaedic 
conditions, gastrointestinal conditions, respiratory conditions, neurological conditions, 
cardiac conditions, renal conditions. endocrine conditions, infectious diseases, and 
others). No significant variation in the OR estimates were seen, with adjusted ORs in the 
range of 0.49-0.55 for never-smokers, and 0.28-0.39 for smokers (Table 6.4).  
The inverse association of aspirin was present even when participants who used aspirin 
within 1 year of diagnosis of lung cancer (in cases), or admission to hospital (for 
controls) were excluded, with ORs and 95%CI for never-smokers and smokers of 0.44 
(0.24-0.81) and 0.40 (0.15-1.04) respectively. Finally, exclusion of 32 cases of lung 
cancer diagnosed on radiological grounds did not materially affect the results observed, 







Table 6.1. Baseline Characteristics of long-term users and never-users of aspirin 
 Cases Controls 






P  Use of 
aspirin 
(n=129) 




Age at diagnosis   <0.001   <0.001 






69.45 +/-8.83  
Fruit consumption   0.74   0.42 
mean +/-SD 7.68+/- 
8.36 
7.16 +/- 9.50  8.94 +/-7.51 9.66 +/-9.38  
Vegetable consumption   0.28   0.92 




 23.07 +/- 
21.64 
22.88 +/-19.98  
 n (%) n (%)  n (%) n (%)  
Current housing 0.28   0.34 
1-3 room public flat 11 (28.2) 112 (32.6)  45 (35.2) 165 (32.9)  
4 room or larger public flat 24 (61.5) 169 (49.1)  71 (55.5) 265 (52.8)  
Private apt or house 4 (10.3) 63 (18.3)  12 (9.4) 72 (14.3)  
Years of Education 0.087   0.006 
Nil 19 (47.5) 139 (40.1)  64 (49.6) 179 (35.5)  
≤6 years 15 (37.5) 98 (28.2)  40 (31.0) 171 (33.9)  
7 years or more 6 (15.0) 110 (31.7)  25 (19.4) 155 (30.7)  
Environmental Tobacco Smoke exposure at home 0.62   0.67 
< daily 15 (38.5) 145 (42.7)  59 (46.1) 219 (44.0)  
Every day 24 (61.5) 195 (57.4)  69 (53.9) 279 (56.0)  
Family history of cancer1 0.009   0.674 
No 36 (90.0) 223 (66.4)  99 (78.0) 370 (74.2)  
Yes, other sites 3 (7.5) 77 (22.9)  21 (16.5) 98 (19.6)  
Yes, lung cancer 1 (2.5) 36 (10.7)  7 (5.5) 31 (6.2)  
Abbreviation: SD, standard deviation.    




















Regular use of 
aspirin 
No 227 (89.7) 443 (79.5) 1.0 122 (89.7) 63 (80.8) 1.0 
Yes 26 (10.3) 114 (20.5) 0.50 (0.31-0.81) 14 (10.3) 15 (19.2) 0.38 (0.16-0.93) 
Regular use of 
non-aspirin 
NSAID 
No 244 (96.4) 542 (97.3) 1.0 134 (97.8) 74 (96.1) 1.0 
Yes 9 (3.6) 15 (2.7) 1.72 (0.71-4.17) 3 (2.2) 3 (3.9) 0.57 (0.10-3.12) 
Regular use of 
COX-2 inhibitor 
No 252 (99.6) 553 (99.3) 1.0 137 (100) 77 (100) - 
Yes 1 (0.4) 1 (0.7) 0.56 (0.06-5.24) 0 0 - 
Regular use of 
panadol 
No 243 (95.7) 531 (95.5) 1.0 128 (92.8) 75 (96.2) 1.0 
Yes 11 (4.3) 25 (4.5) 1.11 (0.53-2.35) 10 (7.2) 3 (3.8) 2.58 (0.62-10.78) 
Regular use of 
steroid creams 
No 246 (97.2) 537 (97.1) 1.0 133 (97.1) 77 (98.7) 1.0 
Yes 7 (2.8) 16 (2.9) 0.84 (0.33-2.13) 4 (2.9) 1 (1.3) 2.84 (0.29-28.27) 
Regular use of 
steroid pills 
No 245 (96.8) 540 (97.0) 1.0 135 (98.5) 75 (97.4) 1.0 
Yes 8 (3.2) 17 (3.0) 1.35 (0.54-3.38) 2 (1.5) 2 (2.6) 1.13 (0.14-9.15) 
 
1 Adjusted for age at diagnosis/admission, average weekly fruit and vegetable consumption (in servings), years of education, housing type, and history of cancer in 1st degree relative 
2 Adjusted for age at diagnosis/admission, average weekly fruit and vegetable consumption (in servings) years of education, housing type, history of cancer in 1st degree relative and 
duration (in years) of smoking 






Table 6.3 Association between onset and length of aspirin use and lung cancer in 








Onset of aspirin use    
No use 227 (89.7) 443 (79.5) 1.0 
Start using <1yr from admission 11 (4.4) 39 (7.0) 0.61 (0.30-1.23) 
Start using 1-<3 yrs from admission 4 (1.6) 27 (4.9) 0.34 (0.11-1.00) 
Start using 3-<5 years from 
admission 
2 (0.8) 12 (2.1) 0.37 (0.08-1.74) 
Start using 5 years and more from 
admission 
9 (3.6) 36 (6.5) 0.54 (0.25-1.17) 
    
Duration of aspirin use    
No use 227 (89.7) 443 (79.5) 1.0 
Duration of use 12 month or less 11 (4.4) 40 (7.2) 0.61 (0.30-1.24) 
Duration of use 12-<36 months 5 (2.0) 33 (5.9) 0.33 (0.13-0.87) 
Duration of use 36-<60 months 2 (0.8) 10 (1.8) 0.51 (0.11-2.41) 
Duration of use 60 months or more 8 (3.2) 31 (5.6) 0.54 (0.24-1.22) 
 
1 Adjusted for age at diagnosis/admission, average weekly fruit and vegetable consumption (in servings), years of 







Table 6.4 Aspirin use and lung cancer risk – Sensitivity analyses 
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13 Diagnoses not 
associated with NSAID 
use ( ie excluded 






1 Adjusted for age at diagnosis/admission, average weekly fruit and vegetable consumption (in servings), 
years of education, housing type, and history of cancer in 1st degree relative 
2 Adjusted for age at diagnosis/admission, average weekly fruit and vegetable consumption (in servings) 










These results suggest that regular aspirin consumption may be associated with a 
reduced risk of cancer in both never-smokers and ever-smokers.  Among never-
smokers, the inverse association is most prominent among those who started using 
aspirin more than a year from diagnosis or admission, but less than 3 years from 
admission or diagnosis, and those for whom duration of use of aspirin was between 12 
and 36 months. Non-aspirin NSAIDs, and paracetamol and other forms of 
acetaminophen use were not associated with lung cancer, though the numbers of 
regular users in each group were small. The risk estimates were not significantly 
different in the subgroup of non-smokers with histologically-confirmed adenocarcinomas, 
compared to the overall group of cases. 
A protective effect of aspirin and other NSAIDs is biologically plausible – COX2 is an 
inducible enzyme with pro-inflammatory and pro-carcinogenic properties, and in vitro 
and animal studies lend support to the role of COX2 in carcinogenesis (143-151). 
However, reported results of aspirin use and lung cancer risk are conflicting, with both 
protective (154-162) and null effects (163-173) being reported.  Three clinical trials 
focusing on chemoprevention with aspirin reported non-significant inverse effects (176-
178), and a recent pooled analysis of individual-level data from 7 clinical trials of daily 
aspirin reported an inverse effect on lung cancer death, with a protective latent period of 
about 5 years. The authors also reported a greater inverse effect against 
adenocarcinomas (179). The reasons for the inconsistency in findings include small 
numbers of lung cancer cases, failure to distinguish between aspirin and other NSAIDs, 
and inadequate control of smoking status (as have been pointed out by some of the 





175) – the differences in results appear to be due to the inclusion of different studies in 
the meta-analyses and to the use of different definitions of exposure (aspirin and 
NSAIDs examined separately or in combination).  
Further, the effect of aspirin and other NSAIDs may be modified by gender, and this 
could also explain the heterogeneity in results. The estrogen and prostaglandin 
pathways are known to interact, and estradiol increases COX-2 production in some cell 
types (180). The effect of COX-2 inhibition by aspirin and NSAIDs may thus be stronger 
in women. The available epidemiologic evidence is not consistent either, with reports of 
stronger inverse effects in men (161), stronger inverse effects in women (163, 164), and 
similar effects in both genders (158, 159). A possible explanation may be inadequate or 
residual confounding by smoking in populations where there are strong gender 
differences in smoking rates.  
Among the studies that distinguished between aspirin and non-aspirin NSAID use, some 
reported stronger inverse effects of aspirin than non-aspirin NSAID (160), while others 
reported that the effect of non-aspirin NSAIDs was stronger (157, 158, 162). Residual 
confounding by smoking (because aspirin but not non-aspirin NSAIDs use may be 
higher in smokers as anti-thrombotic treatment for cardiovascular disease risk) may shift 
effects towards the null and explain the smaller effect of aspirin compared to non-aspirin 
NSAIDs detected in some studies (158). In contrast, our study found an inverse 
association of aspirin even in non-smokers, but no association in a much smaller group 
of regular users of non-aspirin NSAID.  
Our study contributes to the growing literature on the role of NSAIDs and aspirin on lung 





female non-smokers, for which the effect of aspirin and non-aspirin NSAIDs have not 
been well-characterised. Our study also distinguished between aspirin and non-aspirin 
NSAID, and examined the duration and onset of use in relation to a diagnosis of lung 
cancer.  
There are a number of limitations in this study. Aspirin and NSAID use in Singapore are 
commonly prescribed by physicians for the treatment of medical conditions rather than 
as health supplements. Hence, hospital controls may have a higher-than-representative 
prevalence of aspirin and NSAID use. This would bias our estimates away from the null. 
We have tried to minimize this by recruiting controls from a variety of admitting 
diagnoses, and, in line with the theory of control selection proposed by Wacholder 
(1996) (259), have also excluded controls whose admission diagnoses are likely to be 
associated (both positively and negatively) with the exposures of interest. We excluded 
individuals admitted for chest pain, acute myocardial infarction, or heart failure, stroke or 
transient ischaemic attack, and for management of musculoskeletal pain, including knee, 
hip and back pain, as NSAIDs and aspirin are commonly used in the management of 
these conditions. In addition, we also excluded individuals who were admitted for 
complications arising from NSAID use. We also evaluated the impact of including 
controls from particular diagnoses groups on the OR estimates for aspirin use and lung 
cancer risk, by systematically excluding controls based on their diagnoses group and 
testing the effect of aspirin. These analyses suggest that the results we obtained were 
fairly robust, and were not likely due to high aspirin use in any particular group of 
controls.   
We relied on self-reports of medication use, and under- or over- reporting of medication 





conducted in the hospital, such misreporting should affect cases and controls equally. 
We were unable to obtain information about the dosage and frequency of use of these 
medications in our participants, and we did not distinguish between low-dose or normal 
dose aspirin, thus limiting our ability to define more precisely the effect of aspirin.  
Because of the relatively small size of our study and the low frequency of use of some 
medications such as steroid pills, some estimates reported in this study are imprecise, 
with wide confidence intervals. OR estimates presented in Table 6.2 for steroid pills and 
COX-2 inhibitors, and in Table 6.3 showing the effect of duration of aspirin use and date 
of onset of aspirin use in relation to lung cancer risk should be viewed as preliminary in 
nature. Additional well-designed studies conducted in similar populations of never-
smokers are necessary to confirm our results. 
Conclusion 
In summary, our data suggest that regular aspirin consumption may confer protection 
against lung cancer in Chinese women. This finding is consistent with the well-
characterised inhibitory effect of aspirin on cyclooxygenase 2, which has pro-
inflammatory and pro-carcinogenic properties.  
 
This study has been published (Lim WY, et al., Lung Cancer 2012; Apr 3, epub ahead of 






CHAPTER 7 STUDY 3 - FEMALE REPRODUCTIVE FACTORS, GENE 
POLYMORPHISMS IN THE ESTROGEN METABOLISM PATHWAY AND LUNG 
CANCER  
Introduction 
Epidemiologic studies conducted in the 1980s implicated reproductive factors and 
female hormonal factors in lung carcinogenesis (108, 181-183), and this hypothesis 
gained momentum with evidence of the potential biological and pathological roles of 
estrogen in lung development and carcinogenesis.  Estrogen receptors (ER), 
predominantly the ERβ isoform, are found in both normal lung and carcinomatous tissue 
(184), and ER signaling pathways are active in lung cancer cells (185), increasing cell 
proliferation and promoting angiogenesis. This pathway also interacts with the Epidermal 
Growth Factor Receptor (EGFR) pathway (186), which is believed to drive 
carcinogenesis in a subset of lung cancers (lung adenocarcinomas among 
predominantly female never-smokers) (61). In vitro and mouse model studies suggest 
that estrogens increase tumour growth, and ER antagonists significantly inhibit growth in 
Non-Small Cell Lung Cancer (NSCLC) cell lines (187, 188). These findings have spurred 
renewed interest in the possible role of female hormonal factors in lung cancer, and, 
including the earlier studies, at least 29 studies (46, 47, 108, 181-183, 189-211) have 
investigated the association of various factors such as parity (46, 47, 108, 182, 189-192, 
194-200, 202-203, 211), menstrual history (46, 108, 181-183, 190, 191, 194), age at 
menopause (46, 47, 108, 181-183, 189, 191-194, 196, 198, 200, 203, 211), age at 
menarche (46, 47, 108, 182, 183, 189, 191-194, 197-200, 203, 211), estrogen 
replacement therapy use (46, 47, 182, 189, 196, 197, 199, 200, 203-209), and oral 





Findings from these studies are inconsistent, suggesting that the effects of female 
reproductive factors are not strong and therefore difficult to detect, or that reproductive 
factors interact with other host genetic or environmental factors in complex ways. The 
evidence that have emerged do not appear to conform to the well-established model for 
the association of reproductive factors with breast cancer (where early menarche and 
late menopause, nulliparity and late age at first birth consistently increase breast cancer 
risk), but no alternative model has yet emerged.  
Understanding the estrogen metabolic pathway in relation to lung cancer may shed light 
on the role of estrogen in lung carcinogenesis. To date, few studies have examined the 
association of estrogen-metabolism gene polymorphisms with lung cancer. Two recent 
papers have investigated gene polymorphisms in estrogen-metabolism enzymes 
[CYP17( 17-α hydroxylase), CYP19A1 (aromatase) and COMT (Catechol-O-Methyl 
Transferase)] (212) and in ER β (Estrogen Receptor β) (213), although these studies 
have used populations where non-smokers were a small minority.   
Data obtained from the first case-control study conducted in 1995-1998 have been 
previously published and showed that among never-smokers, parity and menstrual cycle 
length were associated with a significantly reduced risk of lung cancer (191). The aims of 
Study 3 are to extend this analysis to a larger group of 702 cases and 1578 hospital 
controls so as to better delineate possible differences between smokers and never-
smokers, and to investigate the association of estrogen metabolism gene 








In both case-control studies, the age at menarche, age at menopause, usual length of 
menstrual cycles, the number of children, and the age at first birth were elicited from 
participants via the in-person questionnaire. Among post-menopausal women, the 
reproductive period was calculated as the period of time between menopause and 
menarche. In the second case-control study, participants were also asked about the use 
of hormone replacement therapy and oral contraceptives – the age when use 
commenced and the period of use were obtained.  
Five polymorphisms in four estrogen pathway genes (rs743572 in CYP17, rs10046 in 
CYP19A1, rs4680 in COMT, rs1256049 and rs4986938 in ERβ) were genotyped. These 
genes were selected because the proteins they encode are important within the 
estrogen pathway. CYP17 is an upstream enzyme that produces estrogen precursors, 
while CYP19A1 converts testosterone to estradiol. COMT is the rate-limiting enzyme in 
the detoxification of catechol estrogens (214). ERβ are found in lung tissue (184).  
A total of 559 blood or saliva samples from cases (79.6% of all cases) and 988 blood or 
saliva samples from controls (62.6% of all controls) were obtained. Among 131 subjects 
having both blood and saliva samples, saliva DNA from 89% was successfully 
genotyped while all blood DNA were successfully genotyped. The genotypes from saliva 
DNA samples matched completely (100%) those of the corresponding blood DNA 
samples.  Three positive controls and two negative controls were included in each 96-
well plate, and 10% of DNA samples were genotyped in duplicate for each 
polymorphism. The concordance rate for the duplicate analyses was 100%. Call rates for 






Participants from both GEL studies were used. In total, there were 702 cases and 1578 
controls. A total of 559 blood or saliva samples that were obtained from cases (79.6% of 
all cases) and 988 blood or saliva samples from controls (62.6% of all controls) were 
used for genetic analyses.   
High parity was associated with a lower risk of lung cancer in never-smokers (OR of 
0.92, 95% CI 0.87, 0.97 for every additional child). Similar ORs, but with non-significant 
P values, were obtained in the smaller number of ever-smokers (Table 7.1). Higher age 
at first birth was positively associated with lung cancer in never-smokers (ORs 1.54, 
2.17, 1.30 in those whose first child was born when they were 21-25, 26-30 and 31 years 
and above respectively, compared to those 20 years or fewer at first birth.) The effect 
was less clear among ever-smokers (adjusted Pinteraction 0.14) (Table 7.1). 
Among never-smoking post-menopausal women, age at menopause was positively 
associated with lung cancer (ORs 1.37, 1.59 for age at menopause of 49-51 years and 
52 years or older, compared to an age of menopause at 48 years or younger, Ptrend 
0.003), but not among ever-smoking women (ORs 0.95, 0.94, respectively, Ptrend 0.81), 
adjusted Pinteraction 0.22 (Table 7.1).  Similarly, a longer reproductive period was positively 
associated with lung cancer risk among never smokers (ORs 1.06, 1.25, 1.45 and 1.47 
for reproductive periods of 31-33, 34-36, 37-39, and 40 years and more respectively, 
compared to those with a reproductive period of 30 years or fewer, Ptrend 0.026) but not 
in ever-smokers (adjusted Pinteraction 0.34) (Table 7.1).  
Long menstrual cycle lengths were inversely associated with lung cancer in never-





Table 7.1 Reproductive factors, exogenous reproductive hormone use and lung cancer 
 
 All Never-smokers Ever-smokers            
 Cases Controls ORa 95% CI Cases Controls ORb 95% CI Cases Controls ORc 95% CI 









1.0  33 
(12.3) 































46 (22.7) 0.89  0.42, 
1.86 














95 (46.8) 0.54 0.27, 
1.09 
Ptrend   0.001    0.006    0.038  




  0.93  0.90, 
0.98 
P=0.002 
  0.92  0.87, 
0.97 
P=0.002 




Age at first birth (years)d 
No children 87 176 -  54 153 -  33 23   








1.0  83 
(35.8) 































24 (13.5) 0.86  0.40, 
1.85 












14 (7.9) 1.32  0.51, 
3.42 




  1.01 0.98, 
1.03 
P=0.58 
  1.01 0.98, 
1.04 
P=0.63 








Reproductive Period (years) 
Pre-
menopausal 
45 129 -  37 118 -  8 11 -  








1.0  65 
(26.8) 
44 (25.1) 1.0  














































33 (18.9) 0.73 0.37, 
1.41 















20 (11.4) 0.86  0.40, 
1.85 
Ptrend   0.11    0.026    0.54  




  1.02  1.00, 
1.04 
P=0.13 
  1.02  1.00, 
1.05 
P=0.071 















1.0  29 
(11.3) 
30 (15.2) 1.0  















95 (48.0) 0.92  0.47, 
1.82 
















73 (36.9) 1.11  0.54, 
2.28 




  1.02  0.97, 
1.08 
P=0.38 
  1.01  0.95, 
1.07 
P=0.74 










aAdjusted for age at diagnosis, fruit and vegetable consumption (in servings/week), country of origin, dwelling type, years of education, history of cancer in first degree relatives (no 




45 129 -  37 118 -  8 11 -  











1.0  109 
(44.0) 

















59 (33.3) 0.95  0.59, 
1.54 
52 years of 















43 (24.3) 0.94  0.55, 
1.60 
Ptrend   0.027    0.003    0.81  




  1.02  1.00, 
1.04 
P=0.053 
  1.03  1.00, 
1.05 
P=0.036 




Menstrual cycle length 

















44 (6.5) 159 
(10.3) 










19 (9.6) 0.73  0.35, 
1.49 
Likelihood Ratio test for interaction between smoking status and menstrual cycle length P=0.22;(adjusted for multiple comparisons, P=0.33) 
 
Exogenous reproductive hormone use 








1.0  116 
(82.3) 
73 (70.9) 1.0  
Used for 5 















20 (19.4) 0.54  0.24, 
1.21 
Used for 
more than 5 
years 




45 (6.3) 1.23  0.68, 
2.23 
6 (4.3) 10 (9.7) 0.45  0.13, 
1.55 





bAdjusted for age at diagnosis, fruit and vegetable consumption (in servings/week), country of origin, dwelling type, years of education, history of cancer in first degree relatives (no 
history, history of other cancers, history of lung cancer), environmental tobacco exposure at home and a dummy variable for the study set 
cAdjusted for age at diagnosis, fruit and vegetable consumption (in servings/week), country of origin, dwelling type, years of education, history of cancer in first degree relatives (no 
history, history of other cancers, history of lung cancer), smoking duration (in years), environmental tobacco exposure at home and a dummy variable for the study set 







days, compared to those reporting lengths of 30 days or fewer) but not in ever-smokers 
(adjusted Pinteraction 0.33). There were relatively few women who reported cycle lengths 
longer than 30 days. There was no association between hormone use and lung cancer, 
although the prevalence of hormone use was low. There was also no association 
between age at menarche and lung cancer (Table 7.1). 
Of the five SNPs studied, only the SNP in the COMT gene was associated with lung 
cancer (Table 7.2). The A allele at rs4680 was associated with lung cancer in never-
smokers (OR 1.46, 95%CI 1.12, 1.90 for G/A or A/A genotypes, compared to G/G 
genotype) but not in ever-smokers (OR 0.77, 95%CI 0.47, 1.28), adjusted Pinteraction 0.14.  
In analyses stratified by age, the positive association of longer reproductive periods in 
never-smokers was seen only among those older than 65 years, but not in the younger 
age-group (adjusted Pinteraction 0.22). The inverse association of increasing parity also 
appeared to be stronger in the older age-group than the younger, although this 
interaction was not statistically significant (adjusted Pinteraction 0.95) (Table 7.3). The 
associations of age at menopause, age at first birth, menstrual cycle length and the 
rs4680 polymorphism on COMT with lung cancer were not modified by age (data not 
shown).  Odds ratio estimates for never-smoker cases restricted to those with a 
confirmed histology of adenocarcinomas were similar to those obtained for all never-
smokers (data not shown). Further adjustment with self-reports of exposure to cooking 
fumes shifted odds ratio estimates of all reproductive factors and SNPs on lung cancer 






Table 7.2 Polymorphisms in the estrogen pathway and lung cancer 
 All Never-smokers Smokers 






1.0  102 (29.7) 299 
(35.3) 























36 (17.7) 15 (12.8) 1.30 0.59, 
2.86 
G/A or A/A     1.21  0.95, 
1.55 
  1.26  0.95, 
1.68 
  1.21 0.72, 
2.04 
 





1.0  90 (26.5) 222 
(26.4) 























52 (25.5) 28 (23.9) 1.02 0.48, 
2.16 
A/G or A/A   0.95 0.73, 
1.24 
  1.01 0.75, 
1.36 








1.0  167 (49.1) 488 
(57.6) 
1.0  117 
(57.6) 















63 (6.5) 1.33 0.85, 
2.08 
25 (7.4) 56 (6.6) 1.30 0.77, 
2.19 
14 (6.9) 7 (5.9) 1.28  0.46, 
3.55 
G/A or A/A   1.27  1.01, 
1.60 
  1.46 1.12, 
1.90 
  0.77  0.47. 
1.28 







1.0  135 (39.7) 320 
(38.2) 









1.00  0.78, 
1.28 
















32 (15.8) 15 (12.9) 1.02  0.46, 
2.26 
G/A or A/A   1.00 0.79, 
1.27 
  0.91 0.70, 
1.20 








1.0  277 (81.5) 704 
(83.2) 









1.17  0.87, 
1.59 




34 (16.7) 14 (11.9) 1.36  0.66, 
2.78 
A/A 3 (0.6) 9 (0.9) 2 (0.6) 8 (1.0) 1 (0.5) 1 (0.9) 
 
aAdjusted for age at diagnosis, fruit and vegetable consumption (in servings/week), country of origin, dwelling type, years of education, history of cancer in first degree relatives (no 
history, history of other cancers, history of lung cancer), smoking status (current, ex- or never smoker), environmental tobacco exposure at home and a dummy variable for the study 
set 
bAdjusted for age at diagnosis, fruit and vegetable consumption (in servings/week), country of origin, dwelling type, years of education, history of cancer in first degree relatives (no 
history, history of other cancers, history of lung cancer), environmental tobacco exposure at home and a dummy variable for the study set 
cAdjusted for age at diagnosis, fruit and vegetable consumption (in servings/week), country of origin, dwelling type, years of education, history of cancer in first degree relatives (no 





Table 7.3 Selected reproductive factors and lung cancer, by age-group 
 
 
 All Never-smokers 
 Age 65 or lower Age >65 Age 65 or lower Age >65 
Cases/Controls  
(Nos) 
311/801 391/777 243/725 190/650 
 ORa 95%CI ORa 95%CI ORb 95%CI ORb 95%CI 
Reproductive 
period (years) 
        
30 or less     1.0  1.0  
31-33      0.60 0.31, 
1.18 
1.77  0.98, 
3.19 




37-39     0.94 0.54, 
1.64 
2.24  1.24, 
4.04 
40 and more     0.82  0.44, 
1.54 
2.66  1.41, 
5.00 
Ptrend     0.99  0.001  
As continuous 
variable 
    0.99  0.96, 
1.03, 
P=0.77 
1.05  1.01, 
1.09 
P=0.005 
     Likelihood ratio test for interaction 









        
0 1.0  1.0      
1-2 1.25  0.82, 
1.90 
0.84  0.46, 
1.51 
    




    
5 or more 0.76 0.42, 
1.38 
0.50  0.30, 
0.84 
    
Ptrend 0.22  0.001      
As continuous 
variable 
0.96  0.88, 
1.04 
P=0.32 
0.92  0.88, 
0.97 
P=0.002 
    
 Likelihood ratio test for interaction P=0.65 
(adjusted for multiple comparisons P 
=0.95) 
    
 
a Adjusted for age at diagnosis, fruit and vegetable consumption (in servings/week), country of origin, dwelling type, years of education, history of cancer in first degree relatives (no 
history, history of other cancers, history of lung cancer), smoking status, environmental tobacco exposure at home and a dummy variable for the study set 
b Adjusted for age at diagnosis, fruit and vegetable consumption (in servings/week), country of origin, dwelling type, years of education, history of cancer in first degree relatives (no 







In this ethnically homogenous population with a high prevalence of never-smokers, later 
age at menopause, longer reproductive period, later age at first birth, short menstrual 
cycle lengths and low parity are associated with lung cancer, particularly among never-
smokers. Low parity is associated with higher blood estrogen levels (215). Shorter 
menstrual cycles suggest an overall increase in the period of unopposed estrogen 
exposure, and late menopause and long reproductive periods imply more reproductive 
cycles over the lifetime and hence longer periods of estrogen exposure in total. Our 
results are therefore consistent with an association between higher levels of 
endogenous estrogen exposure over the lifetime and risk of lung cancer.  
An association with reproductive history was previously observed in our first study 
involving a smaller group of participants (191), where high parity and long menstrual 
cycles were protective. This current analysis additionally finds an increased risk 
associated with later ages at first birth, later age at menopause, and longer reproductive 
period. A recently-published Singapore cohort study (189) reported similar inverse 
associations for parity among Chinese women never-smokers; although it did not find a 
significant association with age at menopause (189). While we are not able to fully 
explain this particular difference, we feel that, taken as a whole, data from this 
population suggest a role for estrogens in lung carcinogenesis among never-smoking 
women.   
Other published studies have reported results similar to ours- namely an inverse 
association with higher parity (189, 191, 200, 202, 203), and positive association with 
higher age at menopause (108, 181, 182). A cohort study (47) did not find a main effect 





menarche (>15 yrs) and early age of menopause (<51 years), women with either early 
menarche or late menopause had a higher risk of lung cancer, and proposed that the 
length of exposure to estrogen may partly account for the increased risk. 
Yet other studies, however, have reported null findings (46, 47, 108, 182, 192, 194, 196-
198, 211) or increased risk (195, 199) with regard to parity, reduced risk with later age at 
menopause (192, 193, 200, 211), and inverse associations with longer reproductive 
period (200).  
The inconsistency in findings across the various studies may be due to differences in the 
study populations. Studies conducted on smokers or populations containing a high 
proportion of smokers might not have been able to detect a weaker effect of estrogens. 
There is growing evidence that smoking-related lung cancer and never-smoker lung 
cancer are etiologically distinct. It is plausible that the effect of estrogens may 
specifically affect never-smoker lung cancer, given that EGFR mutations appear to be 
key drivers of this disease (61), and the estrogen pathway interacts at the cellular level 
with the EGFR signaling pathway (186). A recent Japanese case-control study noted 
that the increased risk associated with longer reproductive periods was seen only in 
EGFR mutation positive cancers (198). 
The effect of estrogen may be modified by other biological factors. For example, Paulus 
et al (202) proposed that the different age distributions of women in the studies may 
explain the inconsistency of results with regard to parity, and their own data suggest that 
the effect of parity was seen only in late-onset lung cancer (using a cut-off of 50 years), 
thus suggesting that high parity may protect against post-menopausal lung cancer, but 





parity had more convincing effects in older women, although the possible reasons for 
this are yet to be elucidated.  
We did not find an association with key polymorphisms in the estrogen metabolism 
pathway, other than the rs4680 polymorphism in the COMT gene, where the A allele 
was associated with lung cancer in never-smokers. The oxidative metabolism of 17-β 
estradiol and estrone to catechol estrogens is postulated to be a risk factor in 
carcinogenesis: catechol estrogens are oxidized to quinines that can form DNA adducts 
and produce DNA and lipid-damaging reactive oxygen species (214). COMT methylates 
(thus eliminating) catechol estrogens, and is the key rate-limiting enzyme in that pathway 
(214). The A allele at rs4680 (codon 158) results in a point mutation, substituting the 
amino acid methionine for valine (216). Val/Met and Met/Met genotypes appear to have 
lowered enzymatic activity, with consequently increased cellular levels of catechol 
estrogens.  
Two other case-control studies have investigated the effect of polymorphisms at this site 
on lung cancer risk with similar results. The Met/Met or Val/Met genotypes were also 
positively associated with lung cancer in a population of smokers (217). Cote et al (212), 
found that the A allele had no independent effect in a group of predominantly smokers, 
but lung cancer was increased among those with the A allele and a GSTM1 null 
genotype compared to those with the G/G genotype and a GSTM1 non-null genotype. In 
that same study, an independent effect of rs743572 (in CYP17) on lung cancer was not 
seen, although a positive association as seen with the C allele in combination with risk 
alleles in GSTM1 and GSTT1. The authors did not find a relationship with CYP19A1 and 
lung cancer, although the polymorphism they studied (the tetranucleotide tandem repeat 





ERβ SNPs (the same two in our study, and two others), did not find an association of 
individual SNPs nor haplotypes with lung cancer risk, consistent with our results.  
We had anticipated that polymorphisms in CYP19A1 and CYP17 would be important if 
the effect of reproductive factors is mediated through estrogen levels in target tissue 
(such as the lungs). Current evidence, including ours, however, is more consistent with a 
risk-conferring effect of catechol estrogens on lung carcinogenesis. There have been 
few studies looking at estrogen pathway polymorphisms in lung carcinogenesis, and 
further work is necessary to determine if this hypothesis is true. Inclusion of more SNPs 
for which functional studies indicate an effect on enzyme activity or estrogen levels, or a 
systematic interrogation of polymorphisms in the CYP19A1, CYP 17 and COMT genes 
for association with lung cancer may be useful in this regard.   
We noticed suggestive interactions between smoking status, and the COMT SNP and 
age at first birth, and between age and reproductive period among never-smokers. 
However, our study is not adequately powered to detect interactions, and the 
interactions were no longer significant after adjustment for multiple testing. Further 
research using larger study populations are needed to confirm these observations.  
Homogeneity with regard to gender and ethnicity and the large number of never-
smokers which allows detailed investigation into risk factors pertinent to this group are 
particularly important in this analysis, in the light of recent understanding that smoking 
and non-smoking lung cancers may be different diseases.  To reduce bias introduced by 
use of hospital controls, we chose controls from a wide variety of admitting diagnoses, 
and gynaecological diseases as the admitting diagnoses were very rare among our 





Our study suggests that reproductive factors are involved in lung carcinogenesis, 
particularly among never-smokers. However, the specific functional role of estrogens in 
lung cancer is still not known, and while our data suggests a role for catechol estrogens, 
the mechanisms involved are likely to be complex. Given the relationship between the 
estrogen and the EGFR pathways, and the significance of the latter in never-smoker 
lung cancer, it is clear that further studies, both mechanistic and epidemiologic, are 
needed in this area.   
 
This study has been published (Lim WY, et al., American Journal of Epidemiology 2012; 







CHAPTER 8 STUDY 4 - EXPOSURE TO INDOOR INHALANTS AND LUNG CANCER 
Introduction 
Fumes and airborne particulates in the indoor environment are potential risk factors for 
lung cancer: examples are exposure to cooking oil fumes, cooking and heating fuels 
(household coal & wood combustion), incense & mosquito coils and indoor radon (31, 
32, 218, 219). 
 Exposure to cooking fumes may potentially play a role in the occurrence of lung cancer. 
Cooking oil fumes are known to contain at least two carcinogenic compounds, 
benzo[a]pyrene (BaP) and 2, 4-decadienal (2, 4-DDE), which induce lung cell survival 
and proliferation via the NF-κB pathway (220, 221). Cumulative exposure to cooking 
(frequency and duration) by means of frying (stir-frying, frying and deep-frying) increased 
the risk of lung cancer among female non-smokers in Hong Kong (32). Women 
nonsmokers were at higher risk for lung cancer if they were exposed to cooking oil 
fumes emitted at high temperatures and the risks were higher when the fumes were not 
reduced by an extractor (31).  
 The combustion by-products from heating and cooking are also sources of indoor air 
pollution. The use of coal for heating has been implicated in the high incidence of lung 
cancer among residents of Xuanwei, China (222), and the International Agency for 
Research in Cancer considers coal fuel use a Class 1 carcinogen (27). Recent results 
from a pooled analysis of 4181 cases and 5125 controls (223) found an increased risk 
with wood smoke exposure OR 1.21, 95%CI 1.06-1.38 among individuals from Europe 
and North America who reported predominant use of wood fuels in the house.  No effect 





use was risk-conferring in ever-smokers (OR 1.22, 95%CI 1.05-1.42). Traditional heating 
and cooking fuels (coal & wood) produce a variety of indoor pollutants, including 
respirable particles, heavy metals, polycyclic aromatic hydrocarbons, carbon monoxide, 
carbon dioxide, nitrogen dioxide, sulphur dioxide, and formaldehyde (219).   
Incense burning, a traditional practice in Chinese households, is also powerful producer 
of particulate matter; and incense smoke contains carcinogens such as polycyclic 
aromatic hydrocarbons (PAHs), carbonyls, and benzene (30, 224, 225). Incense smoke 
condensates have mutagenic and genotoxic activities, and the genotoxicity of certain 
incense smoke condensates in mammalian cells has been shown to be higher than that 
of tobacco smoke condensate (226, 227). The potential impact of incense on health has 
also been studied outside the home (228, 229). A large prospective cohort study in 
Singapore reported an association between long-term incense use and the development 
of squamous cell carcinomas of the respiratory tract, particularly among women (33).   
 Mosquito coils are frequently burned indoors in Asia and to a limited extent in other 
parts of the world, including the United States (230). The major ingredients of the 
mosquito coils are pyrethrins and plant-based materials, such as wood powder, coconut 
shell powder, joss powder, binders, dyes, oxidants, and other additives to allow for 
controlled smoldering (34, 231). The combustion of the remaining materials generates 
large amounts of submicrometer particles and gaseous pollutants. These submicrometer 
particles may reach the lower respiratory tract and be coated with a wide range of 
organic compounds such as polycyclic aromatic hydrocarbons (PAHs). A study of 
mosquito coil smoke and lung cancer in Taiwan between 2002 and 2004 showed that 
lung cancer risk among smokers with the highest exposure to mosquito coil smoke could 





In Study 4, we investigate if inhalant exposure from these sources is associated with 
lung cancer. We also predict that the impact of these compounds is modified by tobacco 
smoke exposure, and hypothesize that the effect of domestic inhalants is greater in 
never-smokers than in smokers where the effect may be masked by the more significant 
impact of cigarette smoking.  
Methods 
Participants were asked to recall exposures to domestic inhalants at 25 years prior to the 
diagnosis of lung cancer (for cases) or the current admission (for controls). They were 
asked about regular household cooking and the frequency which they cooked, the use of 
wood stove and charcoal stove, the use of joss sticks and scented coil/ powder, and the 
use of mosquito coils in their homes. In total, data from 702 cases and 1578 controls 
were analysed.  
Results 
Table 8.1 presents the effect of exposure to incense or mosquito coils, as well as 
cooking, on lung cancer separately for smokers and nonsmokers. A statistically 
significant positive relationship was observed only among smokers, and there was no 
association observed among lifetime nonsmokers. Among smokers, daily cooking was 
positively associated with lung cancer (adjusted OR 1.61, 95% CI 1.01-2.56), Also, 
among smokers, daily exposure to incense or mosquito coils was also positively 
associated with lung cancer (OR 1.53, 95% CI 0.97-2.41), after adjustment for potential 
confounders, although this result just missed the traditionally accepted level of 
significance of P<0.05. Daily use of charcoal or wood stove did not result in an 





Table 8.1 Adjusted ORs and 95% CIs for lung cancer by cooking, incense or 






 Nonsmokers  
 No. of 
cases/controls OR(95% CI)
1 No. of cases/controls OR(95% CI)
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1 Adjusted for age (years), education(years), housing type, environmental tobacco exposure (daily vs less than daily 
exposure), history of cancer in the first degree relative, duration of smoking (in yrs), intake of fruit and vegetable 
(servings/week) and a dummy variable indicating the study to which the participant belonged, by logistic regression 
analysis. 
2 Adjusted for age (years), education(years), housing type, environmental tobacco exposure (daily vs less than daily 
exposure), history of cancer in the first degree relative, intake of fruit and vegetable (servings/week) and a dummy 









There was a statistically significant interaction between smoking and exposure to 
incense or mosquito coils (P=0.016) or frequency of cooking (P<0.001), respectively, 
after adjustment for potential confounders (Table 8.2). Relative to nonsmokers without 
daily incense or mosquito coils exposure, smokers without exposure had a two and a 
half-fold increase in risk (OR 2.80, 95% CI 1.86-4.21) and those with daily exposure had 
a four-fold (OR 4.61, 95% CI 3.41-6.24) increase in risk. The same pattern of risk was 
observed for daily cooking exposure (OR 2.31, 95% CI 1.52-3.51; OR 4.50, 95% CI 
3.21-6.30), and for wood stove use, although the latter was not statistically significant 
(P=0.061). There was no interaction between smoking and daily use of charcoal (P= 
0.128). 
Discussion 
We evaluated the effects of cooking and exposure to burning of incense and mosquito 
coils on lung cancer risk among Singapore Chinese women, and their modification by 
tobacco smoking exposure. We observed strong interactions between exposure to these 
sources, and smoking on lung cancer risk. The results indicate that tobacco exposure is 
not only an important risk factor for development of lung cancer, but smokers are also 
more susceptible to the risk-enhancing effect of these inhalants on lung cancer.  
A possible explanation for our findings is the presence of a chronic inflammatory state in 
the airways induced by smoking. Tobacco smoke carcinogens are known to activate pro-
inflammatory responses through the action of pro-oxidative chemicals, leading to the 
release of cytokines, production of reactive oxygen species (ROS) and ultimately to DNA 
damage (232, 233). A chronic inflammatory process in the lung could also lead directly to 
DNA damage, enhance the effects of other carcinogenic exposures and stimulate cell 





Table 8.2 Combined effects of indoor inhalants and tobacco smoke exposure on 
lung cancer risk  


























Daily Current or ex-smokers 
 
340 4.50(3.21-6.30) 
Pinteraction2 < 0.001 
 

























Daily Current or ex-smokers 
 
345 4.61(3.41-6.24) 
Pinteraction2 = 0.016 
 

























Daily Current or ex-smokers 
 
51 4.88(2.68-8.91) 
Pinteraction2 = 0.128 
 


































1 Adjusted for age (years), education(years), housing type, environmental tobacco exposure (daily vs less 
than daily exposure), history of cancer in the first degree relative, intake of fruit and vegetable 
(servings/week) and a dummy variable indicating the study to which the participant belonged, by logistic 
regression analysis. 
2 P for the Likelihood Ratio test for interaction between smoking and cooking, incense or mosquito coils, 







concentrations of reactive oxygen species (ROS) in the particulate gas phase of the 
emissions, and might damage DNA and other biomolecules when inhaled (235). 
Our findings that risk among nonsmokers is not significantly increased by these 
exposures are at variance with other studies which have reported a positive association 
in this group. The odds ratio for female nonsmokers cooking three meals/day compared 
with those cooking one meal/day was 3.4 (95%CI, 1.6-7.0) in a study conducted in 
Taiwan (31). In the study among women in Taiwan, higher frequency of mosquito coil 
smoke use enhanced risk of lung cancer in both smokers and nonsmokers, although the 
interaction with cigarette smoke was, as in the current study, synergistic (34). 
Differences in cooking practices, use of fume extractors, type and intensity of use of 
mosquito coils, or simply in the average amount of time spent at home may contribute to 
the difference in findings between studies, even within Chinese populations. The 
proportion of women who had never been employed outside the home in our study was 
only 22% among controls, suggesting, overall, exposure to air pollutants in the domestic 
environment may be less substantial than in more traditional societies.  
Contrary to previous reports, we did not find an association between use of charcoal or 
wood stove and lung cancer risk, among both smokers and nonsmokers. Local residents 
infrequently use traditional fuels (charcoal or wood), and usually use modern fuels (gas, 
kerosene or electricity) for cooking in Singapore, and the low frequency of use may be 
the chief explanation for our findings. Recall and reporting bias, if present, would shift 
the association towards the null, as they would likely affect both cases and controls to 
the same extent.  
We had hypothesized that cooking and exposure to domestic inhalants such as burning 





effects would be stronger in never-smokers than in smokers, in whom the stronger effect 
of smoking might mask the effects due to these exposures. In contrast, the interaction 
between exposure to these sources and smoking on lung cancer risk was different to 
that expected, in which these exposures were associated with lung cancer only in the 
presence of smoking, and did not have an effect on never-smokers. Our study suggests 
that tobacco exposure is not only an important risk factor for development of lung 
cancer, but that smokers are more susceptible to the risk-enhancing effects of other 
inhalants. A possible mechanism consistent with recent findings is the presence of a 
chronic inflammatory state in the airways induced by smoking (14). The interaction 
observed is supportive of a model in which host susceptibility acts in concert with the 
exposures of interest to promote lung carcinogenesis. On the other hand, we did not find 
any evidence that these specific exposures contribute to increased risk of lung cancer 
among nonsmokers. As these are fairly common exposures in the indoor environment, it 
is important that smokers are aware of the significant additional risk afforded by these 
exposures. Further research is needed to establish more definitively the level of risk from 
these ubiquitous compounds in the domestic environment.   
 
This research has been published (Tang L, et al. Environmental Health Perspectives 







CHAPTER 9 STUDY 5 – MEAT CONSUMPTION AND LUNG CANCER 
Introduction 
Dietary factors are likely to influence risk in never-smokers (28). While current evidence 
suggests that fruits and vegetables protect against the development of lung cancer, the 
role of meat and meat components such as saturated fats and cholesterol is less well-
established (236-245). Some studies have found a protective effect (243) while others 
have found no effect (240-242, 245) or an increased risk (239, 244). The majority of 
studies have been conducted in European populations, where red meat comprised a 
large proportion of total meat consumed. The effect of meat on lung cancer is 
complicated for a few reasons: red and white meat may vary in their effects. Cooking 
methods may also be important. Well-done red meat has been associated with an 
increased risk of lung cancer (36), a finding which has been attributed to the presence of 
heterocyclic amines (HCAs), which are produced when meats are cooked at high 
temperatures (246). HCAs are mutagenic in vitro (247), and have been shown to 
produce tumors in rodents (248), and to increase risk in population-based studies (37, 
249, 250).  
Few studies have included sufficient numbers of never-smokers to be able to identify 
small effects of meat and meat components in this group and most results have been 
reported in studies where cases were primarily smokers. It is hence not known whether 
effects differ substantially between smokers and non-smokers. 
Dietary patterns in Singapore differ substantially from those in western countries (251). 
Among the Chinese, fish represents a high proportion of meat consumed, and chicken 





like mutton and lamb are rarely consumed.  Cooking methods in the Chinese population 
are also distinct from those in the west, with boiling, steaming, stewing and wok-frying 
being common methods of meat cooking, while grilling and deep-frying are much less 
common. As a consequence, meat cooking methods among the Chinese population in 
Singapore appear to generate much lower levels of dietary HCA compared to common 
cooking methods in the West (252).The relationship of meat consumption to lung cancer 
risk among the Chinese may therefore differ from that found in Western populations, and 
is not well-delineated in the literature. 
In Study 5, we explore the effect of self-reported fresh and processed meat, and 
evaluate HCA exposure on lung cancer risk.  
Methods 
Data for this analysis were obtained from the second case-control study, comprising 399 
cases and 815 controls.  
Information on usual dietary intake of commonly available fruit (17 items), vegetables (21 
items), soy products (10 items) and meats (18 items) was obtained via a semi-
quantitative food frequency questionnaire.  Consumption of the 6 common meat groups 
(fish, chicken, pork, duck, squid & prawns and beef) was elicited. For each meat type, 
participants indicated their consumption frequency (number of times per week) and 
portion size. Portion size was elicited as multiples of a standard serving specific to each 
food item. A standard serving was defined and weights of portion sizes calculated from a 
pilot study among a group of middle-aged and older Chinese women. Pictures of food 





multiplied to define the number of standard servings per week. Consumption of each 
food item was then categorized in tertiles (based on the distribution among controls).  
 The questionnaire also elicited information on cooking methods for nine selected meat-
cooking method combinations (e.g. pan-fried fish, pan fried chicken, roasted pork) and 
on the consumption of processed meats (bacon, ham, luncheon meat, sausages and 
Chinese sausages).  The concentrations of 5 different heterocyclic amines (HCAs) had 
been previously determined in 25 commonly consumed and available meat items in 
Singapore (252). Five food items were found to have relatively high heterocyclic amine 
concentrations and were commonly consumed in our population (pan-fried fish, deep-
fried chicken, pan-fried chicken, grilled/roasted pork and pan-fried pork). We used the 
estimates of HCA concentration for each food item obtained from our previous study 
(252) to derive an estimate for the usual weekly intake of HCAs (in nanogrammes) in our 
participants. We investigated the effects of 3 HCAs – PhIP (2-amino-1-methyl-6-
phenylimidazo[4,5-b]pyridine), MeIQx (2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline, 
4,8-DiMeIQx (2-amino-3,4,8-trimethlimidazo[4,5-f]quinoxaline, as well as total HCA 
consumption. 
Results 
Table 9.1 describes the association between dietary factors and lung cancer. High 
consumption of fruits was inversely associated with lung cancer, with an odds ratio of 
0.38 (Ptrend< .001) in the highest tertile compared to the lowest. Consumption of 
vegetables was also inversely associated, with an odds ratio of 0.57 (Ptrend = .005) in the 
highest tertile compared to the lowest, as were cruciferous vegetables (ORs 1.19, 0.65 





Overall, meat consumption was inversely associated with lung cancer in this study 
population, with an odds ratio of 0.84 and 0.57 in the 2nd and 3rd tertiles respectively 
compared to the 1st tertile (Ptrend= .001). Among controls, fish comprised 50% of the meat 
consumed by servings, pork 19% and chicken 24%. Duck, prawns and squid were not 
commonly consumed (with median consumption of only 1 serving a week). Beef was 
very rarely consumed, with about 80% of the study population reporting no consumption 
(data not shown).  
We observed a strong inverse relationship between fish consumption and risk of lung 
cancer in non-smokers (odds ratio, 0.75, 0.45 for 2nd and 3rd tertiles of fish consumption 
respectively, Ptrend < .001). We further examined the effect of fish by quintiles of intake. 
The inverse association was seen only in the 4th and 5th quintiles of fish consumption 
(Figure 9.1). These two quintiles were equivalent to consumption at 7.5-15 servings of 
fish per week, and more than 15 servings per week, respectively. Chicken and pork 
consumption had no significant effect on risk of lung cancer.  
Overall, processed meats were not associated with lung cancer risk (ORs 0.97, 0.76, 
Ptrend 0.17).   Of the various constituents comprising processed meats, bacon increased 
lung cancer risk (OR 1.51, 95% CI 1.07-2.15, compared to participants who do not 
consume bacon). Ham, luncheon meat, sausages and Chinese sausages were not 
associated with lung cancer (Table 9.2). None of the 3 HCAs examined (PhIP, MelQx 






Table 9.1 Fruit, vegetable and meat consumption and risk of lung cancer in 










Fruits2     
     1st tertile  
     (<3.88) 
97 (37.6) 226 (31.7) 1.0 
     2nd tertile 
     (>3.87-11.02) 
108 (41.9) 246 (34.6) 0.86 (0.61,1.21) 
     3rd tertile  
     (>11.02) 
53 (20.5) 240 (33.7) 0.38 (0.25,0.58) 
     Ptrend   <0.001 
    
Vegetables3     
     1st tertile  
     (<11.88) 
103 (39.9) 233 (32.7) 1.0 
     2nd tertile 
     (>11.87-24.00) 
88 (34.1) 236 (33.2) 0.77 (0.54,1.10) 
     3rd tertile  
     (>24.00) 
67 (26.0) 243 (34.1) 0.57 (0.40,0.83) 
     Ptrend   0.003 






     1st tertile 
     (<5.61) 
83 (32.2) 232 (32.6) 1.0 
     2nd tertile  
     (>5.60-12.00) 
110 (42.6) 241 (33.9) 1.19 (0.84,1.69) 
     3rd tertile 
     (>12.00) 
65 (25.2) 239 (33.6) 0.65 (0.44,0.96) 
     Ptrend   0.035 
    
                                                          
1 Adjusted for age, history of cancer in 1st degree relative, country of origin , dwelling type, years of education, and fruit & 
vegetable intake (only for meat variables) 
2 Summed weekly consumption of: banana; papaya; apple; orange or mandarin orange; pineapple; watermelon; mango; 
starfruit; jackfruit; plum; cantaloupe/rock melon; dried prunes; fresh fruit juice; canned peaches; pear; Chinese pear; grape 
3 Summed weekly consumption of: wong-nga-pak; pak choy (Chinese cabbage); kai lan (Chinese kale); head cabbage; 
cauliflower; kai choy; choy sum; sai yong choy (watercress); broccoli; kang kong (water convolvulus); por choy (spinach); 
sang choy (Chinese lettuce); tomatoes; french beans; long beans; snow peas; ladies’ fingers (okra); red carrot and sweet 
potato 
4 Cruciferous vegetables – wong-nga-pak; pak choy (Chinese cabbage); kai lan (Chinese kale); head cabbage; 





Total meats5     
     1st tertile  
     (<9.70) 
103 (40.1) 232 (32.9) 1.0 
     2nd tertile 
     (9.70-19.60) 
93 (36.2) 238 (33.7) 0.84 (0.59,1.20) 
     3rd tertile  
     (>19.60) 
61 (23.7) 236 (33.4) 0.57 (0.39,0.86) 
     Ptrend   0.007 
    
Fish    
     1st tertile   
     (<2.51) 
112 (43.4) 231 (32.4) 1.0 
     2nd tertile 
     (>2.50-10.00) 
100 (38.8) 265 (37.2) 0.75 (0.53,1.05) 
     3rd tertile  
     (>10.00) 
46 (17.8) 216 (30.3) 0.45 (0.29,0.68) 
     P trend   <0.001 
    
Chicken    
     1st tertile  
     (<1.01) 
125 (48.5) 358 (50.3) 1.0 
     2nd tertile 
     (>1.00-2.50) 
49 (19.0) 132 (18.5) 1.03 (0.68,1.54) 
     3rd tertile  
     (>2.50) 
84 (32.6) 222(31.2) 0.99 (0.69,1.42) 
     P trend   0.96 
    
Pork    
     1st tertile  
     (<1.01) 
106 (41.1) 323 (45.5) 1.0 
     2nd tertile 
     (>1.00-2.50) 
68 (26.4) 176 (24.8) 1.09 (0.75,1.58) 
     3rd tertile  
     (>2.50) 
84 (32.6) 211 (29.7) 1.15 (0.81,1.63) 
    P trend   0.43 
 
  
                                                          





Figure 9.1 Odds ratios and the 95% confidence intervals of the association of fish 
consumption with lung cancer among Chinese female never smokers, by quintile 
of consumption,  
 
 
*Adjusted for age, history of cancer in first-degree relative, country of origin, dwelling type, yr of education, 






Table 9.2 Consumption of processed meats and risk of lung cancer in never-
smoking Chinese women 
Servings/ 
week 





Processed meats7     
     1st tertile  
     (<0.30) 
73 (28.6) 192 (27.2) 1.0 
     2nd tertile  
     (0.30-<0.70) 
100 (39.2) 263 (37.3) 0.97 (0.67,1.40) 
     3rd tertile 
     (>0.69) 
82 (32.2) 251 (35.6) 0.76 (0.51,1.13) 
     Ptrend 
 
  0.17 
Bacon8     
     1st tertile  
     (0) 
173 (67.6)  548 (77.1) 1.0 
     2nd tertile 
     (>0) 
83 (32.4) 163 (22.9) 1.51 
(1.07, 2.15) 
    
Ham9     
     1st tertile  
     (0) 
148 (59.6) 424 (59.6)  1.0 
     2nd tertile 
     (>0-0.10 
67 (26.0) 156 (21.9) 1.10 (0.76,1.59) 
     3rd tertile  
     (>0.10) 
43 (16.7) 132 (18.5) 0.80 (0.52,1.24) 
     Ptrend   0.47 
    
Luncheon Meat10     
     1st tertile 
      (<5.61) 
101 (39.3) 306 (43.2) 1.0 
     2nd tertile  
     (>5.60-12.00) 
84 (32.7) 182 (25.7) 1.45 (1.01,2.09) 
     3rd tertile 72 (28.0) 221 (31.2) 1.05 (0.73,1.52) 
                                                          
6 Adjusted for age, history of cancer in 1st degree relative, country of origin , dwelling type, years of education, and fruit & 
vegetable intake 
7 Sum of serving portions consumed per week of the following 5 processed meat types: ham, bacon, luncheon meat, 
sausages and Chinese sausages 
8 1 serving defined as 1 slice of bacon  
9 1 serving defined as 1 slice of ham 





     (>12.00) 
     Ptrend   0.65 
    
Sausages11     
     1st tertile  
     (<9.70) 
147 (57.0) 436 (61.3) 1.0 
     2nd tertile 
     (9.70-19.60) 
34 (13.2) 77 (10.8) 1.31 
(0.82,2.09) 
     3rd tertile  
     (>19.60) 
77 (29.8) 198 (27.9) 1.00 
(0.70,1.42) 
     Ptrend   0.90 







     1st tertile   
     (<2.51) 
113 (43.8) 355 (49.9) 1.0 
     2nd tertile 
     (>2.50-10.00) 
58 (22.5) 123 (17.3) 1.51 (1.01,2.24) 
     3rd tertile  
     (>10.00) 
87 (33.7) 233 (32.8) 1.13 (0.80,1.58) 
     Ptrend   0.41 
 
  
                                                          
11 1 serving defined as 0.5 sausages 





Table 9.3 Dietary Heterocyclic Amines (HCA) and risk of lung cancer in never-
smoking Chinese women 







Total HCA     
     1st tertile  
     (<92.32) 
83 (32.4) 237 (33.6) 1.0 
     2nd tertile 
     (>92.32-275.90) 
98 (38.3) 238 (33.7) 1.21 (0.85-1.74) 
     3rd tertile   
     (>275.90) 
75 (28.3) 231 (32.7) 0.91 (0.62-1.34) 
     Ptrend   0.66 
PhIP    
     1st tertile  
     (<55.70) 
83 (32.4) 239 (33.9) 1.0 
     2nd tertile 
     (>55.70-160.47) 
97 (37.9) 233 (33.0) 1.20 (0.83-1.71) 
     3rd tertile  
     (>160.47) 
76 (29.7) 234 (33.1) 0.89 (0.61-1.31) 
     Ptrend   0.58 
MelQx    
     1st tertile  
     (<19.80) 
90 (35.2) 238 (33.7) 1.0 
     2nd tertile 
     (>19.79-62.90) 
98 (38.3) 241 (34.1) 1.12 (0.78-1.59) 
     3rd tertile  
     (>62.90) 
68 (26.6) 228 (32.3) 0.78 (0.53-1.15) 
     Ptrend   0.23 
DiMelQx    
     1st tertile  
     (<11.22) 
92 (35.9) 238 (33.7) 1.0 
     2nd tertile 
     (>11.22-34.85) 
100 (39.1) 241 (34.1) 1.15 (0.81-1.63) 
     3rd tertile  
     (>34.85) 
64 (25.0) 228 (32.3) 0.71 (0.48-1.06) 
     Ptrend   0.12 
                                                          







Further adjustment with self –reported exposure to meat cooking fumes did not alter the 
results obtained for fresh meat, processed meat and dietary HCA consumption and the 
association with lung cancer (data not shown). 
Discussion 
In this study of never-smokers, total meat intake (of mostly white meat – fish and 
chicken) is associated with a lower risk of lung cancer. Among meat components, fish 
consumption is inversely associated with lung cancer. Processed meats do not appear 
to be associated with lung cancer, although bacon may increase lung cancer risk among 
never-smokers. Dietary HCA levels arising from Chinese-style meat-cooking were not 
associated with lung cancer.  
Recent research into the effect of meat on lung cancer risk have focused on red and 
processed meat. Carcinogenic compounds arising from the cooking of red meat such as 
HCAs (37, 244, 249, 250) and the Polycyclic Aromatic Hydrocarbon benzo(a)pyrene  
(244, 249) have been implicated as the mechanism conferring risk.  In addition, 
processed meat products have also been identified as a possible risk factor for lung 
cancer (244, 249). Nitrosamines are formed from nitrates and nitrites added to 
processed meats (253), are carcinogenic (254) and may be the biological mechanism 
linking processed meats with lung cancer. The association of processed meats was not 
convincing in our study- most processed meats did not show a relationship with lung 
cancer, and while bacon appeared to be associated with lung cancer cases in our study, 
this increase was in the context of a comparison between non-consumers and ever-





sausages) were generally low in our population. It is likely therefore that any risks 
associated with processed meats would be difficult to identify in our population.  
We did not find a relationship with lung cancer of total HCA or any of the 3 common 
HCAs. This is not unexpected, as red meat consumption is relatively low in our 
population, and the Chinese cooking methods employed by our population do not 
generate significant quantities of HCAs as a by-product of cooking (251).  Indeed, the 
consumption levels of the 3 HCAs studied in our population was about 6-8 times lower 
than that reported in the Missouri study (37). 
Studies that have differentiated white from red meat have generally not shown any 
association of white meat with lung cancer (239, 240). This may be because white meat 
in general does not produce significant quantities of HCAs when cooked. Unusually, we 
show an inverse association with (mostly white) meat consumption in our population. A 
substitution effect of red meat by white meat intake is not a plausible explanation, given 
that red meat consumption is not high in our population, and no positive associations 
were seen with either pork or beef consumption. Confounding by socio-economic status 
is unlikely, since the relationship was significant in multivariate analyses, where we 
adjusted for SES using proxies of dwelling type and years of education. An inverse 
association of body mass index (BMI) with lung cancer risk, particularly in current 
smokers, has been proposed (255), and it is possible that meat consumption is 
confounded by BMI in our study, However, the relationship between meat consumption 
and lung cancer was not changed even after further adjustment for BMI based on “usual” 
weight, or weight before illness (data not shown). The most likely reason for the inverse 
effect of white meat is because of high fish consumption, which was the most common 






The nature of the relationship between fish intake and lung cancer risk has not been 
clearly elucidated despite many studies looking at diet in lung cancer. Some case-control 
studies, especially those conducted in population with relatively low rates of fish 
consumption, have reported that fish consumption is positively associated with lung 
cancer (243, 256, 257). Other case-control studies, however, report inverse effects (239, 
258, 259). In general, all these studies had a high proportion of smokers among cases, 
and did not look at effects separately in smokers and non-smokers. 3 case-control 
studies that did look specifically at never-smokers did not find an effect of fish 
consumption (241, 242, 260). An ecological study concluded that high fish consumption 
at the country level is associated with a reduction in lung cancer mortality in men, but 
only in countries with high levels of cigarette smoking or animal fat consumption (261). A 
Japanese cohort study (262) reported an inverse association of fish on incidence of lung 
cancer, but other studies did not find a relationship with lung cancer incidence in two 
cohorts in Norway (238, 263), nor with lung cancer mortality in one other cohort in Japan 
(264).  Our data suggest that an inverse association is seen in never-smokers, and at 
intakes of more than 1 serving a day (Figure 9.1), and we speculate that the inconsistent 
findings between studies could be due to the high proportion of smokers among cases in 
these studies, and to differences in the range of consumption of fish in the base 
populations. (For example, the Galician study (243) that showed a positive relationship 
compared <1 time per week to >1 time per week, while the Japanese case-control study 
(258) showing an inverse relationship compared <1 time per week with 5 or more times 





A protective effect of fish intake is biologically plausible.  In vitro studies demonstrate 
that the omega -3 fatty acids eicosapentaenoic acid (EPA) and docosahexoic acid 
(DHA), both prominent constituents of fish oil, have anti-inflammatory, pro-apoptotic and 
anti-carcinogenic effects through their interactions with Peroxisome Proliferator-
Activated Receptor-γ, nuclear factor kappa B, cyclooxygenase-2 and integrin-linked 
kinase (265-269).  Some, but not all, epidemiologic studies investigating lung cancer risk 
with fish oil consumption support this (238, 270). Singapore imports almost all fish for 
retail consumption, of which 96-98% is consumed fresh (rather than as processed fish) 
(251), and relatively fatty fish such as mackerel and salmon represent a substantial 
proportion of fish consumed in Singapore (Agri-Food & Veterinary Authority of 
Singapore, unpublished data). The authors of a recent study of omega-3 content of local 
fish (271) estimated that consumption of about 50-60g of local fish (equivalent to about 2 
serving sizes in this study) would provide about 350mg of DHA/EPA per day. It is also 
possible that the protective effect of fish is mediated through other vitamin or mineral 
constituents of fish such as selenium.  
We used a semi-quantitative Food Frequency Questionnaire(FFQ), and reporting errors 
associated with FFQs are well-known. Such errors associated with the dietary 
instrument would likely be non-differential, and would bias estimates towards the null. 
Other types of reporting errors are also possible. We cannot exclude the possibility that 
dietary effects observed might have been due to dietary changes as a consequence of 
symptoms or disease. Because we used hospital controls, our control population’s 
dietary intake may differ substantially from the general population because of their 
disease status. Further analyses excluding participants who reported that they had 





31% of cases reported that they had done so) did not alter the relationship seen 
between meat and fish consumption and lung cancer risk in this population (data not 
shown). Our questionnaire did not allow us to control for total calorie intake; however, if 
the main findings were due to reduced overall consumption amongst cases compared to 
controls, we would have expected to see inverse associations across all food items. 
Further, adjusting for usual adult weight (as BMI) did not alter the results.  
In summary, within the range of consumption prevalent in this Asian population, our 
findings support a protective role for white meat intake, and, specifically, fish intake, in 
the development of lung cancer in never-smokers.   
 
This study has been published (Lim WY, et al. Nutrition and Cancer 2011; 63(6): 850-9, 






CHAPTER 11  CONCLUSION 
The research upon which this thesis is based investigated possible etiologic factors for 
never-smoker lung cancer. We took advantage of the relatively high incidence of lung 
cancer among a study population with low smoking prevalence (Singaporean Chinese 
females) to achieve sufficiently large numbers of never-smoker lung cancer cases. This 
permitted a case-control study with sufficient power to identify main effects (both 
environmental and genetic factors) with Odds Ratios of about 1.2-1.4. Through 
genotyping of biologic samples from participants, we were also able to extend the 
classical epidemiologic study of environmental factors by considering genetic risks and 
the potential interactions between the two.   
In Studies 1 & 2, we added to the growing evidence in the literature that inflammation is 
important in lung carcinogenesis. We showed that this is true also in never-smokers, a 
group for which inflammatory factors, in particular genetic factors, have not been 
explored to any great extent. We further showed intriguing interactions between a 
previous history of atopic conditions and genetic polymorphisms in key genes in the 
inflammatory pathway. In paper 5, we found that meat consumption, and in particular of 
fish were inversely associated with lung cancer. Although we were unable to determine 
which component/s of fish this protective mechanism worked through, we highlighted the 
possibility that the protective effect of fish could be due to omega-3 fatty acids and their 
effects, among others, in reducing inflammation in the local tissue milieu through 
interaction with the cyclo-oxygenase pathway. 
In Study 3, we explored another pathway that is currently under intense scrutiny – the 





factors were implicated in lung carcinogenesis, especially in never-smoker lung cancer. 
We also postulated that the effects of reproduction were mediated through overall 
estrogen levels, and the effect of an estrogen metabolite – catechol estrogens. 
In Study 4, we considered domestic inhalants as potential risk factors. Apart from the 
direct toxic effects on cellular processes and on DNA, some constituents of these 
inhalants are also known to be pro-inflammatory mediators. However, our hypothesis 
that such inhalants alone would be risk-conferring in never-smokers was not supported, 
and instead our data implied that a synergistic effect of inhalant exposure in the 
domestic environment with cigarette smoking on lung cancer might exist. 
Collectively, our data identify both the inflammatory and estrogen signaling pathways to 
be important in lung carcinogenesis. Perhaps the most significant aspect of this set of 
findings is that chronic inflammation may play a bigger role in never-smoker lung cancer 
that has been previously recognized. This is consistent with what is known about 
carcinogenesis in general – inflammation is known to play a key role in the etiology of 
hepatocellular carcinoma and gallbladder carcinoma.  Figure 10.1 summarises the 
etiologic mechanisms that this study has elucidated. 
It is worthwhile to recall potential limitations of the case-control study design that may 
make data interpretation difficult, which include recall and interviewer bias, and reverse 
causation. The use of hospital controls may result in a control population that is not 
representative of the source population for some exposures of interest, such as NSAID 
use.  Finally, the study was also underpowered to look at gene-environment interactions.  
We have tried to address these issues at both the implementation and analysis level, as 
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Further, in the field of observational epidemiology, where confounding and selection can 
be strong influences on findings, it is well-accepted by the research community that very 
few, if indeed, any, studies can be conclusive on their own. Instead, scientific consensus 
is usually reached only slowly, after evidence from the breadth of research conducted in 
different communities and with different study designs has been evaluated and 
synthesised. Further research then, will be helpful to confirm many of the observations 
we have made on the role of the inflammatory and estrogen pathways in lung 
carcinogenesis.  
From an epidemiologic standpoint, further evaluation of exposures and genetic factors in 
both pathways in large well-designed case-control and cohort studies conducted in 
populations with a low prevalence of smoking are necessary, including pooling results 
from existing cohorts and case-control studies or performing meta-analyses of published 
results.  If additional studies are conducted, improved precision in exposure delineation 
would improve the power of such studies to detect a true relationship. Examples of such 
improvements include a) using case-notes and medical records to obtain information 
about the presence of chronic lung, allergic or atopic conditions and use of NSAIDs; b) 
consideration of related factors such as ventilation and room partitioning, room size and 
amount of time spent by an individual in the presence of a fume source in the 
assessment of domestic inhalant exposure; and c) use of exposure biomarkers such as 
measures of estrogen activity in postmenopausal women, serum omega-3 fatty acid 
levels, and measures of fume emission products such as benzo(a)pyrene in the serum 
or plasma. Outcomes ascertainment should preferably be based on case-notes, medical 





It is also important to consider gene-environment interaction, as our study suggests that 
these interactions may explain inconsistent findings in the literature. This implies that 
collection of biological samples for genetic analyses will be needed. It may also be 
useful to do a systematic evaluation of key genes in the inflammatory (such as IL10, IL1, 
IL6 and IL1-receptor antagonist) and estrogen (such as ER alpha and beta, CYP17 and 
CYP19, and COMT pathways). Such systematic evaluation should also consider 
possible effect modification by other exposures in the same pathway; in this regard, 
assessment of environmental exposures would be important. Genetic analyses should 
consider other types of genetic variations beyond Single Nucleotide Polymorphisms, 
such as Copy Number Variation, and DNA methylation patterns. 
Non-epidemiologic biological research will also be useful. Such research includes 
genetic analyses to document all known variations in key genes of both pathways, taking 
into account ethnic variation, and functional assays to understand the effect of these 
polymorphisms. Finally, studies in in vitro and animal models are needed to understand 
the exact etiologic mechanism that underlies the role of inflammation and the 
mechanisms by which estrogen exerts effects in lung carcinogenesis.  
Despite many advances in diagnostics and therapeutics, the survival for lung cancer 
remains exceedingly poor, with 5-year survival less than 10% (8). Lung cancer screening 
is still currently experimental, and there is as yet no consensus on its effectiveness in 
clinical use. For the foreseeable future, prevention will continue to be the key strategy in 
the public health control of lung cancer. The major advances in lung cancer control in the 
last half-century have been the identification of cigarette-smoking as a major preventable 
risk factor for lung cancer and the relatively successful public health efforts undertaken 





the area of tobacco control, in particular in developing countries such as Indonesia and 
China, where smoking rates remain very high, and even in Singapore, which previously 
has had much success in reducing smoking prevalence but in recent years has seen a 
resurgence in smoking behavior (86-88).  
Nevertheless, as lung cancer in never-smokers is not uncommon, identification of risk 
factors other than smoking is needed. These risk factors would unlikely have the 
extremely high impact that smoking has had, both because of the extremely high relative 
risk associated with smoking and the high prevalence of smoking. Nevertheless, further 
advances in lung cancer prevention will depend on the identification of such risk factors 
and the elucidation of the mechanisms through which these factors work to influence 
risk. Once such risk factors have been accurately identified, and the feasibility of 
reducing risk by removing these factors proven, public health practitioners can then use 
this knowledge to design and test lung cancer prevention strategies, thereby translating 
scientific findings into concrete measures aimed at influencing human behavior.  
The research contained in this thesis should therefore be seen in this context. Although 
it is premature at this point to consider applying the results contained in this thesis in 
public health policy, this research nevertheless constitutes a small, but hopefully, 
significant and original contribution to etiologic research, and will in time form a part of 
the scientific pillars upon which public health practitioners can build a sound and 
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Inflammation appears to be important in lung carcinogenesis
among smokers, but its role among never-smokers is not well es-
tablished. We hypothesized that inflammatory medical conditions
and gene polymorphisms interact to increase lung cancer risk in
never-smokers. We interviewed 433 Singaporean female never-
smoker lung cancer patients and 1375 hospital controls, and
evaluated six polymorphisms in the interleukin 1-b, interleukin
6 (IL6), cyclooxygenase-2, peroxisome proliferator-activated
receptor-g and interleukin 1-b receptor antagonist (IL1RN)
genes. Tuberculosis was associated with a non-significant elevated
risk of lung cancer [odds ratio (OR) 1.58, 95% confidence interval
(CI) 0.95–2.62]. There was no effect of asthma, atopy or chronic
productive cough individually. However, the presence of one or
more of these conditions (asthma, cough or atopy) increased risk
(OR 2.24, 95%CI 1.15–4.38) in individuals possessing the T/T
genotype at interleukin 1-b -31T/C, but not in those possessing
the C/T (OR 0.87, 95%CI 0.51–1.57) or C/C genotypes (OR 0.58,
95%CI 0.27–1.27), and in individuals having the 2 variable num-
ber of tandem repeat allele of IL1RN [OR 5.09 (1.39–18.67)], but
not in those without (OR 0.93, 95%CI 0.63–1.35). The IL6-634 G
allele increased the risk of lung cancer (OR 1.44, 95%CI
1.07–1.94). Lung cancer risk also increased with the number of
polymorphism sites where at least 1 ‘risk’ allele was present [in-
terleukin 1-b -31T/C (Tallele), IL1RN (2 allele) and IL6-634C/G
(G allele)] among those with asthma, cough or atopy (Ptrend 0.001)
but not in those without (Ptrend 0.47). Our results suggest that the
effect of inflammatory medical conditions on lung cancer in never-
smokers is modulated by host genetic susceptibility and will need
to be confirmed in other studies conducted in similar populations.
Introduction
Tobacco use has been identified as the major risk factor for lung cancer,
and over the past several decades, lung cancer incidence and mortality
rates have paralleled tobacco use (1,2). However, there is substantial
variation in the incidence of lung cancer that cannot be accounted for
by tobacco use alone. In particular, the incidence of lung cancer in
Chinese women in various populations around the world is much
higher than expected given their relatively low smoking prevalence
(3). Recent evidence suggests that lung cancer in never-smokers may be
a different clinical entity from smoking-related lung cancer: its median
age of onset is about a decade earlier than that of smoking-related lung
cancer and it appears to have a better prognosis (4), incidence rates
may be higher in women than men (5), and the cancer histology is
more probably to be adenocarcinoma than other types (6). Mutations
in the epithelial growth factor receptor are also more common in lung
cancer in never-smokers than in smoking-related cancer (7).
Other risk factors such as environmental tobacco exposure (8), in-
door air pollution from coal-burning heaters (9) or stoves (10), house-
hold radon exposure (11) and diet (12) have all been reported to
contribute to lung cancer development in never-smokers, but the
major etiologic pathways for this disease remain poorly understood.
Recent research has focused on identifying a unifying hypothesis that
could account for the risks seen in these disparate exposures, and the
role of inflammation has been proposed as a possible candidate.
Inflammation is implicated in the pathogenesis of other cancers
such as hepatocellular carcinoma (13), and disruptions in inflamma-
tory signaling due to chronic inflammation of altered immune re-
sponse may be a common pathway in carcinogenesis (14). One of
the etiologic mechanisms by which tobacco use confers risk in lung
cancer may be through its effects on the immune response in the
lung and the resultant excess of proinflammatory molecules in the
lung tissue milieu (15). Previous studies implicate a past history of
chronic inflammatory lung disease such as tuberculosis (16,17),
chronic bronchitis and emphysema (18), pulmonary fibrosis (19)
and chronic rhinosinusitis (20), as risk factors for increased lung can-
cer risk in never-smokers. Asthma, allergic rhinitis and atopic derma-
titis/eczema are related conditions that appear to be manifestations of
an underlying systemic atopic disorder characterized by acute and
chronic inflammation in target organs (lower respiratory tract, upper
respiratory tract and skin, respectively). Although asthma has been
reported previously to be associated with an increase in lung cancer
risk (21–23), the effect of atopy is uncertain, with reports of null or
protective effects (24–26). Other studies have identified genetic poly-
morphisms in key molecules in the inflammatory pathway, such as the
interleukins [in particular interleukin 1-b (27–32) and interleukin 6
(IL6)] (33,34), the interleukin receptor antagonist (interleukin 1-b
receptor antagonist (IL1RN)] (35,36), cyclooxygenase 2 (37,38) and
peroxisome proliferator-activated receptor-c (39) as risk factors.
It is probably that the role of inflammation in lung cancer is medi-
ated through interplay between host susceptibility (as reflected through
polymorphisms in key inflammatory genes) and environmental expo-
sures that either cause inflammatory insult to the lung or confer pro-
tection in the lung from these insults. Therefore, a rational approach to
identifying and quantifying lung cancer risks should consider both
gene and environment factors in tandem. Such analyses may offer
insights into the major biological pathways that drive carcinogenesis
in lung cancer tissue. By identifying population groups at high risk of
lung cancer, these findings may also have public health implications.
We hypothesize that previous inflammatory medical conditions
(chronic lung disease, chronic cough and atopy) increase lung cancer
risk in never-smokers and predict that these risks would be modulated
by polymorphisms in inflammatory genes that have previously been
identified as risk factors, in line with the concept of interplay between
host genetic and acquired environmental factors.
Lung cancer is the second most common cancer in Singapore and
the leading cause of cancer death (40). The incidence rate of lung
cancer among Singaporean Chinese women is unexpectedly high
(1,40) for the historically low rates of smoking in this group
(41), and a significant proportion of lung cancers occur amongst
never-smokers. We examined the association of six inflammatory
gene polymorphisms and self-reported history of previous medical
Abbreviations: CI, confidence interval; IL6, interleukin 6; IL1-b, interleukin
1-b; IL1RN, IL1-b receptor antagonist; OR, odds ratio; PCR, polymerase chain
reaction; SNP, single nucleotide polymorphism; VNTR, variable number of
tandem repeat.
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conditions with lung cancer in a hospital-based case–control study of
Chinese women.
Materials and methods
Participants were recruited in two hospital-based case–control studies in 1996–
1998 (42) and 2005–2008 (43) from the five major public sector hospitals in
Singapore. Both studies used similar study designs and questionnaires. Eligible
cases were Chinese females with incident primary carcinoma of the lung (all
histological types) identified within 3 months of diagnosis. Seven hundred and
eighty-seven eligible lung cancer patients were identified in the five hospitals,
of whom 702 (89.2%) agreed to participate. The response rate for cases was
95.0% in the first study and 84.6% in the second. Histological or cytological
reports were reviewed and confirmed the diagnosis of primary lung carcinoma
in 673 cases; 29 cases were confirmed on the basis of radiological investiga-
tions, in which metastatic cancer to the lung from other sites was deemed to be
unlikely on clinical grounds.
Controls were selected from Chinese female patients admitted to the same
hospitals and frequency matched for age (within 10 years) and date of admis-
sion. Patients admitted for a diagnosis and treatment of cancer or chronic
respiratory disease were excluded, and10% of controls were recruited within
a single diagnostic category.
The response rate among controls was 91% (96.9% in the first study and
85.4% in the second), and data from a total of 1578 controls were available for
analysis. Control patients were admitted for a wide range of conditions: 27%
had diseases of skin, bones, joints and connective tissue, 11% were admitted
for gastrointestinal or hepatobiliary system complaints, 14% were admitted for
acute trauma, 8% were admitted for neurological or psychiatric conditions and
12% had diseases of the cardiovascular system.
Both cases and controls gave written, informed consent for the interview and
the tracing of their medical records. Where consent was given, blood samples
were also obtained. The study was approved by the Institutional Review Board
of the National University of Singapore and participating healthcare institu-
tions. In total, 702 cases and 1578 controls were recruited in the two studies, of
which 433 cases (61.7%) and 1375 controls (87.1%) were never-smokers, de-
fined as individuals who had not smoked at least one cigarette a day for a year.
Of these, 298 cases and 718 controls provided blood samples.
A structured questionnaire was administered in-person by trained inter-
viewers. Interviewers were not blinded to case or control status, but possible
observer bias was monitored by recording and reviewing at random a sample of
interviews conducted. The structured questionnaire elicited information of
participants’ demographic characteristics, occupational history, smoking his-
tory, family history of cancer, personal medical history (self-reported history of
tuberculosis, chronic productive cough, asthma, allergic rhinitis and atopic
eczema), diet (including intake of fruit and vegetable), childhood living con-
ditions, reproductive history, exogenous hormone use and use of other medi-
cations and indoor environmental exposures such as passive tobacco exposure
and exposure to kitchen fumes and inhalants such as incense and mosquito coils.
For cases and controls who provided blood samples, genomic DNA was
extracted from the buffy coat of 5 ml of whole blood samples using the
FlexiGene DNA kit (QIAGEN, Germantown, Maryland), in accordance with
the manufacturer’s protocol. Six polymorphisms in five inflammatory genes
[31 C/T (rs 1143627) and 511 C/T (rs16944) in the interleukin 1-b gene,
634 C/G (rs1800796) in the IL6 gene, 8473 C/T (rs5275) in the cyclooxy-
genase 2 gene, Pro12Ala in exon 2 (rs1801282) of the peroxisome proliferator-
activated receptor-c gene and the 86 base pair variable number of tandem
repeats (VNTR) polymorphism in intron 2 of the IL1RNgene] were genotyped.
The selection of sequence polymorphisms for genotyping was based on (i) their
location in the promoter, untranslated region, or exons of the gene, or published
evidence showing possible effects of the polymorphism on the level and ac-
tivity of the gene products; (ii) a minor allele frequency  5% in the Chinese
population from the NCBI database and (iii) associations with lung cancer
reported previously by other researchers.
All single nucleotide polymorphisms (SNPs) were genotyped using a high-
throughput genotyping platform base on a 5# nuclease allelic discrimination
assay in a 96-well format on the ABI StepPlusOne real-time polymerase chain
reaction (PCR) system (Applied Biosystems, Carlsbad, California). The Taq-
man universal PCR master mix and predesigned SNP-genotyping assay mix
containing PCR primers and probes were purchased from ABI. To ensure the
accuracy of genotyping results, three positive controls and two negative con-
trols were included in each 96-well plate, and 10% of DNA samples were
genotyped in duplicate for each polymorphism. The concordance rate for the
duplicate analyses was 100%. Call rates for the five SNPs studied ranged from
99.8 to 100%.
The intron 2 VNTR in the IL1RN gene was determined as described pre-
viously (35): primers (5#-CCCCTCAGCAACACTCC-3# and 5#-GGTCA-
GAAGGGCAGAGA-3#) flanking the 86 bp tandem repeat region were used
to amplify a DNA fragment containing the polymorphic region. PCR conditions
comprised an initial denaturing step at 95C for 5 min, followed by 35 cycles of
95C for 30 s, 56C for 40 s and 72C for 45 s, with a final extension at 72C for
10 min. The PCR products were then analyzed on 2% agarose gel electropho-
resis along with a 100bp DNA marker. The wild-type allele designated allele I
(IL1RN1) (44) contains four 86 bp repeats and generated a 410 bp PCR
product. The minor alleles were designated allele II to allele V (43) and corre-
sponded to 240 bp (two repeats), 325 bp (three repeats), 500 bp (five repeats)
and 959 bp (six repeats) PCR products. 10% of DNA samples were also gen-
otyped in duplicate to ensure genotyping accuracy, and the concordance rate for
the duplicates was 100%. The call rate was 99.7% for this analysis. All SNPs
studied were in Hardy–Weinberg equilibrium in the control population.
Based on biologic considerations, as well as results from reverse stepwise
analyses, we decided on a set of 11 variables for adjustment: age at diagnosis,
country of origin, dialect group, housing type, number of years in school,
environmental tobacco exposure at home, environmental tobacco exposure at
work, history of cancer in a first degree relative, mean intake of fruit and of
vegetable (in servings/week) as well as a study set variable to indicate which
case–control study the participant belonged to.
Odds ratios (ORs) and their 95% confidence intervals (CIs) were calculated
using unconditional logistic regression. We used STATA statistical software,
version SE 10.1 (StataCorp LP, College Station, TX) for data analyses. All
P values were calculated using two-tailed statistical tests, and the criterion for
significance was set at P, 0.05. We adjusted for multiple testing using the
method proposed by Benjamini et al.(45) to control the false discovery rate in
our analyses of gene–environment interaction.
Results
Table I gives a summary of relevant characteristics of the lung cases
and their controls in this study. The dialect group, birthplace, educa-
tion level (in years of school) and current housing type of the partic-
ipant, as well as a history of cancer in a first-degree relative, and her
intake of fruit and vegetable were all significantly different between
cases and controls in bivariate analyses. Two-thirds (63%, 271 cases)
of cancers were adenocarcinomas.
Table II summarizes the effect of past history of lung disease or
atopy on risk of lung cancer. Tuberculosis (OR 1.58, 95% CI 0.95–
2.62) appeared to be associated with an increased risk of lung cancer
although this was not statistically significant. Asthma (OR 1.01, 95%
CI 0.66–1.56), chronic cough (OR 1.73, 95% CI 0.65–4.60) and al-
lergic rhinitis/atopic eczema (OR 0.93, 95% CI 0.69–1.26) were not
associated with an increased risk of lung cancer in our study popula-
tion. The composite measure of chronic cough, asthma or allergic
rhinitis/atopic eczema was also not associated with an increased risk
of lung cancer (OR 0.97, 95%CI 0.74–1.27).
When stratified by31T/C polymorphism genotype in IL-1b, a his-
tory of chronic cough, asthma or atopy increased risk only among
participants with the T/T genotype (OR 2.24, 95% CI 1.15–4.38) but
not in participants with the T/C or C/C genotype (Table III). The P for
interaction, after adjustment for multiple testing, was 0.051. Because
the polymorphism at the 511 position was in tight linkage disequi-
librium with this polymorphism (R250.97), similar results (data not
shown) were obtained for the SNP at the 511 position and a history
of asthma, atopy or chronic cough.
When stratified by genotype at the VNTR polymorphism in the
IL1RN gene, a history of chronic cough, asthma or atopy increased
the risk of lung cancer only in participants with the 2 allele (OR 5.09,
95% CI 1.39–18.67), but not in those with the 1 allele. The P value for
interaction, after adjustment for multiple testing, was 0.058. Compared
with having the 1/1 genotype of the IL1RN gene and no history of
chronic cough, asthma or atopy, the presence of at least 1 2 allele and
a positive history of chronic cough, asthma or atopy, but not either
factor alone, was associated with an increased risk of lung cancer (OR
2.96, 95% CI 1.23–7.12). There was no modification of the effect of
chronic cough, asthma or atopy by the other three genotypes studied.
Of the six sequence variations studied, the634 C/G polymorphism
in IL6 exhibited a main effect (Table IV). Using a codominant model,
compared with the C/C genotype, the C/G genotype was associated
with an increased risk of lung cancer (OR 1.51, 95% CI 1.11–2.05).
Inflammation and lung cancer risk
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The G/G genotype was not associated with an increased risk (OR 1.00,
95% CI 0.49–2.05) although there were relatively small numbers in
this group. Using a dominant model, the presence of the G allele
was associated with an increased risk of lung cancer (OR 1.44, 95%
CI 1.07–1.94) compared with having no G allele. This effect was
not modulated by a history of tuberculosis, asthma, chronic cough or
atopy.
Table V shows the additive effects of possessing one or more ‘risk’
alleles at the three gene polymorphism sites for which an association
with lung cancer was found in our study (the T allele at IL-1b-31T/C
SNP site, the G allele at IL6-634C/G CNP site and 2 allele at IL1RN
86bp VNTR site). Compared with those without any alleles at these
three sites, those persons having risk alleles at one site had an OR of
1.20, those with alleles at two sites, an OR of 1.57, and those with
alleles at all three sites, an OR of 1.89. Although none of the individ-
ual ORs were statistically significant, the P value for trend was 0.026.
The additive effect was seen only in those with a positive history of
chronic cough, asthma or atopy (ORs 2.87, 6.76 for those with risk
alleles at one and two or three sites, respectively, P for trend 0.001)
but not in those without (ORs 0.98, 1.14 for those with risk alleles at
Table I. Sociodemographic characteristics of lung cancer cases and controls among Singaporean Chinese women never-smokers
Cases [n, (%)] Controls [n, (%)] P valueb
N 5 433 N 5 1375
Age in yearsa (mean, SD) 63.0 ± 12.5 63.6 ± 12.2 0.42
Dialect groupc 0.008
Hokkien 151 (35.2) 577 (42.8)
Teochew 109 (25.4) 265 (19.7)
Cantonese 85 (19.8) 252 (18.7)
Hainanese 38 (8.9) 80 (5.9)
Hakka 31 (7.2) 125 (9.3)
Other 15 (3.5) 49 (3.6)
Birthplace 0.012
Singapore 274 (63.3) 900 (65.5)
Malaysia 57 (13.2) 239 (17.4)
China 85 (19.6) 198 (14.4)
Other 17 (3.9) 38 (2.8)
Education(year) 0.041
Nil 169 (39.0) 561 (40.8)
6 years 119 (27.5) 435 (31.6)
7 years or more 145 (33.5) 379 (27.6)
Dwellingc 0.001
1–3 room flat 145 (33.7) 517 (37.8)
4 room or larger flat 202 (47.0) 682 (49.8)
Private apartment or house 83 (19.3) 170 (12.4)
Marital status 0.809
Ever married 403 (93.1) 1275 (92.7)
Never married 30 (6.9) 100 (7.3)
Occupational statusc 0.406
Currently employed outside home 128 (29.6) 374 (27.2)
Ever employed outside home 202 (46.7) 691 (50.3)
Never employed outside home 103 (23.8) 308 (22.4)
Environmental tobacco smoke exposure at homec 0.297
, Daily 226 (53.1) 764 (55.9)
Daily, ,20 years 39 (9.2) 117 (8.6)
Daily, 20 or more years 161 (37.8) 485 (35.5)
Environmental tobacco smoke exposure at workc 0.061
No exposure/never worked outside the home 320 (74.8) 1084 (79.1)
Exposed to smoking coworkers 108 (25.2) 287 (20.9)
Family history of cancerd ,0.001
No 309 (71.4) 1112 (80.9)
Yes, other sites 88 (20.3) 208 (15.1)
Yes, lung cancer 36 (8.3) 55 (4.0)
Intake of fruit, (mean, SD) (servings/week) 7.5 ± 7.1 9.3 ± 8.5 ,0.001
Intake of vegetable, (mean, SD) (servings/week) 22.3 ± 19.4 25.9 ± 21.3 0.002
Histologic type
Adenocarcinomase 271 (62.6)
Squamous cell carcinomasf 25 (5.8)
Small cell carcinomasg 5 (1.2)
Other histologyh 115 (26.6)
No histology/cytology 17 (3.9)
aRefers to age at diagnosis (cases) and age at interview (controls)
bPearson chi-square test for categorical variables and one way anova for continuous variables
cNumbers do not add up toN5433 for cases and N51375 for controls because of missing responses to some of these variables: 31 missing for dialect group, 9 missing for
dwelling type, 2 missing for occupational status, 16 missing for environmental tobacco exposure at home, and 9 missing for environmental tobacco exposure at work
dFirst-degree relative
eHistology codes (ICD-O-3) 8140/3—adenocarcinoma NOS, 8260/3—papillary adenocarcinoma, NOS, 8480/3—mucinous adenocarcinomas
fHistology code (ICD-O-3) 8070/3 squamous cell carcinoma, NOS
gHistology code (ICD O-3) 8041/3 small cell carcinoma, NOS












one and two or three sites, respectively, P for trend 0.47), and this
interaction was significant at P50.035.
Supplementary Table 1, available on Carcinogenesis Online shows
the likelihood ratio test P values for the interaction between the five
SNPs with, separately, a history of tuberculosis, history of chronic
cough, history of asthma and history of atopic eczema/allergic rhini-
tis. As IL1b511C/T and IL1b31T/C are in strong linkage disequilib-
rium, only the results for IL1b31T/C are shown. The P values for
interaction for history of asthma with IL1b31T/C and IL1RN and for
history of allergic rhinitis/atopic eczema with IL1RN are significant.
Supplementary Table 2, available on Carcinogenesis Online shows
the results for the joint effect of the composite variable of chronic
cough, asthma and allergic rhinitis/atopic eczema and the remaining
three SNPs (IL6-634C/G, peroxisome proliferator-activated receptor
Pro12Ala and cyclooxygenase 2 8973T/C). No statistical interactions
were observed for the composite variable of chronic cough, asthma
and allergic rhinitis/atopic eczema.
Supplementary Table 3, available on Carcinogenesis Online shows
the ORs and 95% CIs for the joint effect of the two SNPs of interest
(i.e. IL1b31T/C and IL1RN) with, separately, a history of chronic
cough, asthma and allergic rhinitis/atopic eczema. The joint effects
for each of these three variables are similar for both polymorphisms,
and support our use of a composite variable comprising these three
variables of chronic cough, asthma and allergic rhinitis/atopic eczema.
Discussion
Our results suggest that among inflammatory conditions of the lung,
a history of tuberculosis (but not asthma, allergic rhinitis and atopic
eczema and chronic cough, individually or in combination) may be
associated with an increased risk of lung cancer although the ORs
did not reach statistical significance. A positive association of chronic
cough, asthma or atopy with lung cancer risk was evident in the
presence of the T/T genotype in the IL1b and the 2 allele in the
IL1RN genes. We also demonstrated an independent effect of IL6-
634 C to G polymorphism in conferring risk. We found increasing
ORs for lung cancer with increasing number of polymorphism sites
where there was at least one ‘risk’ allele in those with a history of
chronic cough, asthma and atopy but not in those without such a his-
tory. Taken collectively, these data support the hypothesis that inflam-
mation plays a role in lung carcinogenesis among never-smokers.
In our study, the number of cases with a history of tuberculosis was
relatively small, and the study was inadequately powered to detect
a true association of this magnitude. Our finding of an increased,
although non-significant, risk is consistent with other studies that have
also reported increased risks associated with tuberculosis (46–48).
Asthma was associated with a 1.8-fold increased risk of lung cancer
in a meta-analysis of five case–control studies that studied the asso-
ciation in never-smokers (23), and other cohort studies support this
finding (21,22). On the other hand, studies of the relationship of
Table II. Effect of past medical history of lung disease or atopy on risk of lung cancer in Singaporean Chinese women never-smokers
Past medical history Cases (n 5 433) Controls (n 5 1375) ORa (95% CI) P value
Tuberculosis Yes 27 (6.2) 53 (3.8) 1.58 (0.95–2.62) 0.080
No 406 (93.8) 1322 (96.2) 1.0
Chronic productive coughb Yes 7 (1.6) 12 (0.9) 1.73 (0.65–4.60) 0.27
No 425 (98.4) 1361 (99.1) 1.0
Asthma Yes 34 (7.8) 97 (7.1) 1.01 (0.66–1.56) 0.96
No 399 (92.2) 1278 (92.9) 1.0
Allergic rhinitis/atopic eczema Yes 79 (18.2) 244 (17.8) 0.93 (0.69–1.26) 0.64
No 354 (81.8) 1131 (82.2) 1.0
Asthma or allergic rhinitis/atopic eczema Yes 101 (23.3) 311 (22.6) 0.93 (0.70–1.22) 0.59
No 332 (76.7) 1064 (77.4) 1.0
Chronic productive cough, asthma or allergic rhini-
tis/atopic eczema
Yes 106 (24.5) 315 (22.9) 0.97 (0.74–1.27) 0.84
No 327 (75.5) 1060 (77.1) 1.0
aAdjusted for age, history of cancer in first degree relative, fruit and vegetable consumption, country of origin, dialect group, housing type, number of years in
school, environmental tobacco exposure at home, environmental tobacco exposure at work and study set
bThree (one case and two controls) participants did not respond to this question
Table III. ORs and 95% CIs for the interaction between IL1b and IL1RN genotypes and a history of chronic cough/asthma/allergic eczema/atopic rhinitis on risk
of lung cancer in Singaporean Chinese women never-smokers
Polymorphism History of chronic cough, asthma







P values Stratified analyses,
by genotype ORa (95% CI)
P values
IL1b-31T/C
C/C No 49 (16.4) 119 (16.6) 1.0 1.0
Yes 16 (5.4) 43 (6.0) 0.60 (0.29–1.23) 0.16 0.58 (0.27–1.27) 0.17
T/C No 121 (40.6) 292 (40.8) 0.90 (0.59–1.38) 0.64 1.0
Yes 31 (10.4) 66 (9.2) 0.80 (0.44–1.43) 0.44 0.87 (0.51–1.49) 0.62
T/T No 51 (17.1) 158 (22.1) 0.62 (0.38–1.01) 0.053 1.0
Yes 30 (10.1) 38 (5.3) 1.44 (0.76–2.72) 0.26 2.24 (1.15–4.38) 0.018
LR test for interaction P valueb 5 0.051 (unadjusted P 5 0.011)
IL1RN
1/1 No 187 (63.6) 486 (68.5) 1.0 1.0
Yes 64 (21.8) 135 (19.0) 0.93 (0.64–1.36) 0.70 0.93 (0.63–1.35) 0.70
1/2 or 2/2 No 31 (10.5) 78 (11.0) 1.00 (0.62–1.62) 0.98 1.0
Yes 12 (4.1) 11 (1.6) 2.96 (1.23–7.12) 0.015 5.09 (1.39–18.67) 0.014
LR test for interaction P valueb 5 0.058 (unadjusted P 5 0.029)
aAdjusted for age, history of cancer in first-degree relative, fruit and vegetable consumption, country of origin, dialect group, housing type, number of years in
school, environmental tobacco exposure at home, environmental tobacco exposure at work and study set
bLikelihood Ratio test for interaction P value adjusted for multiple testing using the method of Benjamini et al.(45)
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systemic atopic conditions such as food allergies, allergic rhinitis or
atopic eczema with lung cancer have mainly reported null or negative
associations (24–26). Some authors (20) have proposed that local lung
effects such as mucosal inflammation are the reason for the increased
risk seen in asthma, rather than the shift of T lymphocyte response to
a Th2-dominated activity in the hyperreactive state of the immune
system, which is found also in systemic atopic conditions. If so, mild
and infrequent asthmatic attacks and the use of local medications such
as inhaled corticosteroids may mitigate the risk association and may
explain our null findings. Chronic cough has been identified as an
independent risk factor for lung cancer (49,50), especially among
smokers. In our population of never-smokers, chronic productive
cough are probably due to either undiagnosed asthma or to chronic
obstructive pulmonary disease. Asthma is a known risk factor for
chronic obstructive pulmonary disease in non-smokers (51), and ec-
zema, allergic rhinitis and asthma are known to occur in the same
patient in sequence, an effect known as the atopic march (52). We
believe, therefore, that the cluster of symptoms or diagnoses of
chronic cough, asthma, allergic rhinitis and atopic eczema are related
and point to persons with an underlying atopic phenotype and a pre-
disposition to chronic inflammation in the lungs.
We observed a main effect with the IL6-634 polymorphism in our
study population. There is biological plausibility for the role of the
IL6-634 G allele in increasing lung cancer risk. The 634 SNP is in
the promoter region of the IL6 gene, and in vitro studies have in-
dicated that the G allele is associated with an increased production
and secretion of IL-6 by peripheral blood mononuclear cells (53).
Our group had previously reported (33), using data from the first
Table IV. Effect of polymorphisms in six inflammatory pathway genes on the risk of lung cancer in Singaporean Chinese women never-smokers
Inflammatory gene Genotype Cases (n 5 298) Controls (n 5 718) ORa (95% CI) P value OR (95% CI)b
IL1b 31T/C (rs 1143627)c
T/T 81 (27.2) 196 (27.4) 1.0
C/T 152 (51.0) 358 (50.0) 1.14 (0.80–1.61) 0.47
C/C 65 (21.8) 162 (22.6) 1.13 (0.74–1.71) 0.57
511 C/T (rs16944)c
C/C 83 (27.9) 200 (27.9) 1.0
C/T 155 (52.0) 359 (50.1) 1.14 (0.81–1.60) 0.46
T/T 61 (20.1) 157 (21.9) 1.07 (0.70–1.63) 0.75
IL6 634 C/G (rs1800796)
C/C 163 (54.7) 449 (62.5) 1.0 1.0
C/G 123 (41.3) 231 (32.2) 1.51 (1.11–2.05) 0.008 1.44 (1.07–1.94)
G/G 12 (4.0) 38 (5.3) 1.00 (0.49–2.05) 0.99 P value 5 0.015
PPAR-c Pro12Ala (rs1801282)
C/C 274 (92.0) 653 (91.0) 1.0
C/G 23 (7.7) 64 (8.9) 1.04 (0.62–1.76) 0.87
G/G 1 (0.3) 1 (0.1)
COX-2 8973 T/C (rs5275)c
T/T 182 (61.3) 462 (64.4) 1.0
T/C 100 (33.7) 228 (31.8) 1.20 (0.88–1.64) 0.25
C/C 15 (5.0) 28 (3.9) 1.32 (0.66–2.64) 0.44
IL1RN 86 bp VNTR in intron 2c,d
1/1 251(85.4) 621 (87.5) 1.0
1/2 40 (13.6) 89 (12.5) 1.26 (0.83–1.92) 0.28
2/2 3 (1.0) 0 (0)
IL1b -31 T/C and IL1b-511C/T are in linkage disequilibrium, R2 5 0.97. COX-2, cyclooxygenase; PPAR- c, peroxisome proliferator-activated receptor.
aAdjusted for age, history of cancer in first-degree relative, fruit and vegetable consumption, country of origin, dialect group, housing type, number of years in
school, environmental tobacco exposure at home, environmental tobacco exposure at work and study set
bAdjusted ORs, comparing participants with a genotype of C/G or G/G at IL6 634C/G versus those with a C/C genotype
cExcludes samples with no-calls—two samples for IL1b 31 T/C (rs 1143627) and 511 C/T (rs16944), one sample for COX2 8973 T/C (rs5275) and three
samples for 86bp VNTR in intron 2 in IL1RN
dFurther excludes seven participants with 1/4 and two participants with 1/5 genotypes





All No history of chronic cough, asthma or
allergic rhinitis/atopic eczema
History of chronic cough, asthma or
allergic rhinitis/atopic eczema
Cases/controls N5298/718 ORs (95% CI)c P value Cases/controls ORs (95% CI) P value Cases/controls ORs (95% CI) P value
0 25/91 1.0 21/68 1.0 4/23 1.0
1 143/362 1.20 (0.71–2.01) 0.50 105/279 0.98 (0.55–1.75) 0.99 38/83 2.87 (0.71–11.53) 0.14
2 117/240 1.57 (0.93–2.67) 0.093 86/201 1.14 (0.64–2.05) 0.66 31/39 6.76 (1.68–27.13) 0.007
3 11/22 1.89 (0.75–4.75) 0.18 8/20 3/2
P for trend 0.026 P for trend 0.47 P for trend 0.001
P value for interaction 0.035
aExcludes five samples with no-calls in at least one of the three polymorphism sites
bCounts were made for each individual based on the number of polymorphism sites in which there was at least one ‘risk’ allele: [IL1b-31TC (T allele), IL1RN 86bp
VNTR (2 allele) and IL6-634CG (G allele)]
cAdjusted for age, history of cancer in first-degree relative, fruit and vegetable consumption, country of origin, dialect group, housing type, number of years in











case–control study conducted between 1996–1998, that although
a history of asthma or atopy and the G allele of IL6-634 did not
increase risk of lung cancer on their own, the combined effect of
the G allele and a history of asthma or atopy resulted in an OR of
3.1 (95% CIs 1.2–8.3) compared with the group with the C/C geno-
type and no history of asthma. We did not find any other studies
investigating the IL6-634 SNP with lung cancer. Other groups have
primarily investigated another SNP in the IL6 gene–IL6-174G/C
(rs1800795), and most of these studies have reported null findings
with this SNP (29–31,54).
Our study implicates the C allele in IL1b511C/T and the T allele in
IL1b 31T/C and the 2 allele of IL1RN as alleles that confer risk to
lung cancer in the presence of a background of atopy (allergic rhinitis
or atopic eczema), chronic cough or asthma. The 31T/C polymor-
phism is a TATA-box polymorphism; the C allele disrupts this box and
reduces binding and induction; hence suggesting that the T allele may
be proinflammatory (55). Zienolddiny et al. (27) previously reported
an increased risk of lung cancer with the T allele at IL1b31T/C, and
Wu et al. (56) also reported that the T allele was associated with
increased risk in a Chinese population, although other groups have
reported null effects (29,31), and results from one other study impli-
cated, in contrast, the C allele of31T/C as the risk allele (32). These
studies were conducted in study populations of smokers or mixed
populations with high proportions of smokers (ranging from 84 to
96%). The inconsistencies in results could have been due to the dif-
ferent ethnic populations that were studied, as well as to the different
distribution of relevant host factors such as exposure to environmental
pollutants and pre-existing health conditions such as asthma. Results
for C3954T (rs1143634), the other SNP in the IL1b gene that has been
commonly studied, have been similarly inconsistent, with reports both
of an increased risk associated with the T allele (31,57) and null
effects (58).
The 86bp VNTR polymorphism of the IL1RN gene contains po-
tential regulatory protein-binding sites (43), and probably has func-
tional significance in the regulation of IL1-Ra production. In
opposition to our findings, Hu et al. (35) reported reduced risks
of lung cancer with the 2 allele in ethnic Chinese, but the
study population in that report was predominantly (70%) male and
smokers (60% of cases and 48% of controls), with relatively fewer
adenocarcinomas among the lung cancer cases (38% of cancers).
Further epidemiologic studies to delineate the main effect and
possible interactions of IL1RN alleles are needed, as are functional
studies to clearly describe the effect of the 2 allele in biological
systems.
Our analysis of the summed effect of alleles at these three poly-
morphism sites suggests that there is an additive effect in lung cancer
risk with increasing number of polymorphism sites where there was at
least one allele present among those with a history of chronic cough,
asthma and atopy, but not among those without. Although this anal-
ysis was based on relatively small numbers of cases and controls with
chronic cough, asthma and atopy, this finding, if replicated, would
suggest that the effects of inflammatory gene polymorphisms are
important only in the presence of relevant host factors such as pre-
vious medical history.
The gene–environment interactions observed in our study suggest
that failure to take into account environmental and personal risk fac-
tors may explain the inconsistency of results obtained thus far with
studies looking at the association of inflammation with lung cancer
risk. Rothman et al. (59) conceptualized a causal pie where combi-
nations of risk factors explain the occurrence of non-communicable
diseases with multiple etiologies such as cancer. Most of these factors
are neither necessary nor sufficient in themselves to cause illness, and
it is the combination of factors that determine the risk to any individ-
ual. Some risk factors (for example, smoking) may have such strong
biological effects that, regardless of the underlying host genetic sus-
ceptibility or the presence of other risk factors, these factors invari-
ably confer risk. Other factors may have weaker effects, and the risk
associated with these factors may manifest only in hosts with
underlying predisposition. Applying this concept to the role of
inflammation in lung carcinogenesis, and in the light of our findings,
the development of inflammatory pathway perturbations that result in
lung carcinogenesis may depend on both the presence of ‘environ-
mental’ risks that predispose to inflammatory pathway disruptions
such as personal medical history as well as on underlying host genetic
susceptibility to such perturbations.
Our study represents, to our knowledge, the first study of inflam-
matory genotypes and lung cancer in a large group of never-smokers.
This feature has allowed us to investigate weak associations in this
subgroup, which may be overshadowed by smoking-related effects in
other populations.
Previous studies of genetic polymorphisms have used study popu-
lations of smokers or mixed populations where smokers comprised
a heavy majority. Despite the inconsistencies in findings, the evidence
overall appears to suggest that both a medical history of lung or in-
flammatory conditions and genetic variation in the inflammatory gene
pathways are associated with lung cancer risk in smokers. Our study
adds to this body of knowledge by suggesting that similar associations
are seen in never-smokers.
On the other hand, the retrospective nature of our study and the use of
hospital controls may complicate the interpretation of our results. To
reduce possible selection bias, we sampled from a wide variety of
hospital departments and admission symptoms. In addition, we ex-
cluded patients admitted for cancers or chronic respiratory conditions.
Even if there were a selection bias in our study (with enrichment of
persons with chronic diseases in the control group), the direction of this
bias would have resulted in an underestimate of the true risk. We
depended on participant reports of their medical history, and there
may have been reporting bias with cases being more probably to report
a positive medical history than controls. Because of the similarity of
symptoms, some cases might have been misdiagnosed as asthma
prior to the diagnosis of lung cancer being made. As we had not asked
the age of onset of their pre-existing medical condition, we were not
able to exclude reports of medical conditions of recent onset that
could have been misdiagnosed lung cancer. However, we do not be-
lieve that this was a major source of bias because diagnostic chest
imaging is readily available to family practitioners in Singapore, and
this would have correctly identified lung cancer as the cause of their
symptoms for most patients. We did not conduct any interviews solely
with next of kin, hence eliminating possible biases resulting from
proxy reports.
Furthermore, our results, especially with regard to those showing
gene–environment interactions, should be considered to be explor-
atory in nature. Only a subset of participants provided blood samples.
Our analysis suggested that there were minimal differences between
cases and controls that provided blood samples and those who did not
(data not shown). The exception to this was in environmental tobacco
smoke exposure amongst controls: 52% of those who provided blood
specimens reported environmental tobacco smoke exposure compared
with 44% in the study population as a whole (P,0.05). Environmen-
tal tobacco smoke exposure has been linked to asthma, and the higher
proportion of asthma among controls providing blood samples may
have resulted in an attenuation of the actual effect of the composite
variables of cough, asthma and atopy in analyses stratified by geno-
type. Mechanistic or biological effect is plausible for these interac-
tions, but the likelihood ratio tests for interaction, although significant
without adjustment for multiple testing at P,0.05, gave borderline
significant P values after adjustment, and confirmation of these find-
ings in other well-designed studies of lung cancer in never-smokers is
needed.
In summary, our results suggest that acquired inflammatory medi-
cal conditions and inherited polymorphisms of genes in the inflam-
matory response pathway may interact to confer risk in lung
carcinogenesis among never-smokers. Our finding that the cluster of
conditions of chronic cough, asthma and atopy confer risk only in the
presence of proinflammatory genotypes linked to the IL-1 cytokine
emphasizes the need to consider host genetic susceptibility when in-
vestigating putative environmental or acquired risk factors in etiologic
studies.
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There  is  evidence  that  aspirin  and  non-aspirin  non-steroidal  anti-inﬂammatory  drug  (NSAID)  have  anti-
carcinogenic  properties,  but  their  effect  on lung  cancer,  in  particular  in  never-smokers,  is unclear.
Information  on  past  or  current  use  of  anti-inﬂammatory  medication  was  obtained  in  398  Chinese  female
primary  lung  cancer  cases  and  814  controls  in  a  hospital-based  study  in  Singapore.  65%  of  cases  and  88%






ated with  aspirin  or NSAID  use  (n =  174).  Regular  aspirin  use  (twice  a  week  or  more,  for  a  month  or  more)
was  associated  with a reduced  risk  of  lung  cancer  (adjusted  odds  ratio  [OR]  0.50,  95%  conﬁdence  inter-
vals  [95%CI]  0.31–0.81  in non-smokers;  OR 0.38,  95%CI  0.16–0.93  in  smokers).  Regular  use  of non-aspirin
NSAID,  paracetamol,  steroid  creams  and  steroid  pills was uncommon  and  no  association  with lung  cancer
was detected.  Our  results  suggest  that  aspirin  consumption  may  reduce  lung  cancer  risk  in Asian  women
and are  consistent  with  current  understanding  of  the  role  of  cyclooxygenase  in lung  carcinogenesis.. Introduction
Aspirin and non-aspirin non-steroidal anti-inﬂammatory drugs
NSAIDs) are widely prescribed analgesic and anti-inﬂammatory
gents. Low-dose aspirin has also been prescribed as prophylaxis
gainst ischaemic cardiac and neurological events. The biological
ffect of aspirin and NSAIDs appears to be mediated mainly through
he inhibition of cyclooxygenase (COX) enzyme. COX converts
rachidonic acid to prostaglandin G and H2, which are further con-
erted to a variety of eicosanoids [1].  Activities of these eicosanoids
nclude anti-apoptosis, promotion of angiogenesis, and stimulation
f estrogen synthesis [2,3]. There are 2 isoforms of COX: constitu-
ively expressed COX-1, and COX-2, which is inducible [1]. While
spirin and earlier NSAIDs are non-selective, a new class of COX-
 speciﬁc inhibitors such as celecoxib was developed in the early
000s. Aspirin and other NSAIDs differ from each other both inPlease cite this article in press as: Lim W-Y, et al. Aspirin and non-aspirin no
Cancer  (2012), doi:10.1016/j.lungcan.2012.03.005
erms of their relative afﬁnity for the 2 isoforms of COX, and in
heir mechanism of inhibition of COX. Notably, aspirin causes irre-
ersible inhibition through covalent bonding of the COX molecule
∗ Corresponding author. Fax: +65 64789913.
E-mail address: wei-yen lim@nuhs.edu.sg (W.-Y. Lim).
169-5002/$ – see front matter ©  2012 Elsevier Ireland Ltd. All rights reserved.
oi:10.1016/j.lungcan.2012.03.005© 2012 Elsevier Ireland Ltd. All rights reserved.
while most other NSAIDs exhibit competitive reversible inhibition
[3].
In vitro and animal studies support a protective effect of aspirin
and non-aspirin non-steroidal anti-inﬂammatory drugs (NSAIDs)
on cancer risk. Initial studies in colorectal cancer found increased
cyclo-oxygenase-2 (COX-2) expression in colorectal tumour tis-
sue compared to non-tumour tissue [4].  In mice studies, COX-2
null APC716 (a mouse model where truncation of the Adenoma-
tous Polyposis Coli gene induces intestinal polyposis) mice showed
decreased intestinal polyp formation compared to COX-2 positive
mice; polyp formation was reduced in COX-2 positive mice fed a
novel COX-2 inhibitor [5].  Human epidemiologic evidence supports
the role of aspirin in protecting against colorectal cancer, with risk
reduction estimates of 20–50% [6,7].
There is increasing evidence that aspirin and non-aspirin NSAIDs
may  also play a protective role in lung cancer. COX-2 enzymes
are constitutively expressed in lung neoplastic tissue at higher
levels than in non-tumour tissue [8].  Animal studies show that
these drugs protect against experimentally induced lung cancern-steroidal anti-inﬂammatory drug use and risk of lung cancer. Lung
[9]. Clinical evidence in human patients also suggests that COX-2
expression is associated with poorer lung cancer survival [10]. Fur-
ther, experimental studies suggest that COX-2 regulates the activity
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tself regulated by EGFR in complex ways that appear to depend on
ell-type speciﬁcity and cell environment [11,12]. This interaction
ould be important in the light of recent ﬁndings that EGFR muta-
ions are common in lung adenocarcinomas among non-smokers,
omen, and Asians [12]. The role of inﬂammation (and the effect of
nti-inﬂammatory agents such as NSAIDs) in lung carcinogenesis
ay  therefore be subject to effect modiﬁcation by factors such as
thnicity, gender and smoking status.
Epidemiologic studies of the role of NSAIDs and aspirin on
ung cancer risk have been suggestive but not conclusive [13–38],
ith both protective and null effects being reported. Three
eta-analyses have been performed on the available data, with
ontrasting results: one [17] reported a non-statistically signiﬁcant
educed pooled OR for non-aspirin NSAID, but no effect for aspirin,
 second [33] reported signiﬁcant reductions in risk with regular
se of aspirin and NSAIDS, but cautioned that the association may
ot be causal, while the third [34] reported a borderline signiﬁcant
eduction in risk, with signiﬁcant differences in results of pooled
nalysis of case–control studies (signiﬁcant protective effect) com-
ared to cohort studies (null effect). Few studies have looked at the
ffect in never-smokers, and, to our knowledge, no studies have
een performed in an Asian population.
Lung cancer is the second most common cancer and the lead-
ng cause of cancer death in Singapore [39]. The incidence rate of
ung cancer among Singaporean Chinese women is unexpectedly
igh [39] for the historically low rates of smoking in this group
40], and a signiﬁcant proportion of lung cancers occur among non-
mokers. We  investigate the possible association between regular
spirin and non-aspirin NSAID use and lung cancer, and explored
hether smoking status and lung cancer tumour type modiﬁed the
ssociation, using data from a hospital-based case–control study
f 398 Chinese female lung cancer patients and 814 controls con-
ucted in 2005–2008 in the 5 major public sector hospitals in
ingapore.
. Materials and methods
A detailed account of our methodology is given elsewhere [41].
rieﬂy, eligible cases were Chinese women with a diagnosis of pri-
ary lung carcinoma (all histological types). Of 496 lung cancer
atients identiﬁed, 473 were eligible, and 400 (84.6%) consented
o the interview. Histological or cytological reports were reviewed
nd conﬁrmed the diagnosis of primary lung carcinoma in 366 of
hese women; we excluded 2 patients who were diagnosed with
etastatic cancer to the lung. 32 cases were conﬁrmed on the
asis of radiological investigations in which metastatic cancer to
he lung from other sites was deemed clinically unlikely. A total of
98 conﬁrmed lung cancer cases were included.
Controls were obtained from patients admitted to the same hos-
itals, frequency-matched by 10-year age groups. Exclusion criteria
ere the diagnosis or management of malignancy or chronic res-
iratory disease (excluding tuberculosis). Controls were admitted
rom a wide range of diagnoses and no more than 10% of controls
hared the same diagnosis. 821 out of 962 patients (85.4%) agreed
o participate. 6 were subsequently excluded because malignancy
as diagnosed, and 1 was reclassiﬁed as a case. In total 814 con-
rols were enrolled. Of these, 85 were admitted for chest pain, acute
yocardial infarction, or heart failure, 11 for stroke or transient
schaemic attack, and 73 for musculoskeletal pain. A further 5 were
dmitted for conditions directly related to NSAID use (2 persons
ith ulcers due to NSAID use, 1 person with migraine and reboundPlease cite this article in press as: Lim W-Y, et al. Aspirin and non-aspirin no
Cancer  (2012), doi:10.1016/j.lungcan.2012.03.005
eadache secondary to analgesia use, 1 person with non-ulcer dys-
epsia secondary to NSAID use, and 1 person with nephropathy
econdary to NSAID use). These were excluded for this analysis,
eaving 640 controls for this analysis. PRESS
r xxx (2012) xxx– xxx
Research nurses conducted face-to-face interviews of both cases
and controls using a standardised questionnaire. A random sample
of interviews were recorded and reviewed as part of quality checks.
Next-of-kin were allowed to corroborate information provided
by the subjects, but proxy interviews were not used. The study
protocol was  approved by the National University of Singapore
Institutional Review Board and the Ethics Committees of the par-
ticipating healthcare institutions.
The structured questionnaire elicited information about demo-
graphic characteristics, occupational history, smoking history,
family history of cancer, personal medical history, diet (including
intake of fruits and vegetables), and indoor environmental expo-
sures. History of regular use (deﬁned as use at least twice a week for
a period of a month or more) of aspirin, non-aspirin NSAID and COX-
2 selective NSAID, paracetamol, steroid cream and steroid pills was
obtained. For each drug, the age at which use was  started and the
duration of use (in months) were also elicited. Never-smokers were
deﬁned as participants who had not smoked at least 1 cigarette a
day for at least a year. Ex-smokers were deﬁned as those who had
not smoked any cigarette in the 30 days prior to the interview.
Univariate analyses were performed using the chi-square test, t-
test and one-way ANOVA, where appropriate. Odds ratios (ORs) and
their 95% conﬁdence intervals (CIs) were calculated using uncondi-
tional logistic regression. STATA statistical software, version SE 10.1
(StataCorp LP, TX, USA) was used for data. All P value calculations
are two-tailed, with signiﬁcance set at P < 0.05.
Based on the results of reverse stepwise analyses and our own
literature review, we decided on a set of 6 variables for adjust-
ment in the multivariate analyses: age at diagnosis, housing type,
educational history (in years of school), history of cancer in ﬁrst
degree relative, and intake of fruits and vegetables. Among smok-
ers, smoking duration, the average number of cigarettes smoked,
and the duration since an individual stopped smoking were inde-
pendent risk factors (not shown). Logistic models of combinations
of these 3 variables showed that the duration of smoking alone
adequately explained the variation in risk attributable to smok-
ing among smokers, and this alone was added as an adjustment
variable for smokers.
3. Results
Table 1 gives a summary of relevant characteristics of the lung
cases and their controls in this study, stratiﬁed by smoking status.
Among never-smokers, cases and controls differed signiﬁcantly in
terms of average weekly fruit and vegetable consumption, housing
type, educational level, and family history (in 1st degree relative) of
cancer. Two-thirds (65%) of cases and 88% of controls were never-
smokers. The majority of histological diagnoses (64% among never-
smoker cases and 42% of smoker cases) were adenocarcinomas.
Comparing long-term aspirin users to non-users in cases and
controls, aspirin users were older than non-users in both cases and
controls, and also had fewer years of education than non-users.
Among cases, aspirin users were less likely to report a positive
family history of lung cancer (see Supplementary Table 4).
Table 2 summarises the overall results of self-reported regular
intake of 6 medication groups on lung cancer risk. Previous regu-
lar intake of aspirin was associated with a statistically signiﬁcant
lower risk of lung cancer in both never-smokers (OR 0.50, 95%CI
0.31–0.81) and smokers (OR 0.38, 95%CI 0.16–0.93 in smokers). No
associations were seen with non-aspirin NSAID, paracetamol and
COX-2 inhibitors, although the numbers reporting regular use weren-steroidal anti-inﬂammatory drug use and risk of lung cancer. Lung
very small. No associations were seen with regular use of steroid
pills or cream.
Table 3 summarises the association between onset of aspirin
use and duration of use on lung cancer risk in non-smokers. The
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Table 1
Baseline characteristics of female Chinese lung cancer patients and controls, Singapore, 2005–2008.
All Never-smokers Smokers
Cases (n = 398) Controls (n = 640) P Cases (n = 257) Controls (n = 561) P Cases (n = 141) Controls (n = 79) P
Age in years
Mean ± SD 66.68 ± 11.63 65.02 ± 11.69 0.026 63.85 ± 12.01 64.44 ± 11.51 0.50 71.84 ± 8.85 69.14 ± 12.18 0.31
Median (68) (66) (64) (66) (72) (72)
Average  weekly fruit consumption (servings)
Mean ± SD 7.40 ± 9.52 9.55 ± 9.05 <0.001 9.84 ± 9.01 7.69 ± 7.32 <0.001 6.87 ± 12.60 7.49 ± 9.10 0.70
Median  (4.85) (7.51) (5.76) (7.81) (3.39) (5.01)
Average weekly vegetable consumption (servings)
Mean ± SD 19.64 ± 20.38 23.03 ± 20.34 0.009 20.37 ± 20.38 23.53 ± 20.85 0.043 18.30 ± 20.38 19.43 ± 15.85 0.67
Median (13.76) (17.95) (14.50) (18.21) (12.51) (15.36)
All Never-smokers Smokers
Cases, n (%) Controls, n (%) P Cases, n (%) Controls, n (%) P Cases, n (%) Controls, n (%) P
Dialect group 0.71 0.38 0.08
Hokkien 175 (44.1) 287 (45.0) 92 (35.9) 242 (43.2) 83 (58.9) 45 (57.7)
Teochew 87(21.9) 129 (20.2) 65 (25.4) 115 (20.5) 22 (15.6) 14 (18.0)
Cantonese 74 (18.6) 103 (16.1) 47 (18.4) 94 (16.8) 27 (19.2) 9 (11.5)
Hainanese 18 (4.5) 35 (5.5) 17 (6.6) 29 (5.2) 1 (0.7) 6 (7.7)
Hakka 31 (7.8) 58 (9.1) 26 (10.2) 56 (10.0) 5 (3.6) 2 (2.6)
Others 12 (3.0) 26 (4.1) 9 (3.5) 24 (4.3) 3 (2.1) 2 (2.6)
Country of birth 0.31 0.49 0.81
Singapore 270 (67.8) 455 (71.1) 177 (68.9) 402 (71.7) 93 (66.0) 53 (67.1)
Malaysia 60 (15.1) 102 (15.9) 38 (14.8) 87 (15.5) 22 (15.6) 15 (19.0)
China  51 (12.8) 65 (10.2) 30 (11.7) 56 (10.0) 21 (14.9) 9 (11.4)
Others 17 (4.3) 18 (2.8) 12 (4.7) 16 (2.9) 5 (3.6) 2 (2.5)
Current housing 0.15 0.011 0.70
1–3  rooms public ﬂat 126 (32.1) 213 (33.5) 76 (29.9) 181 (32.4) 50 (36.0) 32 (41.0)
4  rooms or larger public ﬂat 197 (50.1) 338 (53.1) 120 (47.2) 297 (53.2) 77 (55.4) 41 (52.6)
Private  apt or house 70 (17.8) 85 (13.4) 58 (22.8) 80 (14.3) 12 (8.6) 5 (6.4)
Years of education 0.52 0.014 0.50
Nil  161 (40.6) 247 (38.6) 81 (31.5) 203 (36.2) 80 (57.1) 44 (55.7)
≤6  years 118 (29.7) 212 (33.1) 72 (28.0) 189 (33.7) 46 (32.9) 23 (29.1)
7  years or more 118 (29.7) 181 (28.3) 104 (40.5) 169 (30.1) 14 (10.0) 12 (15.2)
Marital status 0.17 0.23 0.73
Currently or previously married 372 (93.5) 583 (91.1) 240 (93.4) 510 (90.9) 132 (93.6) 73 (92.4)
Never  married 26 (6.5) 57 (8.9) 17 (6.6) 51 (9.1) 9 (6.4) 6 (7.6)
Ever  worked outside the home 0.12 0.68 0.19
Yes  312 (78.4) 526 (82.3) 209 (81.3) 462 (82.5) 103 (73.1) 64 (81.0)
No  86 (21.6) 113 (17.7) 48 (18.7) 98 (17.5) 38 (26.9) 15 (19.0)
Smoking status <0.001
Current smoker 44 (11.1) 24 (3.7)
Ex-smokera 97 (24.4) 55 (8.6)
Never smoker 257 (64.6) 561 (87.7)
Environmental tobacco smoke exposure at home 0.34 0.64 0.91
<Daily 161 (41.4) 281 (44.5) 121 (48.6) 259 (46.8) 40 (28.6) 22 (27.9)
Every  day 228 (58.6) 351 (55.5) 128 (51.4) 294 (53.2) 100 (71.4) 57 (72.2)
Family  history of cancerb 0.037 0.006 0.37
No  265 (68.7) 475 (75.2) 165 (65.5) 414 (74.6) 100 (74.6) 61 (79.2)
Yes,  other sites 84 (21.8) 119 (18.8) 59 (23.4) 110 (19.8) 25 (18.7) 9 (11.7)
Yes,  lung cancer 37 (9.6) 38 (6.0) 28 (11.1) 31 (5.6) 9 (6.7) 7 (9.1)
Histologic type
Adenocarcinomasc 224 (56.3) 165 (64.2) 59 (41.8)
Squamous cell carcinomasd 31 (7.8) 9 (3.5) 22 (15.6)
Small cell carcinomase 19 (4.8) 3 (1.2) 16 (11.3)
Other histologyf 92 (23.1) 62 (24.1) 30 (21.3)
No  histology/cytology 32 (8.0) 18 (7.0) 14 (9.9)
Abbreviation: SD, standard deviation.
a Have not smoked any cigarette in the 30 days prior to admission.
b First degree relatives.
c Histology codes (ICD-O-3): 8140/3 – adenocarcinoma NOS; 8260/3 – papillary adenocarcinoma, NOS; 8480/3 – mucinous adenocarcinomas.









ae Histology code (ICD O-3): 8041/3 – small cell carcinoma, NOS.
f Other histology codes, the most common being (ICD-O-3): 8012/3 – large cell
arcinoma.
umbers of ever-smoker users in our study were too small for
eaningful interpretation. The lowest risks of lung cancer occurred
n non-smokers who started using aspirin between 1 and 5 yearsPlease cite this article in press as: Lim W-Y, et al. Aspirin and non-aspirin no
Cancer  (2012), doi:10.1016/j.lungcan.2012.03.005
efore admission/diagnosis, and whose duration of aspirin use was
etween 12 and 60 months (OR 0.35, 95%CI 0.14–0.85, and OR 0.37,
5% CI 0.16–0.85, respectively). Duration of use and onset of use
ppeared to be correlated (data not shown), so it was  not possiblenoma, NOS; 8046/3 – non-small cell carcinoma, NOS; 8250/3 – bronchio-alveolar
to study the separate effects of duration or onset of use adjusting
for the other variable.
Restricting cases to non-smokers with lung adenocarcinomasn-steroidal anti-inﬂammatory drug use and risk of lung cancer. Lung
(n = 165), an OR of 0.43, 95% CI 0.24–0.78 was obtained for the asso-
ciation between aspirin use and lung cancer. A pattern similar to
that in Table 3 was observed when we  investigated the onset of
aspirin use and the duration of use in this subgroup, with lowest ORs
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Table 2
Association between use of a variety of medications and lung cancer in Chinese lung cancer patients and their controls, Singapore, 2005–2008.
Non-smokers N = 818 Smokers N = 220
Cases N = 257 Controls N = 561 OR (95%CI)a Cases N = 141 Controls N = 79 OR (95%CI)b
Regular use of aspirinc No 226 (89.7) 442 (79.5) 1.0 122 (89.7) 63 (80.8) 1.0
Yes  26 (10.3) 114 (20.5) 0.50 (0.31–0.81) 14 (10.3) 15 (19.2) 0.38 (0.16–0.93)
Regular use of
non-aspirin NSAIDc
No 243 (96.4) 541 (97.3) 1.0 134 (97.8) 74 (96.1) 1.0
Yes 9 (3.6) 15 (2.7) 1.72 (0.71–4.19) 3 (2.2) 3 (3.9) 0.57 (0.10–3.12)
Regular use of COX-2
inhibitorc
No 251 (99.6) 552 (99.3) 1.0 137 (100) 77 (100) –
Yes  1 (0.4) 4 (0.7) 0.56 (0.06–5.25) 0 0 –
Regular use of panadolc No 243 (96.0) 530 (95.5) 1.0 128 (92.8) 75 (96.2) 1.0
Yes  10 (4.0) 25 (4.5) 1.02 (0.47–2.21) 10 (7.2) 3 (3.8) 2.58 (0.62–10.78)
Regular use of steroid
creamsc
No 245 (97.2) 536 (97.1) 1.0 133 (97.1) 77 (98.7) 1.0
Yes 7 (2.8) 16 (2.9) 0.84 (0.33–2.14) 4 (2.9) 1 (1.3) 2.84 (0.29–28.27)
Regular use of steroid
pillsc
No 244 (96.8) 539 (96.9) 1.0 135 (98.5) 75 (97.4) 1.0
Yes  8 (3.2) 17 (3.1) 1.35 (0.54–3.38) 2 (1.5) 2 (2.6) 1.13 (0.14–9.15)




























db Adjusted for age at diagnosis/admission, average weekly fruit and vegetable co
elative and duration (in years) of smoking.
c Regular use refers to use of at least two times a week for at least a month or mo
chieved in persons starting use 1–5 years prior to admission, and
n those who had used aspirin for 12–60 months (data not shown).
To assess the impact of controls with speciﬁc diagnoses on
he estimation of the effect of aspirin use on lung cancer risk,
e systematically excluded groups of controls based on their
dmission diagnoses (in broad groupings of accidents and injuries,
rthopaedic conditions, gastrointestinal conditions, respiratory
onditions, neurological conditions, cardiac conditions, renal con-
itions, endocrine conditions infectious diseases, and others). No
igniﬁcant variation in the OR estimates were seen, with adjusted
Rs in the range of 0.49–0.55 for never-smokers, and 0.28–0.39 for
mokers (see Supplementary Table 5).
The protective effect of aspirin was present even when par-
icipants who used aspirin within 1 year of diagnosis of lung
ancer (in cases), or admission to hospital (for controls) were
xcluded, with ORs and 95%CI for never-smokers and smokers of
.44 (0.24–0.81) and 0.40 (0.15–1.04), respectively. Finally, exclu-
ion of 32 cases of lung cancer diagnosed on radiological grounds
id not materially affect the results observed, with ORs of 0.49
95%CI 0.30–0.81) for never-smokers and 0.33 (95%CI 0.13–0.84)
or smokers.Please cite this article in press as: Lim W-Y, et al. Aspirin and non-aspirin no
Cancer  (2012), doi:10.1016/j.lungcan.2012.03.005
. Discussion
Our results suggest that regular aspirin consumption may  be
ssociated with a reduced risk of cancer in both never-smokers
able 3
ssociation between onset and length of aspirin use and lung cancer in Chinese female lu
Non-smokers
Cases n = 257 
Onset of aspirin use
No use 226 (89.7) 
Start  using <1year from admission 11 (4.4) 
Start  using 1–<5 years from admission 6 (2.4) 
Start  using 5 years and more from admission 9 (3.6) 
Duration of aspirin use
No use 226 (89.7) 
Duration of use 12 month or less 11 (4.4) 
Duration of use 12–<60 months 7 (2.8) 
Duration of use 60 months or more 8 (3.2) 
a Adjusted for age at diagnosis/admission, average weekly fruit and vegetable consum
egree relative.tion (in servings), years of education, housing type, history of cancer in 1st degree
and ever-smokers. Non-aspirin NSAIDs, and paracetamol and other
forms of acetaminophen use were not associated with reduced risk
of lung cancer, though the numbers of regular users in each group
were small. The risk estimates were not signiﬁcantly different in
the subgroup of non-smokers with histologically conﬁrmed ade-
nocarcinomas, compared to the overall group of cases.
A protective effect of aspirin and other NSAIDs is biologically
plausible – COX2 is an inducible enzyme with pro-inﬂammatory
and pro-carcinogenic properties, and in vitro and animal studies
lend support to the role of COX2 in carcinogenesis [1–9]. However,
reported results of aspirin use and lung cancer risk are conﬂict-
ing, with both protective [13–21] and null effects [22–32] being
reported. Three clinical trials focusing on chemoprevention with
aspirin reported non-signiﬁcant protective effects [35–37],  and a
recent pooled analysis of individual-level data from 7 clinical trials
of daily aspirin reported a protective effect on lung cancer death,
with a protective latent period of about 5 years. The authors also
reported a greater protective effect against adenocarcinomas [38].
The reasons for the inconsistency in ﬁndings include small num-
bers of lung cancer cases, failure to distinguish between aspirin and
other NSAIDs, and inadequate control of smoking status (as have
been pointed out by some of the authors). The widely contrastingn-steroidal anti-inﬂammatory drug use and risk of lung cancer. Lung
results from meta-analyses [17,33,34] – the differences in results
appear to be due to differences in studies included, and to the use
of different deﬁnitions of exposure (aspirin and NSAIDs examined
separately or in combination).
ng cancer patients and their controls, restricted to never-smokers.
Controls n = 561 ORs (95%CI)a
442 (79.5) 1.0
39 (7.0) 0.61 (0.30–1.23)
39 (7.0) 0.35 (0.14–0.85)
36 (6.5) 0.54 (0.25–1.18)
442 (79.5) 1.0
40 (7.2) 0.61 (0.30–1.24)
43 (7.7) 0.37 (0.16–0.85)
31 (5.6) 0.54 (0.24–1.22)
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The effect of aspirin and other NSAIDs may  be modiﬁed by
ender, and this could also explain the heterogeneity in results.
he estrogen and prostaglandin pathways are known to interact,
nd estradiol increases COX-2 production in some cell types [42].
he effect of COX-2 inhibition by aspirin and NSAIDs may  thus be
tronger in women. The available epidemiologic evidence is not
onsistent, with stronger protective effects in men  [20], stronger
rotective effects in women [22,23], and similar effects in both
enders [17,18] all being reported. A possible explanation may  be
esidual confounding by smoking in populations where there are
trong gender differences in smoking rates.
Among the studies that distinguished between aspirin and non-
spirin NSAID use, some reported stronger protective effects of
spirin than non-aspirin NSAID [19], while others reported that
he effect of non-aspirin NSAIDs was stronger [16,17,21].  Resid-
al confounding by smoking (because aspirin but not non-aspirin
SAIDs use may  be higher in smokers as anti-thrombotic treatment
or cardiovascular disease risk) may  shift effects towards the null
nd explain the smaller effect of aspirin compared to non-aspirin
SAIDs detected in some studies [17]. In contrast, our study found
rotective effects of aspirin even in non-smokers, but no protec-
ive effect in a much smaller group of regular users of non-aspirin
SAID.
Our study contributes to the growing literature on the role of
SAIDs and aspirin on lung cancer by studying the effect of aspirin
nd non-aspirin NSAIDs in a large group of Asian female non-
mokers, for which the effect of aspirin and non-aspirin NSAIDs
as not been well characterised.
There are a number of limitations in this study. We  used
 hospital-based case–control design. Aspirin and NSAID use in
ingapore is prescribed by physicians for the treatment of medi-
al conditions rather than as health supplements. Hence, controls
ay  have a higher-than-representative prevalence of aspirin and
SAID use. This would bias our estimates away from the null.
e have tried to minimise this by recruiting controls from a
ariety of admitting diagnoses, and, in line with the theory of con-
rol selection proposed by Wacholder [43], have also excluded
ontrols whose admission diagnoses are likely to be associated
both positively and negatively) with the exposures of interest.
e excluded individuals admitted for chest pain, acute myocar-
ial infarction, or heart failure, stroke or transient ischaemic
ttack, and for management of musculoskeletal pain, including
nee, hip and back pain, as NSAIDs and aspirin are commonly
sed in the management of these conditions. In addition, we also
xcluded individuals who were admitted for complications aris-
ng from NSAID use. We  also evaluated the impact of including
ontrols from particular diagnoses groups on the OR estimates
or aspirin use and lung cancer risk, by systematically excluding
ontrols based on their diagnoses group and testing the effect of
spirin. These analyses suggest that the results we  obtained were
airly robust, and were not likely due to high aspirin use in any
articular group of controls.
We have tried to mitigate the well-known problems of recall and
nterviewer bias in case–control designs by training our interview-
rs, having them interview both cases and controls, and recording
 random sample of interviews to assess quality. We  do not believe
ecall bias to be a major source of error as the putative relation-
hip between NSAID use and lung cancer is not well known, and
he questions about NSAIDs and aspirin use were embedded in a
onger questionnaire that covered a variety of exposures. We  relied
n self-reports of medication use, and under- or over-reporting of
edication use is possible. However, as this was  a hospital-basedPlease cite this article in press as: Lim W-Y, et al. Aspirin and non-aspirin no
Cancer  (2012), doi:10.1016/j.lungcan.2012.03.005
tudy and interviews were conducted in the hospital, such misre-
orting should affect cases and controls equally. We  were unable
o obtain information about the dosage and frequency of use of
hese medications in our participants, and we did not distinguish PRESS
r xxx (2012) xxx– xxx 5
between low-dose or normal dose aspirin, thus limiting our ability
to deﬁne more precisely the effect of aspirin.
Because of the relatively small size of our study and the low
frequency of use of some medications such as steroid pills, some
estimates reported in this study are imprecise, with wide conﬁ-
dence intervals. OR estimates presented in Table 2 for steroid pills
and COX-2 inhibitors, and in Table 3 showing the effect of dura-
tion of aspirin use and date of onset of aspirin use in relation to
lung cancer risk should be viewed as preliminary in nature. Addi-
tional well-designed studies conducted in similar populations of
never-smokers are necessary to conﬁrm our results.
The key strengths of our study are that we have restricted par-
ticipants to Chinese women, a population sub-group that appears
to be at unusually high risk of lung cancer [44]: this recruitment
strategy increases the precision of our study by reducing the varia-
tion in genetic and environmental factors due to ethnicity that may
also be associated with lung cancer. We  obtained high response
rates in both cases and controls, and were able to control for multi-
ple potential confounders such as smoking, socio-economic status,
and diet.
5. Conclusion
In summary, our data suggest that regular aspirin consumption
may  confer protection against lung cancer in Chinese women.
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The authors examined relations between reproductive factors and 5 estrogen pathway gene polymorphisms
(CYP17 rs743572, CYP19A1 rs10046, ERb rs1256049, ERb rs4986938, and COMT rs4680) among 702 Singapore
Chinese female lung cancer cases and 1,578 hospital controls, of whom 433 cases (61.7%) and 1,375 controls
(87.1%) were never smokers. Parity (per child, odds ratio (OR) ¼ 0.92, 95% conﬁdence interval (CI): 0.87, 0.97) and
menstrual cycle length (for 30 days vs. <30 days, OR ¼ 0.50, 95% CI: 0.32, 0.80) were inversely associated with
lung cancer in never smokers, while age at ﬁrst birth (for ages 21–25, 26–30, and31 years vs.20 years, ORswere
1.54, 2.17, and 1.30, respectively), age at menopause (for ages 49–51 and52 years vs.48 years, ORs were 1.37
and 1.59;Ptrend¼ 0.003), and reproductive period (for 31–33, 34–36, 37–39, and40 years vs.30 years, ORswere
1.06, 1.25, 1.45, and 1.47; Ptrend ¼ 0.026) were positively associated. Among smokers, parity was inversely asso-
ciated with lung cancer, but there was no association with other reproductive factors. The COMT rs4680 A allele was
positively associated with lung cancer in never smokers (for G/A or A/A vs. G/G, OR ¼ 1.46, 95% CI: 1.12, 1.90) but
not in ever smokers. No associations were seen with other polymorphisms. These results support a risk-enhancing
role of estrogens in lung carcinogenesis among never smokers.
estrogen; etiology; lung neoplasms; reproductive history
Abbreviations: PCR, polymerase chain reaction; SNP, single nucleotide polymorphism.
Lung cancer is the leading cause of cancer death in the
world (1), and smoking is the major risk factor for the dis-
ease (2). However, lung cancer among never smokers is not
uncommon, and annual global mortality from lung cancer
among never smokers is as high as 15–20 per 100,000 per-
sons (3). Previous studies suggest that female never smokers
may be more likely to develop lung cancer than men (4),
although this is disputed (5). Women appear more likely
than men to develop adenocarcinoma, especially among
never smokers (6).
Epidemiologic studies conducted in the 1980s implicated
reproductive factors and female hormonal factors in lung
carcinogenesis (7–10), and this hypothesis gained momen-
tum with evidence of the potential biologic and pathologic
roles of estrogen in lung development and carcinogenesis.
Estrogen receptors, predominantly the b isoform, are found
in both normal lung and carcinomatous tissue (11), and es-
trogen receptor signaling pathways are active in lung cancer
cells (12), increasing cell proliferation and promoting an-
giogenesis. This pathway also interacts with the epidermal
growth factor receptor pathway (13), which is believed to
drive carcinogenesis in a subset of lung cancers (lung adeno-
carcinomas among predominantly female never smokers) (14).
In vitro and mouse model studies suggest that estrogens
increase tumor growth, and estrogen receptor antagonists sig-
nificantly inhibit growth in non-small-cell lung cancer cell
lines (15, 16). These findings have spurred renewed interest
in the possible role of female hormonal factors in lung cancer,
and, including the earlier studies, at least 28 studies (7–10,
17–41) have investigated the association of lung cancer
with factors such as parity (8, 9,17–19, 21–29, 31–33, 41),
menstrual history (7–10, 17, 18, 21, 22), age at menopause
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(7–10, 18–23, 25, 27, 29, 32, 33, 41), age at menarche (8–10,
18–23, 26–28, 29, 32, 33, 41), estrogen replacement therapy
(9, 22, 23, 25, 26, 28, 29, 32–39), and oral contraceptive use
(8, 22, 25, 28–30, 32–34, 4–41).
Findings from these studies are inconsistent, suggesting
that the effects of female reproductive factors are not strong
and therefore difficult to detect, or that reproductive factors
interact with other host genetic or environmental factors in
complex ways. The existing evidence does not appear to
conform to the well-established model for the association
of reproductive factors with breast cancer (where early men-
arche and late menopause, nulliparity, and late age at first
birth consistently increase breast cancer risk), but no alter-
native model has yet emerged.
Understanding the estrogen metabolic pathway in relation
to lung cancer may shed light on the role of estrogen in lung
carcinogenesis. To date, few studies have examined the as-
sociation of estrogen-metabolism gene polymorphisms with
lung cancer. Two recent studies investigated gene polymor-
phisms in estrogen-metabolism enzymes (cytochrome P-450
17-a hydroxylase (17,20-lyase) (CYP17), cytochrome P-450
19A1 (aromatase) (CYP19A1), and catechol-O-methyl trans-
ferase (COMT)) (42) and in estrogen receptor b (ERb) (43),
although these studies used populations in which nonsmokers
were a small minority.
Lung cancer is the leading cause of cancer death in
Singapore (44). Despite low rates of smoking (45), the inci-
dence of lung cancer among Singaporean Chinese women
is unexpectedly high (44), with a significant proportion of
cancers occurring in nonsmokers. This suggests that factors
other than smoking may play an unusually important role in
lung cancer in this population.
We previously reported that among never smokers, parity
and menstrual cycle length were associated with a significantly
reduced risk of lung cancer, based on a study of 303 cases
and 765 hospital controls (18). Our aims in the current study
were to extend this analysis to a larger group of 702 cases
and 1,578 hospital controls so as to better delineate possible
differences between smokers and never smokers and to in-
vestigate the association of estrogen metabolism gene poly-
morphisms with lung cancer in Chinese women.
MATERIALS AND METHODS
Data for this study were derived from 2 hospital-based
case-control studies conducted in 1996–1998 and 2005–2008
among participants recruited from the 5 major public-sector
hospitals in Singapore. Both studies used similar study de-
signs and questionnaires, and methods are reported in detail
elsewhere (46, 47). Eligible cases were Chinese women with
incident primary carcinoma of the lung (all histologic types)
who were interviewed within 3 months of diagnosis. The
average interval between diagnosis and interview was 22 days,
and 79% were interviewed within 1 month of diagnosis. A total
of 787 eligible lung cancer patients were identified, of whom
702 (89.2%) agreed to participate. Histologic or cytologic
reports confirmed the diagnosis of primary lung carcinoma
in 673 cases; 29 cases were confirmed on the basis of results
from radiologic investigations, where metastatic spread of
cancer to the lung was deemed unlikely.
Controls were selected from Chinese female patients admit-
ted to the same hospitals and were frequency-matched for age
(within 10 years) and date of admission. Patients admitted for
the diagnosis and treatment of cancer or chronic respiratory
disease were excluded, and no more than 10% of controls
were recruited within a single diagnostic category. Control
patients were admitted for a wide range of conditions, with
few patients (0.4% of controls) having been admitted for
gynecologic or obstetric conditions. The response rate among
controls was 91%, with a total of 1,578 controls recruited.
Of the 702 cases and 1,578 controls, 433 cases (61.7%) and
1,375 controls (87.1%) were never smokers, defined as
never having smoked at least 1 cigarette per day for a year.
Approval for this study was obtained from the institu-
tional review boards of the National University of Singapore
and participating health-care institutions. Written consent
was obtained from all participants. Trained interviewers
administered face-to-face a structured questionnaire which
elicited a detailed reproductive history, including parity,
age at the birth of the first child, usual menstrual cycle length,
age at menarche, and, where relevant, age at menopause.
Among postmenopausal women, the reproductive period
was measured as the time period between menarche and
menopause. Information on exogenous reproductive hormone
use (as hormone replacement therapy or oral contraception)
was elicited only in the second case-control study. Data on
participants’ demographic characteristics, occupational his-
tory, smoking history, family history of cancer, personal
medical history, diet, medication use, and indoor environ-
mental exposures were also obtained.
Blood and/or saliva samples were obtained where consent
was given. A total of 559 samples from cases (79.6% of all
cases) and 988 samples from controls (62.6% of all controls)
were obtained. Genomic DNA was extracted from the buffy
coat of 5 mL of whole blood samples using the FlexiGene
DNA kit (Qiagen Inc., Hilden, Germany). Saliva DNA was
extracted from 2 mL of saliva with the Oragene DNA Self-
Collection Kit (DNA Genotek Inc., Kanata, Ontario, Canada),
and DNA concentration was measured with the Quantifiler
Human DNA Quantification kit (Applied Biosystems (Life
Technologies), Foster City, California).
Five polymorphisms in 4 estrogen pathway genes (rs743572
in CYP17, rs10046 in CYP19A1, rs4680 in COMT, and
rs1256049 and rs4986938 in ERb) were genotyped. We se-
lected these genes because the proteins they encode are in-
fluential in the estrogen pathway. Cytochrome P-450 17-a
hydroxylase is an upstream enzyme that produces estrogen
precursors, while cytochrome P-450 19A1 converts testos-
terone to estradiol. Catechol-O-methyl transferase is the
rate-limiting enzyme in the detoxification of catechol estrogens
(48). Estrogen receptor b is found in lung tissue. Polymor-
phisms within these genes were selected for their potential
role in affecting the activity of the enzymes, as demonstrated
by their location in the gene (promoter regions, the untrans-
lated region, or exons) and by functional and epidemiologic
studies. Single nucleotide polymorphisms (SNPs) chosen
had to have a minor allele frequency of 5% in Chinese
populations.
All SNPs were genotyped on a high-throughput genotyp-
ing platform base using a 5#-nuclease allelic discrimination
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assay in a 96-well format, with the ABI StepPlusOne Real-
Time PCR System (Applied Biosystems). TaqMan universal
polymerase chain reaction (PCR) master mix and prede-
signed SNP genotyping assay mix containing PCR primers
and probes were purchased from Applied Biosystems. Among
131 subjects who had both blood and saliva samples, saliva
DNA was successfully genotyped from 89%, while all blood
DNA samples were successfully genotyped. The genotypes
from saliva DNA samples matched completely (100%) those
of the corresponding blood DNA samples. Three positive con-
trols and 2 negative controls were included in each 96-well
plate, and 10% of DNA samples were genotyped in duplicate
for each polymorphism. The concordance rate for the dupli-
cate analyses was 100%. Call rates for the 5 SNPs studied
ranged from 96.6% to 97.5%.
A set of 10 adjustment variables, chosen on the basis of
biologic considerations and reverse stepwise analyses of the
data set, were used: age at diagnosis, country of birth, housing
type, number of years of education, smoking status, second-
hand smoke exposure, history of cancer in a first-degree
relative, mean intake of fruits and vegetables (servings/week),
and a variable to indicate which case-control study the par-
ticipant belonged to. Among current and former smokers,
duration of smoking (in years), the logarithm of the average
number of cigarettes smoked per day, and time (in years)
since quitting smoking prior to diagnosis (set at 0 for current
smokers) were independent risk factors (not shown). Logistic
regression models using combinations of these 3 variables
showed that smoking duration alone adequately explained
the variation in risk attributable to smoking, and this was
added as an adjustment variable for smokers.
Unconditional logistic regression was used, and odds
ratios and 95% confidence intervals were calculated. Tests
for linear trend were performed by entering the factor of
interest into the logistic regression model as an ordinal vari-
able, where each successively higher category in that factor
was assigned a higher numeric value in the variable. The
likelihood ratio test was used to test for interaction between
factors. Adjustment for multiple comparisons was made
for all tests of statistical interaction using the method of
Benjamini and Hochberg (49). All P values calculated were
2-tailed, and significance was set at P< 0.05. We used Stata
statistical software, version SE 10.1 (StataCorp LP, College
Station, Texas), for data analyses. All SNPs studied were in
Hardy-Weinberg equilibrium in the control population.
RESULTS
Cases were significantly younger than controls and con-
sumed less fruit and vegetables. They were more likely to
have been born in China, to live in private housing, to smoke,
to report daily secondhand smoke exposure, and to have a pos-
itive family history of lung cancer in a first-degree relative.
Among smokers, cases reported a longer duration of smoking
(Table 1). Half of the cases (51.7%) had lung adenocarci-
noma, and the proportion of adenocarcinomas was higher
among never smokers (62.6%) than among smokers (34.2%).
High parity was associated with a lower risk of lung cancer
in never smokers (for every additional child, odds ratio
(OR) ¼ 0.92, 95% confidence interval (CI): 0.87, 0.97).
Similar odds ratios, but with nonsignificant P values, were
obtained in the smaller number of ever smokers (Table 2).
Higher age at first birth was associated with an increased
risk of lung cancer in never smokers (among those whose
first child had been born when they were aged 21–25, 26–30,
and 31 years, odds ratios were 1.54, 2.17, and 1.30, re-
spectively, compared with those aged 20 years at the first
birth). The effect was less clear among ever smokers (adjusted
Pinteraction ¼ 0.14) (Table 2).
Age at menopause was associated with lung cancer
among postmenopausal women who had never smoked
(for ages at menopause of 49–51 years and 52 years
compared with 48 years, odds ratios were 1.37 and 1.59,
respectively; Ptrend ¼ 0.003) but not among those who had
ever smoked (odds ratios were 0.95 were 0.94, respectively;
Ptrend ¼ 0.81); the adjusted P value for interaction was 0.22)
(Table 2). Similarly, a longer reproductive period was as-
sociated with lung cancer risk among never smokers (for
reproductive periods of 31–33, 34–36, 37–39, and 40 years
compared with 30 years, odds ratios were 1.06, 1.25, 1.45,
and 1.47, respectively; Ptrend ¼ 0.026) but not among ever
smokers (adjusted Pinteraction ¼ 0.34) (Table 2).
Long menstrual cycle lengths were protective in never
smokers (for reported cycle lengths of>30 days vs.30 days,
OR ¼ 0.50, 95% CI: 0.32, 0.80) but not in ever smokers
(adjusted Pinteraction¼ 0.33). There were relatively few women
who reported cycle lengths longer than 30 days. There was
no association between hormone use and lung cancer, al-
though the prevalence of hormone use was low. There was
also no association between age at menarche and lung
cancer (Table 2).
Of the 5 SNPs studied, only the SNP in the COMT gene
was associated with lung cancer (Table 3). The A allele at
rs4680 was associated with lung cancer in never smokers
(for the G/A or A/A genotype compared with the G/G geno-
type, OR¼ 1.46, 95% CI: 1.12, 1.90) but not in ever smokers
(OR ¼ 0.77, 95% CI: 0.47, 1.28; adjusted Pinteraction ¼ 0.14).
In analyses stratified by age, the risk-conferring effect of
longer reproductive periods in never smokers was seen only
among women older than 65 years, not in the younger age
group (adjusted Pinteraction ¼ 0.22). The protective effect of
increasing parity also appeared to be stronger in the older age
group than in the younger age group, although this interaction
was not statistically significant (adjusted Pinteraction ¼ 0.95)
(Table 4). The effects of age at menopause, age at first birth,
menstrual cycle length, and the COMT rs4680 polymorphism
were not modified by age (data not shown). Odds ratio
estimates for never-smoker cases restricted to persons with
a confirmed histology of adenocarcinoma were similar to
those obtained for all never smokers (data not shown). Further
adjustment for self-reported exposure to cooking fumes
shifted odds ratio estimates for all reproductive factors and
SNPs by less than 5% in either direction.
DISCUSSION
In this ethnically homogenous population with a high
prevalence of never smoking, later age at menopause, longer
reproductive period, later age at first birth, short menstrual
cycle length, and low parity were associated with lung cancer,
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Table 1. Baseline Characteristics of Female Chinese Lung Cancer Patients and Controls, Singapore, 1996–1998 and 2005–2008
Total Never Smokers Ever Smokers
Cases (n 5 702) Controls (n 5 1,578)
P Value
Cases (n 5 433) Controls (n 5 1,375)
P Value
Cases (n 5 269) Controls (n 5 203)
P Value
Mean (SD) No. % Mean (SD) No. % Mean (SD) No. % Mean (SD) No. % Mean (SD) No. % Mean (SD) No. %
Age, years 65.9 (11.8) 64.1 (12.3) <0.001 63.0 (12.5) 63.6 (12.2) 0.42 70.5 (8.9) 67.3 (12.6) 0.001
Fruit consumption,
servings/week




21.4 (19.3) 25.6 (21.3) <0.001 22.3 (19.4) 25.9 (21.3) <0.001 20.0 (19.0) 23.3 (21.5) 0.08
Years of education 3.6 (4.5) 4.0 (4.4) 0.06 4.8 (4.9) 4.2 (4.5) 0.02 1.7 (2.9) 2.4 (3.7) 0.02
Dialect 0.03 0.008 0.01
Hokkien 290 41.7 673 43.5 151 35.2 577 42.8 139 52.1 96 48.5
Teochew 157 22.6 307 19.9 109 25.4 265 19.7 48 18.0 42 21.2
Cantonese 151 21.7 286 18.5 85 19.8 252 18.7 66 24.7 34 17.2
Hainanese 40 5.8 89 5.8 38 8.9 80 5.9 2 0.8 9 4.6
Hakka 38 5.5 138 8.9 31 7.2 125 9.3 7 2.6 13 6.6
Other 20 2.9 53 3.4 15 3.5 49 3.6 5 1.9 4 2.0
Country of birth 0.001 0.012 0.59
Singapore 442 63.0 1,031 65.3 274 63.3 900 65.5 168 62.5 131 64.5
Malaysia 92 13.1 271 17.2 57 13.2 239 17.4 35 13.0 32 15.8
China 145 20.7 234 14.8 85 19.6 198 14.4 60 22.3 36 17.7






254 36.4 613 39.0 145 33.7 517 37.8 109 40.8 96 47.5
Public apartment,
4 rooms
332 47.6 775 49.3 202 47.0 682 49.8 130 48.7 93 46.0
Private apartment
or house
111 15.9 183 11.7 83 19.3 170 12.4 28 10.5 13 6.4




654 93.2 1,467 93.0 403 93.1 1,275 92.7 251 93.3 192 94.6




Yes 513 73.1 1,224 77.7 330 76.2 1,065 77.6 183 68.0 159 78.3
No 189 26.9 352 22.3 103 23.8 308 22.4 86 32.0 44 21.7
Smoking status <0.001 0.45
Never smokera 433 61.7 1,375 87.1
Ex-smokerb 143 20.4 115 7.3 143 53.2 115 56.7
Current smoker 126 18.0 88 5.6 126 46.8 88 43.3
Duration of smoking,
yearsc
43.7 (17.8) 33.4 (20.3) <0.001
No. of cigarettes
smoked per day
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Years since stopping
smokingd





Less than daily 334 48.1 848 54.1 226 53.1 764 55.9 108 40.2 84 41.6




No 531 75.6 1,286 81.5 309 71.4 1,112 80.9 222 82.5 174 85.7
Yes, lung cancer 45 6.4 63 4.0 36 8.3 55 4.0 9 3.4 8 3.9
Yes, at other sites 126 18.0 229 14.5 88 20.3 208 15.1 38 14.1 21 10.3
Histologic type
Adenocarcinomaf 363 51.7 271 62.6 92 34.2
Squamous cell
carcinomag
84 12 25 5.8 59 21.9
Small cell
carcinomah
38 5.4 5 1.2 33 12.3
Otheri 188 26.8 115 26.6 73 27.1
No histologic or
cytologic data
29 4.1 17 3.9 12 4.5
Abbreviations: ICD-O-3, International Classiﬁcation of Diseases for Oncology, Third Edition; NOS, not otherwise speciﬁed; SD, standard deviation.
a Deﬁned as having never smoked at least 1 cigarette per day for a year.
b Having not smoked any cigarettes during the 30 days prior to admission.
c Deﬁned as the difference between the age at which the participant stopped smoking (taken as the age at diagnosis or admission for participants who were currently smoking) and the age at which she started.
d Deﬁned as the difference between age at diagnosis and age at which the participant stopped smoking; set as 0 for current smokers.
e First-degree relatives.
f Histology codes (ICD-O-3) 8140/3 (adenocarcinoma, NOS), 8260/3 (papillary adenocarcinoma, NOS), and 8480/3 (mucinous adenocarcinoma).
g Histology code (ICD-O-3) 8070/3 (squamous cell carcinoma, NOS).
h Histology code (ICD O-3) 8041/3 (small cell carcinoma, NOS).
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Table 2. Odds Ratios for Lung Cancer According to Reproductive Factors and Use of Exogenous Reproductive Hormones, Singapore, 1996–1998 and 2005–2008







No. % No. % No. % No. % No. % No. % P Value
Adjusted
P Valuee
Parity (no. of children) 0.34 0.34
0 87 12.4 176 11.2 1 54 12.5 153 11.2 1 33 12.3 23 11.3 1
1–2 187 26.7 383 24.3 1.07 0.77, 1.50 135 31.3 344 25.1 1.15 0.79, 1.88 52 19.3 39 19.2 0.90 0.41, 1.93
3–4 209 29.8 490 31.1 0.84 0.60, 1.18 142 32.9 444 32.4 0.88 0.59, 1.29 67 24.9 46 22.7 0.89 0.42, 1.86
5 218 31.1 526 33.4 0.61 0.43, 0.88 101 23.4 431 31.4 0.63 0.40, 0.98 117 43.5 95 46.8 0.54 0.27, 1.09
Ptrend 0.001 0.006 0.038
As a continuous
variable
0.93 0.90, 0.98 0.92 0.87, 0.97 0.95 0.89, 1.02
P value 0.002 0.002 0.19
Age at ﬁrst birth,
yearsf
0.031 0.14
No children 87 176 54 153 33 23
20 146 24.3 412 29.9 1 63 17.0 339 28.2 1 83 35.8 73 41.0 1
21–25 264 43.9 538 39.0 1.49 1.14, 1.96 151 40.8 471 39.2 1.54 1.09, 2.17 113 48.7 67 37.6 1.84 1.12, 3.01
26–30 143 23.8 279 20.2 1.92 1.37, 2.69 121 32.7 255 21.2 2.17 1.46, 3.22 22 9.5 24 13.5 0.86 0.40, 1.85
31 49 8.1 151 10.9 1.22 0.78, 1.89 35 9.5 137 11.4 1.30 0.78, 2.18 14 6.0 14 7.9 1.32 0.51, 3.42
As a continuous
variable
1.01 0.98, 1.03 1.01 0.98, 1.04 1.00 0.95, 1.06




Premenopausal 45 129 37 118 8 11
30 126 21.7 290 22.7 1 61 18.1 246 22.3 1 65 26.8 44 25.1 1
31–33 97 16.7 230 18.0 1.00 0.71, 1.41 52 15.4 197 17.9 1.06 0.69, 1.63 45 18.5 33 18.9 0.89 0.47, 1.69
34–36 159 27.4 327 25.6 1.21 0.89, 1.65 85 25.2 282 25.6 1.25 0.85, 1.84 74 30.5 45 25.7 1.07 0.60, 1.91
37–39 117 20.1 256 20.0 1.22 0.87, 1.70 82 24.3 223 20.2 1.45 0.97, 2.16 35 14.4 33 18.9 0.73 0.37, 1.41
40 82 14.1 174 13.6 1.26 0.87, 1.82 58 17.2 154 14.0 1.47 0.95, 2.24 24 9.9 20 11.4 0.86 0.40, 1.85
Ptrend 0.11 0.026 0.54
As a continuous
variable
1.02 1.00, 1.04 1.02 1.00, 1.05 1.00 0.97, 1.04
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Age at menarche,
years
12 106 15.8 274 17.7 1 77 18.6 244 18.1 1 29 11.3 30 15.2 1
13–15 354 52.7 789 50.9 1.20 0.90, 1.60 234 56.4 694 51.4 1.24 0.90, 1.71 120 46.7 95 48.0 0.92 0.47, 1.82
16 212 31.6 486 31.4 1.04 0.75, 1.45 104 25.1 413 30.6 0.98 0.67, 1.45 108 42.0 73 36.9 1.11 0.54, 2.28
Ptrend 0.92 0.73 0.56
As a continuous
variable
1.02 0.97, 1.08 1.01 0.95, 1.07 1.08 0.98, 1.20




Premenopausal 45 129 37 118 8 11
48 218 36.6 514 39.8 1 109 31.4 439 39.3 1 109 44.0 75 42.4 1
49–51 200 33.6 422 32.6 1.20 0.94, 1.55 118 34.0 363 32.5 1.37 1.01, 1.86 82 33.1 59 33.3 0.95 0.59, 1.54
52 177 29.8 357 27.6 1.34 1.03, 1.74 120 34.6 314 28.1 1.59 1.16, 2.17 57 23.0 43 24.3 0.94 0.55, 1.60
Ptrend 0.027 0.003 0.81
As a continuous
variable
1.02 1.00, 1.04 1.03 1.00, 1.05 1.01 0.97, 1.05




30 638 93.6 1,389 89.7 1 399 94.1 1,210 89.6 1 239 92.6 179 90.4 1




Never used 297 74.4 578 70.9 1 181 70.2 505 70.9 1 116 82.3 73 70.9 1
Used for 5 years 77 19.3 182 22.3 0.82 0.59, 1.15 58 22.5 162 22.8 0.91 0.63, 1.31 19 13.5 20 19.4 0.54 0.24, 1.21
Used for >5 years 25 6.3 55 6.8 0.94 0.55, 1.62 19 7.4 45 6.3 1.23 0.68, 2.23 6 4.3 10 9.7 0.45 0.13, 1.55
Ptrend 0.43 0.84 0.086
Abbreviations: CI, conﬁdence interval; OR, odds ratio.
a Likelihood ratio test for interaction with smoking status.
b Adjusted for age at diagnosis, fruit and vegetable consumption (in servings/week), country of origin, dwelling type, years of education, history of cancer in ﬁrst-degree relatives (no history,
history of lung cancer, history of other cancers), smoking status (current, ex-, or never smoker), secondhand smoke exposure at home, and a dummy variable for the study set.
c Adjusted for age at diagnosis, fruit and vegetable consumption (in servings/week), country of origin, dwelling type, years of education, history of cancer in ﬁrst-degree relatives (no history,
history of lung cancer, history of other cancers), secondhand smoke exposure at home, and a dummy variable for the study set.
d Adjusted for age at diagnosis, fruit and vegetable consumption (in servings/week), country of origin, dwelling type, years of education, history of cancer in ﬁrst-degree relatives
(no history, history of lung cancer, history of other cancers), duration of smoking (in years), secondhand smoke exposure at home, and a dummy variable for the study set.
e Adjusted for multiple comparisons.
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particularly among never smokers. Low parity is associated
with higher blood estrogen levels (50). Shorter menstrual
cycles suggest an overall increase in the period of unop-
posed estrogen exposure, and late menopause and long re-
productive periods imply more reproductive cycles over the
lifetime and hence longer periods of estrogen exposure in
total. Our results are therefore consistent with an association
between higher levels of endogenous estrogen exposure over
the lifetime and risk of lung cancer.
An association with reproductive history was previously
observed in our first study involving a smaller group of par-
ticipants (18), where high parity and long menstrual cycles
were protective. In the current analysis, we additionally found
an increased risk associated with later age at first birth, later
age at menopause, and longer reproductive period. In a re-
cently published Singapore cohort study, Seow et al. (32)
reported similar protective effects for parity among female
Chinese never smokers, although they did not find a signif-
icant association with age at menopause. While we are not
able to fully explain this particular difference, we feel that,
taken as a whole, data from this population suggest a role
for estrogens in lung carcinogenesis among never-smoking
women.
In other published studies, investigators have reported
results similar to ours—namely, a protective effect of higher
parity (18, 29, 31–33) and increased risk with higher age at
menopause (7–9). In a cohort study, Liu et al. (23) did not
find a main effect with menarche or menopause, but they
reported that, compared with women with a late age at men-
arche (>15 years) and an early age at menopause (<51 years),
women with either early menarche or late menopause had
a higher risk of lung cancer. They proposed that the length of
Table 3. Odds Ratios for Lung Cancer According to Polymorphisms in the Estrogen Pathway, Singapore, 1996–1998 and 2005–2008
Polymorphism







No. % No. % No. % No. % No. % No. %
CYP17
rs743572
G/G 177 42.4 346 35.9 1 102 29.7 299 35.3 1 75 37.0 47 40.2 1
G/A 268 49.1 456 47.4 1.18 0.91, 1.53 176 51.3 401 47.4 1.25 0.93, 1.69 92 45.3 55 47.0 1.18 0.68, 2.06
A/A 101 18.5 161 16.7 1.31 0.93, 1.83 65 19.0 146 17.3 1.30 0.89, 1.92 36 17.7 15 12.8 1.30 0.59, 2.86
G/A or A/A 1.21 0.95, 1.55 1.26 0.95, 1.68 1.21 0.72, 2.04
CYP19A1
rs10046
A/A 145 26.7 248 25.9 1 90 26.5 222 26.4 1 55 2.0 26 22.2 1
A/G 268 49.3 487 50.8 0.92 0.69, 1.21 171 50.3 424 50.4 0.99 0.72, 1.36 97 47.6 63 53.9 0.80 0.43, 1.51
G/G 131 24.1 223 23.3 1.04 0.75, 1.44 79 23.2 195 23.2 1.06 0.73, 1.54 52 25.5 28 23.9 1.02 0.48, 2.16
A/G or A/A 0.95 0.73, 1.24 1.01 0.75, 1.36 0.86 0.47, 1.57
COMT rs4680d
G/G 284 52.3 549 56.9 1 167 49.1 488 57.6 1 117 57.6 61 51.7 1
G/A 220 40.5 353 36.6 1.26 0.99, 1.60 148 43.5 303 35.8 1.49 1.13, 1.97 72 35.5 50 42.4 0.70 0.42, 1.20
A/A 39 7.2 63 6.5 1.33 0.85, 2.08 25 7.4 56 6.6 1.30 0.77, 2.19 14 6.9 7 5.9 1.28 0.46, 3.55
G/A or A/A 1.27 1.01, 1.60 1.46 1.12, 1.90 0.77 0.47, 1.28
ERb rs1256049
G/G 206 38.0 371 38.9 1 135 39.7 320 38.2 1 71 35.2 51 44.0 1
G/A 251 46.3 447 46.9 1.00 0.78, 1.28 152 44.7 397 47.4 0.89 0.67, 1.19 99 49.0 50 43.1 1.43 0.83, 2.47
A/A 85 15.7 135 14.2 1.02 0.72, 1.45 53 15.6 120 14.3 0.98 0.66, 1.46 32 15.8 15 12.9 1.02 0.46, 2.26
G/A or A/A 1.00 0.79, 1.27 0.91 0.70, 1.20 1.33 0.79, 2.22
ERb rs4986938
G/G 446 82.0 807 83.7 1 277 81.5 704 83.2 1 169 82.8 103 87.3 1
G/A 95 17.5 148 15.4 1.17 0.87, 1.59 61 17.9 134 15.8 1.08 0.77, 1.52 34 16.7 14 11.9 1.36 0.66, 2.78
A/A 3 0.6 9 0.9 2 0.6 8 1.0 1 0.5 1 0.9
Abbreviations: CI, conﬁdence interval; OR, odds ratio.
a Adjusted for age at diagnosis, fruit and vegetable consumption (in servings/week), country of origin, dwelling type, years of education, history of cancer in
ﬁrst-degree relatives (no history, history of lung cancer, history of other cancers), smoking status (current, ex-, or never smoker), secondhand smoke exposure at
home, and a dummy variable for the study set.
b Adjusted for age at diagnosis, fruit and vegetable consumption (in servings/week), country of origin, dwelling type, years of education, history of cancer in
ﬁrst-degree relatives (no history, history of lung cancer, history of other cancers), secondhand smoke exposure at home, and a dummy variable for the study set.
c Adjusted for age at diagnosis, fruit and vegetable consumption (in servings/week), country of origin, dwelling type, years of education, history of cancer in
ﬁrst-degree relatives (no history, history of lung cancer, history of other cancers), duration of smoking (in years), secondhand smoke exposure at home, and a dummy
variable for the study set.
d Likelihood ratio test for interaction between smoking status and the COMT rs4680 polymorphism: P ¼ 0.047 (adjusted for multiple comparisons, P ¼ 0.14).
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exposure to estrogen may partly account for the increased
risk (23). Yet other investigators, however, have reported null
findings (8, 9, 19, 21–23, 25–27, 41) or increased risk (24, 28)
with regard to parity, reduced risk with later age at menopause
(19, 20, 29, 41), and reduced risk with a longer reproductive
period (29).
The inconsistency in findings across the various studies
may be due to differences in the study populations. Studies
conducted in smokers or in populations containing a high
proportion of smokers might not have been able to detect
a weaker effect of estrogens. There is growing evidence that
smoking-related lung cancer and never-smoker lung cancer
are etiologically distinct. It is plausible that the effect of
estrogens may apply specifically to lung cancer among never
smokers, given that mutations in the epidermal growth factor
receptor gene (EGFR) appear to be key drivers of this disease
(14) and the estrogen pathway interacts at the cellular level
with the epidermal growth factor receptor signaling path-
way (13). In a recent Japanese case-control study, Matsuo
et al. (27) noted that the increased risk associated with longer
reproductive periods was seen only in EGFR mutation-positive
cancers.
The effect of estrogen may be modified by other biologic
factors. For example, Paulus et al. (31) proposed that the dif-
ferent age distributions of women in the studies may explain
the inconsistency of results with regard to parity, and their
own data suggested that the effect of parity was seen only in
late-onset lung cancer (using a cutoff of 50 years), thus sug-
gesting that high parity may protect against postmenopausal
lung cancer but not premenopausal lung cancer. We also
found that both longer reproductive periods and parity had
more convincing effects in older women, although the pos-
sible reasons for this are yet to be elucidated.
We did not find an association with key polymorphisms
in the estrogen metabolism pathway, other than the rs4680
polymorphism in the COMT gene, where the A allele was
associated with lung cancer in never smokers. The oxida-
tive metabolism of 17b estradiol and estrone to catechol
estrogens is postulated to be a risk factor in carcinogenesis:
Catechol estrogens are oxidized to quinines that can form
Table 4. Odds Ratios for Lung Cancer According to Selected Reproductive Factors, by Age Group, Singapore, 1996–1998 and 2005–2008
Total Never Smokers
Age £65 Years
(311 Cases, 801 Controls)
Age >65 Years
(391 Cases, 777 Controls)
Age £65 Years
(243 Cases, 725 Controls)
Age >65 Years
(190 Cases, 650 Controls)




31–33 0.60 0.31, 1.18 1.77 0.98, 3.19
34–36 0.73 0.42, 1.28 2.20 1.26, 3.83
37–39 0.94 0.54, 1.64 2.24 1.24, 4.04




0.99 0.96, 1.03 1.05 1.01, 1.09
P value 0.77 0.005
Parity (no. of children)d
0 1 1
1–2 1.25 0.82, 1.90 0.84 0.46, 1.51
3–4 0.94 0.60, 1.46 0.78 0.45, 1.34




0.96 0.88, 1.04 0.92 0.88, 0.97
P value 0.32 0.002
Abbreviations: CI, conﬁdence interval; OR, odds ratio.
a Adjusted for age at diagnosis, fruit and vegetable consumption (in servings/week), country of origin, dwelling type, years of education, history of
cancer in ﬁrst-degree relatives (no history, history of lung cancer, history of other cancers), smoking status, secondhand smoke exposure at home,
and a dummy variable for the study set.
b Adjusted for age at diagnosis, fruit and vegetable consumption (in servings/week), country of origin, dwelling type, years of education, history of
cancer in ﬁrst-degree relatives (no history, history of lung cancer, history of other cancers), secondhand smoke exposure at home, and a dummy
variable for the study set.
c Likelihood ratio test for interaction: P ¼ 0.036 (adjusted for multiple comparisons: P ¼ 0.22).
d Likelihood ratio test for interaction: P ¼ 0.65 (adjusted for multiple comparisons: P ¼ 0.95).
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DNA adducts and produce DNA- and lipid-damaging re-
active oxygen species (48). Catechol-O-methyl transferase
methylates (thus eliminating) catechol estrogens and is the key
rate-limiting enzyme in that pathway (48). The A allele at
rs4680 (codon 158) results in a point mutation, substituting
the amino acid methionine for valine (51). Val/Met and
Met/Met genotypes appear to have lowered enzymatic activ-
ity, with consequently increased cellular levels of catechol
estrogens.
Two other case-control studies have investigated the effect
of polymorphisms at this site on lung cancer risk, with similar
results. The Met/Met and Val/Met genotypes were also asso-
ciated with an increased risk of lung cancer in a population
of smokers (52). Cote et al. (42) found that the A allele had no
independent effect in a group of subjects who were predom-
inantly smokers, but lung cancer risk was increased among
those with the A allele and a glutathione S-transferase M1
(GSTM1) null genotype in comparison with those with the
G/G genotype and a GSTM1 nonnull genotype. In that same
study, an independent effect of rs743572 (in CYP17) on lung
cancer risk was not seen, although the C allele in combination
with risk alleles in GSTM1 and GSTT1 increased risk (42).
The authors did not find a relation between CYP19A1 and
lung cancer, although the polymorphism they studied (the
tetranucleotide tandem repeat in intron 4) was different from
the one studied here. Paulus et al. (43), examining 4 ERb
SNPs (the same 2 as in our study, and 2 others), did not find
an association of individual SNPs or haplotypes with lung
cancer risk, which is consistent with our results.
We had anticipated that polymorphisms in CYP19A1 and
CYP17 would be important if the effect of reproductive
factors is mediated through estrogen levels in target tissue
(such as the lungs). However, current evidence, including ours,
is more consistent with a risk-conferring effect of catechol
estrogens on lung carcinogenesis. Few studies have examined
estrogen pathway polymorphisms in lung carcinogenesis,
and further work is necessary to determine whether this hy-
pothesis is true. Inclusion of more SNPs for which functional
studies indicate an effect on enzyme activity or estrogen
levels, or a systematic interrogation of polymorphisms in
the CYP19A1, CYP17, and COMT genes for associations
with lung cancer, may be useful in this regard.
We noticed suggestive interactions between smoking status
and the COMT SNP and age at first birth, and between age
and reproductive period among never smokers. However, our
study did not have adequate statistical power to detect in-
teractions, and the interactions were no longer significant
after adjustment for multiple testing. Further research
using larger study populations is needed to confirm these
observations.
The strengths of our study include homogeneity with
regard to gender and ethnicity and the large number of never
smokers, which allowed detailed investigation of risk factors
pertinent to this group. This is particularly important in the
light of recent understanding that smoking lung cancer and
nonsmoking lung cancer may be different diseases. Method-
ological limitations associated with the case-control study
design are well-known, and we attempted to address these
limitations in a variety of ways. Reporting bias is unlikely to
have been a major problem, as the relation between repro-
ductive factors and lung cancer has rarely been reported in
popular media, and participants were asked about reproduc-
tive factors in the context of a long questionnaire investi-
gating a variety of factors. We assessed interviewer bias by
recording and reviewing a random subset of interviews. To
reduce bias introduced by the use of hospital controls, we
chose controls from a wide variety of admitting diagnoses,
and gynecologic diseases as the admitting diagnoses were
very rare among our controls (about 0.4% of controls).
Our study suggests that reproductive factors are involved
in lung carcinogenesis, particularly among never smokers.
However, the specific functional role of estrogens in lung
cancer is still not known, and while our data suggest a role
for catechol estrogens, the mechanisms involved are likely
to be complex. Given the relation between the estrogen and
epidermal growth factor receptor pathways and the signifi-
cance of the latter in lung cancer among never smokers, it is
clear that further studies, both mechanistic and epidemiologic,
are needed in this area.
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Research
Lung cancer accounts for a substantial pro-
portion of cancer incidence and mortality 
throughout the world (Parkin et al. 2005). 
In addition to tobacco smoke exposure (both 
active and secondhand), fumes and airborne 
particulates in the indoor environment have 
been considered as potential risk factors for 
lung cancer; examples include exposure to 
cooking oil fumes, cooking and heating fuels 
(household coal and wood combustion), 
incense and mosquito coils, and indoor radon 
(Ko et al. 2000; Wang et al. 2002; Yu et al. 
2006; Zhang and Smith 2007).
Exposure to cooking fumes may poten-
tially play a role in the occurrence of lung 
cancer. Cooking oil fumes are known to con-
tain at least two carcinogenic compounds, 
benzo[a]pyrene and 2,4-decadienal, which 
induce lung cell survival and proliferation via 
the nuclear factor-κB pathway (Hung et al. 
2005, 2007). Cumulative exposure to cook-
ing (frequency and duration) by means of fry-
ing (stir-frying, frying, and deep-frying) was 
positively associated with the risk of lung can-
cer among female nonsmokers in Hong Kong 
(Yu et al. 2006). Women nonsmokers were 
at higher risk for lung cancer if they were 
exposed to cooking oil fumes emitted at high 
temperatures, and the risks were higher when 
the fumes were not reduced by an extractor 
(Ko et al. 2000).
The combustion by-products from heating 
and cooking are also sources of indoor air pol-
lution. In Canada, a case–control study of lung 
cancer in 1996–2001 reported that, among 
women, the odds ratio (OR) for those exposed 
to both traditional heating and cooking sources 
(coal and wood) was 2.5 [95% confidence 
interval (CI), 1.5–3.6] relative to women not 
exposed to either source (Ramanakumar et al. 
2007). Traditional heating and cooking fuels 
(coal and wood) produce a variety of indoor 
pollutants, including respirable particles, heavy 
metals, polycyclic aromatic hydrocarbons 
(PAHs), carbon monoxide, carbon dioxide, 
nitrogen dioxide, sulfur dioxide, and formalde-
hyde (Zhang and Smith 2007). The use of coal 
for heating has been implicated in the high 
incidence of lung cancer among residents of 
Xuanwei, China (Lan et al. 2002).
Incense burning, a traditional practice in 
Chinese households, is also powerful producer 
of particulate matter, and incense smoke con-
tains carcinogens such as PAHs, carbonyls, 
and benzene (Lin and Tang 1994; Lofroth 
et al. 1991). Incense smoke condensates have 
mutagenic and genotoxic activities, and the 
genotoxicity of certain incense smoke con-
densates in mammalian cells has been shown 
to be higher than that of tobacco smoke con-
densate (Chen and Lee 1996; Rasmussen 
1987). The potential impact of incense on 
health has also been studied outside the home 
(Chiang and Liao 2006; Chiang et al. 2009). 
A large prospective cohort study in Singapore 
reported an association between long-term 
incense use and the development of squamous 
cell carcinomas of the respiratory tract, partic-
ularly among women (Friborg et al. 2008).
Mosquito coils are frequently burned 
indoors in Asia and to a limited extent in other 
parts of the world, including the United States 
(World Health Organization 1998). The major 
ingredients of the mosquito coils are pyrethrins 
and plant-based materials, such as wood pow-
der, coconut shell powder, and joss powder, as 
well as binders, dyes, oxidants, and other addi-
tives to allow for controlled smoldering (Chen 
et al. 2008; Krieger et al. 2003). The combus-
tion of these materials generates large amounts 
of submicrometer particles and gaseous pollut-
ants. These submicrometer particles may reach 
the lower respiratory tract and could be coated 
with a wide range of organic compounds, such 
as PAHs. A study of mosquito coil smoke and 
lung cancer in Taiwan between 2002 and 2004 
showed that lung cancer risk among smokers 
with the highest exposure to mosquito coil 
smoke was 14 times higher than nonsmokers 
without this exposure (Chen et al. 2008).
In this study, we used the case–control 
study design to investigate whether inhalant 
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Background: Epidemiologic data suggest that Chinese women have a high incidence of lung 
cancer in relation to their smoking prevalence. In addition to active tobacco smoke exposure, other 
sources of fumes and airborne particles in the indoor environment, such as cooking and burning of 
incense and mosquito coils, have been considered potential risk factors for lung cancer.
oBjectives: We used a case–control study to explore effects of inhalants from combustion sources 
common in the domestic environment on lung cancer and their modification by active tobacco 
smoking.
Methods: We analyzed 703 primary lung cancer cases and 1,578 controls. Data on demographic 
background and relevant exposures were obtained by face-to-face interviews in the hospital.
results: We observed a positive relationship with daily exposure to incense or mosquito coils and 
to cooking fumes only among smokers, and no association among lifetime nonsmokers. Interactions 
between smoking and frequency of cooking, or exposure to incense or mosquito coils were statisti-
cally significant and consistent with synergistic effects on lung cancer. The odds ratio (OR) compar-
ing smokers without daily incense or mosquito coil exposure with nonsmokers without daily exposure 
was 2.80 [95% confidence interval (CI), 1.86–4.21], whereas the OR comparing smokers with daily 
exposure to the same referent group was 4.61 (95% CI, 3.41–6.24). In contrast, daily exposure to 
incense or mosquito coils was not associated with lung cancer among nonsmokers (OR = 0.91; 95% 
CI, 0.72–1.16). We observed the same pattern of associations for smokers without (OR = 2.31; 95% 
CI, 1.52–3.51) and with (OR = 4.50; 95% CI, 3.21–6.30) daily cooking exposure compared with 
nonsmokers, with no evidence of an association with daily cooking exposure among nonsmokers.
conclusion: Our results suggest that active tobacco smoking not only is an important risk factor 
for development of lung cancer, but also may cause smokers to be more susceptible to the risk-
enhancing effects of other inhalants.
key words: Chinese, combustion sources, females, inhalants, interaction, lung cancer, tobacco 
smoking. Environ Health Perspect 118:1257–1260 (2010). doi:10.1289/ehp.0901587 [Online 
14 May 2010]
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exposure from these sources plays a significant 
role in enhancing risk of lung cancer among 
Singapore Chinese women, a population with 
a large proportion of nonsmokers. We also 
wished to explore whether the impact of these 
compounds is modified by active tobacco 
smoke exposure.
Materials and Methods
Participants were cases and controls who were 
recruited for two hospital-based case–con-
trol studies during 1996–1998 and 2005–
2008, from the five major public hospitals in 
Singapore. Both studies used similar meth-
ods and questionnaires. Eligible cases were 
Chinese females with newly diagnosed pri-
mary carcinoma of the lung. The average time 
between diagnosis and interview was 22 days 
(79.4% were interviewed within 1 month of 
diagnosis). A total of 703 lung cancer patients 
(89.2% of those identified as eligible) agreed 
to participate. Histologic or cytologic reports 
were reviewed and confirmed the diagnosis 
of primary lung carcinoma in 674 cases; 29 
cases were confirmed on the basis of radio-
logic investigations, in which metastatic can-
cer to the lung from other sites was deemed 
to be unlikely on clinical grounds. Controls 
were selected from Chinese female patients, 
frequency matched for age (within 5 years), 
hospital admitted to, and date of admission 
(within 1 month). Patients admitted for a 
diagnosis and treatment of cancer or chronic 
respiratory disease were excluded, and no 
more than 10% of controls were recruited 
within a single diagnostic category.
The response rate among controls was 
90.6%, and data from a total of 1,578 controls 
were available for analysis. Control patients 
were admitted for a wide range of conditions: 
27% had diseases of skin, bones, joints, and 
connective tissue; 11% were admitted for 
gastrointestinal or hepatobiliary system com-
plaints; 14% were admitted for acute trauma; 
8% were admitted for neurological or psychi-
atric conditions; and 12% had diseases of the 
cardiovascular system.
Both eligible cases and controls gave writ-
ten, informed consent for the interview and 
the tracing of their medical records, and the 
study was approved by the Institutional Review 
Board of the National University of Singapore 
and the participating health care institutions.
All subjects were interviewed in person by 
trained interviewers, using a structured ques-
tionnaire. Interviewers were not blinded to case 
or control status, but we recorded and reviewed 
at random a sample of interviews conducted 
to ensure standardization of the data collec-
tion processes. The structured questionnaire 
covered demographic characteristics, occupa-
tional history, active smoking history, fam-
ily history of cancer, personal medical history 
(e.g., history of tuberculosis), dietary intake of 
fruits and vegetables, and indoor environmen-
tal exposures (including secondhand smoking 
exposure, cooking exposure, and exposure to 
incense and mosquito coil burning).
The participant’s smoking history included 
the number of cigarettes smoked daily and the 
total duration of smoking. A regular smoker 
was defined as one who smoked at least one 
cigarette per day for ≥ 1 year. Ex-smokers 
were smokers who had stopped smoking for 
≥ 30 days at the time of interview. Questions 
on secondhand smoke exposure included 
“Did any of your household members smoke 
(including spouse, parents, children, or any 
other relative/friend living with you) in your 
presence more than once a week?” Family 
history of cancer was defined as the presence 
of any cancer within first-degree relatives. 
Information on intake of fruits and vegetables 
was collected using a semiquantitative food 
frequency questionnaire that elicited the usual 
weekly number of servings of 17 fruit and 21 
vegetable items over the 3 years before admis-
sion. The time period for inhalant exposure 
was set at 25 years before admission, and all 
questions asked participants to recall exposures 
25 years before age of diagnosis of lung cancer 
(or age at admission for controls). For cooking 
exposure, participants were asked about the 
frequency with which they personally cooked 
at home (with six categories of response, rang-
ing from “never” to “more than once a day”), 
the cooking methods used, and the age at 
which they began to do this regularly. The fre-
quency of incense/mosquito coil burning (i.e., 
less than daily, once daily, more than once a 
day/throughout the day, throughout the day 
and night) was also ascertained. In each case, 
the question was asked (e.g., “How often were 
joss sticks, scented coil/powder burnt inside 
your house?”), and the respondent asked to 
select the most appropriate frequency category. 
For the purpose of the analysis, exposures were 
categorized as less than daily (“< daily”) and 
once or more every day (“daily”).
ORs and their 95% CIs were calculated 
for risk of lung cancer for smokers and non-
smokers separately using unconditional logistic 
regression adjusting for age (years), education 
(years), housing type, secondhand smoke expo-
sure (daily vs. less than daily exposure), history 
of cancer in the first-degree relative, dura-
tion of smoking (in years; for ex-smokers and 
current smokers), fruit and vegetable intake 
(servings/week), and study set (1996–1998 or 
2005–2008 study). These adjustment variables 
Table 1. Sociodemographic characteristics of lung cancer cases and controls, Singapore Chinese 
women [n (%)].
Characteristic Cases (n = 703) Controls (n = 1,578) p-Valuea
Age [years (mean ± SD)]b 65.9 ± 11.9 64.1 ± 12.3 0.001
Birthplace 0.001
Singapore 443 (63.0) 1031 (65.3)
Malaysia 92 (13.1) 271 (17.2)
China 145 (20.6) 234 (14.8)
Other 23 (3.3) 42 (2.7)
Education (years) 0.037
None 342 (48.7) 678 (43.0)
≤ 6 193 (27.5) 491 (31.1)
≥ 7 167 (23.8) 409 (25.9)
Dwelling 0.020
Flat, 1–3 rooms 255 (36.5) 613 (39.0)
Flat, ≥ 4 rooms 332 (47.6) 775 (49.3)
Private apartment or house 111 (15.9) 183 (11.7)
Marital status 0.956
Ever married 654 (93.0) 1,467 (93.0)
Never married 49 (7.0) 111 (7.0)
Occupational status 0.018
Currently employed outside home 154 (21.9) 415 (26.3)
Ever employed outside home 360 (51.2) 809 (51.3)
Never employed outside home 189 (26.9) 352 (22.3)
Smoking history < 0.001
Nonsmoker 434 (61.7) 1,375 (87.1)
Ex-smokerc 143 (20.3) 115 (7.3)
Current smoker 126 (17.9) 88 (5.6)
Secondhand smoke exposure at home 0.009
< Daily 335 (48.1) 848 (54.1)
Daily 361 (51.9) 720 (45.9)
Family history of cancerd 0.001
No 532 (75.7) 1,286 (81.5)
Yes 171 (24.3) 292 (18.5)
Servings/week of fruit (mean ± SD) 6.8 ± 8.5 9.0 ± 8.6 < 0.001
Servings/week of vegetables (mean ± SD) 21.4 ± 19.3 25.6 ± 21.3 < 0.001
aPearson chi‑square test for categorical variables and t‑test for continuous variables. bAge at diagnosis (cases) and age 
at interview (controls). cHad not smoked any cigarette in the 30 days before admission. dFirst‑degree relative with his‑
tory of cancer of any site.
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were modeled with age, fruit consumption, 
and vegetable consumption as continuous 
variables, and all other variables as categorical 
ones, with the respective categories, as shown 
in Table 1. Among smokers, intensity of 
smoking was highly correlated with duration, 
and further adjustment for the former did not 
affect the ORs, so it was excluded in the final 
statistical model. We used STATA statisti-
cal software (version SE 10.1; StataCorp LP, 
College Station, TX, USA) for data analyses. 
All p-values were calculated using two-tailed 
statistical tests, and the criterion for signifi-
cance was set at p < 0.05. Interactions were 
assessed using the likelihood ratio test to esti-
mate p-values; in each test for interaction, 
models that included the interaction term 
were compared with those that did not.
Results
We analyzed data from 703 cases with primary 
lung cancer and 1,578 controls. Data on expo-
sures of interest and potential confounders were 
available for almost all participants, with the 
highest proportion of missing data for exposures 
being 1.1% (for the cooking variable). Table 1 
describes sociodemographic characteristics of 
the cases and controls. Cases were significantly 
more likely to be current smokers (17.9% vs. 
5.6%) or ever smokers (20.3% vs. 7.3%; ex-
smokers: age-adjusted OR = 3.85; 95% CI, 
2.93–5.01; current smokers: age-adjusted 
OR = 4.49; 95% CI, 3.34–6.02). They were 
also more likely to have been exposed to 
second hand smoke at home daily (51.9% vs. 
45.9% for controls). Cases had a higher pro-
portion of family history of cancer than did 
controls (24.3% vs. 18.5%). The mean weekly 
number of servings of fruits and vegetables was 
lower among cases than among controls (6.8 
and 21.4 vs. 9.0 and 25.6, respectively).
Associations between lung cancer and 
exposure to incense or mosquito coils, and 
with exposure to daily cooking, were strongly 
dependent on smoking status; Table 2 pres-
ents these results separately for smokers and 
nonsmokers. We observed a statistically sig-
nificant positive relationship only among 
smokers and observed no association among 
lifetime nonsmokers. Among smokers, women 
who cooked daily had a higher risk than those 
who cooked less than daily (adjusted OR = 
1.61; 95% CI, 1.01–2.56). Also, smokers 
with exposure to incense or mosquito coils 
daily were more likely to have lung cancer 
than those with less frequent exposure (OR 
= 1.53; 95% CI, 0.97–2.41) after adjustment 
for potential confounders. Daily use of char-
coal or wood stove was not associated with 
lung cancer in either smokers or nonsmokers.
We found a statistically significant inter-
action between smoking and exposure to 
incense or mosquito coils (p = 0.016) or fre-
quency of cooking (p < 0.001), respectively, 
after adjustment for potential confounders 
(Table 3). The OR comparing smokers with-
out daily incense or mosquito coils exposure 
with nonsmokers without daily exposure was 
2.80 (95% CI, 1.86–4.21), whereas the OR 
comparing smokers with daily exposure with 
the same referent group was 4.61 (95% CI, 
3.41–6.24). In contrast, daily exposure to 
incense or mosquito coils was not associated 
with lung cancer among nonsmokers (OR = 
0.91; 95% CI, 0.72–1.16). We observed the 
same pattern of associations for smokers with-
out (OR = 2.31; 95% CI, 1.52–3.51) and with 
daily cooking exposure (OR = 4.50; 95% CI, 
3.21–6.30) compared with nonsmokers, with 
no evidence of an association with daily cook-
ing exposure among nonsmokers. We observed 
the same pattern for wood stove use, although 
the interaction was not statistically significant 
(p = 0.061). We found no interaction between 
smoking and daily use of charcoal (p = 0.128).
Discussion
We examined the effects of cooking and expo-
sure to burning of incense and mosquito coils 
on lung cancer risk among Singapore Chinese 
women, and their modification by active 
tobacco smoking exposure. We observed 
strong interactions between exposure to these 
sources and smoking on lung cancer risk. The 
results indicate that active tobacco smoking 
not only is an important risk factor for devel-
opment of lung cancer, but also may cause 
smokers to be more susceptible than non-
smokers to adverse effects of these inhalants 
on lung cancer as well.
A possible explanation for our findings 
is the presence of a chronic inflammatory 
state in the airways induced by smoking. 
Tobacco smoke carcinogens are known to 
activate proinflammatory responses through 
the action of prooxidative chemicals, lead-
ing to the release of cytokines, production of 
Table 2. Adjusted ORsa and 95% CIs for lung cancer by cooking, incense or mosquito coil use, and char‑
coal and wood stove use, by smoking status.
Current or ex-smokers Nonsmokers
Exposure factor Cases/controls OR (95% CI) Cases/controls OR (95% CI)
Cooking frequency
< Daily 58/73 1.00 145/385 1.00
Daily 210/130 1.61 (1.01–2.56) 282/972 0.89 (0.68–1.16)
Use of incense or mosquito coils
< Daily 62/65 1.00 169/488 1.00
Daily 207/138 1.53 (0.97–2.41) 265/887 0.90 (0.71–1.14)
Use of charcoal stove
< Daily 239/180 1.00 406/1,236 1.00
Daily 30/21 1.08 (0.55–2.12) 26/129 0.67 (0.43–1.05)
Use of wood stove
< Daily 215/167 1.00 387/1,177 1.00
Daily 54/33 1.25 (0.74–2.12) 45/193 0.81 (0.56–1.17)
aAdjusted as described in “Materials and Methods.” 
Table 3. Combined effect estimates for lung cancer in association with indoor inhalants and smoking.
Exposure group Smoking status n OR (95% CI)a
Cooking frequency
< Daily Nonsmokers 530 1.00
Daily Nonsmokers 1,254 0.83 (0.64–1.08)
< Daily Current or ex-smokers 131 2.31 (1.52–3.51)
Daily Current or ex-smokers 340 4.50 (3.21–6.30)
p-Value (interaction)b < 0.001
Use of incense or mosquito coils
< Daily Nonsmokers 657 1.00
Daily Nonsmokers 1,152 0.91 (0.72–1.16)
< Daily Current or ex-smokers 127 2.80 (1.86–4.21)
Daily Current or ex-smokers 345 4.61 (3.41–6.24)
p-Value (interaction)b = 0.016
Use of charcoal stove
< Daily Nonsmokers 1,642 1.00
Daily Nonsmokers 155 0.67 (0.43–1.04)
< Daily Current or ex-smokers 419 4.08 (3.21–5.18)
Daily Current or ex-smokers 51 4.88 (2.68–8.91)
p-Value (interaction)b = 0.128
Use of wood stove
< Daily Nonsmokers 1,564 1.00
Daily Nonsmokers 238 0.78 (0.55–1.13)
< Daily Current or ex-smokers 382 3.95 (3.08–5.07)
Daily Current or ex-smokers 87 5.48 (3.42–8.79)
p-Value (interaction)b = 0.061
aAdjusted as described in “Materials and Methods.” bp‑Value for the likelihood ratio test for interaction between smok‑
ing and cooking, incense or mosquito coils, charcoal stove, and wood stove.
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reactive oxygen species (ROS), and ultimately 
DNA damage (Azad et al. 2008; Hecht 
2008). A chronic inflammatory process in the 
lung could also lead directly to DNA dam-
age, enhance the effects of other carcinogenic 
exposures, and stimulate cell proliferation 
and growth (Ohshima and Bartsch 1994). 
Burning incense generates high concentrations 
of ROS in the particulate gas phase of the 
emissions, and might damage DNA and other 
biomolecules when inhaled (Szeto et al. 2009).
Our findings that these exposures are not 
associated with risk among nonsmokers are 
at variance with other studies that reported 
positive associations in nonsmokers. The OR 
for female nonsmokers cooking three meals/
day compared with those cooking one meal/
day was 3.4 (95% CI, 1.6–7.0) in a study 
conducted in Taiwan (Ko et al. 2000). In 
the study among women in Taiwan, higher 
frequency of mosquito coil smoke use was 
positively associated with lung cancer in both 
smokers and nonsmokers, although the inter-
action with cigarette smoke was synergistic 
(Chen et al. 2008), as in the present study. 
Differences in cooking practices, use of fume 
extractors, type and intensity of use of mos-
quito coils, or simply in the average amount of 
time spent at home may contribute to the dif-
ference in findings among studies, even within 
Chinese populations. The proportion of 
women who had never been employed outside 
the home in our study was only 22% among 
controls, suggesting that overall exposure to air 
pollutants in the domestic environment may 
be less substantial in our population than in 
more traditional societies.
Contrary to previous reports, we did not 
find a significant association between use of 
charcoal or wood stoves and lung cancer risk, 
among either smokers or nonsmokers. In 
Singapore, local residents infrequently use tra-
ditional fuels (charcoal or wood) and usually 
use modern fuels (gas, kerosene, or electricity) 
for cooking, and the low frequency of use may 
be the chief explanation for our findings. We 
also recognize that there are limitations to the 
data presented. Because the study is retrospec-
tive, recall and reporting biases by subjects 
are inevitable concerns. We believe that these 
biases are not likely to be differential, because 
we did not make our hypothesis known to 
our participants, and the possible association 
between inhalant exposure and lung cancer is 
not widely known among the public. These 
errors, if present, would probably shift the 
association toward the null, because they 
would likely affect both cases and controls to 
the same extent.
Conclusions
Our study suggests that active tobacco smok-
ing not only is an important risk factor for 
development of lung cancer, but also may 
cause smokers to be more susceptible to the 
risk-enhancing effects of exposure to cook-
ing and burning of incense and mosquito 
coils. A possible mechanism consistent with 
recent findings is the presence of a chronic 
inflammatory state in the airways induced 
by smoking. The interaction observed sup-
ports a model in which host susceptibility 
acts in concert with the exposures of inter-
est to promote lung carcinogenesis. On the 
other hand, we found no evidence that these 
specific exposures contribute to increased risk 
of lung cancer among nonsmokers. Because 
cooking and burning of incense and mos-
quito coils are fairly common exposures in 
the indoor environment, it is important that 
smokers be aware of the significant additional 
risk afforded by these exposures. Although our 
results suggest a weaker effect, if any, among 
nonsmokers, further research is needed to 
establish more definitively the level of risk 
from these ubiquitous compounds in the 
domestic environment.
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The relationship between diet and lung cancer, apart from the
protective effect of fruit and vegetables, is poorly understood. Re-
ports on the role of dietary components such as meat are inconsis-
tent, and few studies include sufficient numbers of nonsmokers. We
examined the relationship between meat consumption and never-
smoking lung cancer in a hospital-based case–control study of Sin-
gapore Chinese women, a population with low smoking prevalence.
Three hundred and ninety-nine cases and 815 controls were re-
cruited, of whom 258 cases and 712 controls were never smokers.
A standardized questionnaire (which included a food frequency
questionnaire module) was administered by trained interviewers.
Among these never smokers, fruit and vegetable intake were in-
versely associated with lung cancer risk. Seventy-two percent of
meat consumed was white meat (chicken or fish). Meat consump-
tion overall was inversely associated with lung cancer [adjusted
odds ratio (OR), 0.88, 0.59 for second, third tertiles, Ptrend = .012].
An inverse relationship between fish consumption and lung cancer
(adjusted OR, 0.81, 0.47 for 2nd, 3rd tertiles, Ptrend < .001) was ob-
served. No association was seen between consumption of processed
meats and lung cancer, nor between dietary heterocyclic amines
and lung cancer. Our data suggest that fish consumption may be
protective against lung cancer in never smokers.
INTRODUCTION
Lung cancer is the leading cause of cancer death worldwide
(1). Tobacco consumption is the major risk factor for lung cancer
(2). However, lung cancer in nonsmokers would be the seventh
most common cancer worldwide if it were ranked separately
(3). Lung cancer incidence in Chinese women in various pop-
ulations around the world is much higher than expected given
Submitted 9 November 2010; accepted in final form 22 March 2011.
Address correspondence to Wei-Yen Lim, Department of Epidemi-
ology and Public Health, Yong Loo Lin School of Medicine, National
University of Singapore, MD3, 16 Medical Drive S (117597), Singa-
pore. Fax: (65) 64789913. E-mail: wei-yen lim@nuhs.edu.sg
their relatively low smoking prevalence (4). Investigations into
explanations for this increased risk have focused on factors such
as environmental tobacco exposure (5), indoor air pollution from
use of cooking stoves and coal burners (3), occupational expo-
sure to carcinogens (6), household radon exposure (7), fumes
arising from wok-frying of meats (3), and immune system dys-
regulation as reflected by previous medical conditions such as
asthma and atopy (3). It is, however, still not clear what the key
etiologic pathways are for this disease in never smokers.
Dietary factors are likely to influence risk in never smokers
(8). While current evidence suggests that fruits and vegetables
protect against the development of lung cancer, the role of meat
and meat components such as saturated fats and cholesterol is
less well established (9–18). Some studies have found an inverse
effect (16), whereas others have found no effect (13–15,18) or
an increased risk (12,17). The majority of studies have been con-
ducted in European populations, in which red meat comprised a
large proportion of total meat consumed. The effect of meat on
lung cancer is complicated for a few reasons: red and white meat
may vary in their effects. Cooking methods may also be impor-
tant. Well-done red meat has been associated with an increased
risk of lung cancer (19), a finding that has been attributed to the
presence of heterocyclic amines (HCAs), which are produced
when meats are cooked at high temperatures (20). HCAs are
mutagenic in vitro (21), and have been shown to produce tu-
mors in rodents (22) and to increase risk in population-based
studies (23–25).
Few studies have included sufficient numbers of never smok-
ers to be able to identify small effects of meat and meat com-
ponents in this group and most results have been reported in
studies in which cases were primarily smokers. It is hence not
known whether effects differ substantially between smokers and
nonsmokers.
Dietary patterns in Singapore, an Asian city-state with a



































MEAT AND LUNG CANCER RISK IN NEVER SMOKERS 851
Malay, and Indian ancestry, differ substantially from those in
Western countries (26). Among the Chinese, fish represents a
high proportion of meat consumed, and chicken and pork are
other commonly consumed meats. In contrast, beef and other
red meats such as mutton and lamb are rarely consumed. Cook-
ing methods in the Chinese population are also distinct from
those in the West, with boiling, steaming, stewing, and wok-
frying being common methods of meat cooking while grilling
and deep-frying are much less common. As a consequence,
meat-cooking methods among the Chinese population in Sin-
gapore appear to generate much lower levels of dietary HCAs
compared to common cooking methods in the West (27). The
relationship of meat consumption to lung cancer risk among
the Chinese may therefore differ from that found in Western
populations.
Lung cancer is the leading cause of cancer death in Singa-
pore, and it is the most common cancer in men and the third
most common cancer in women (28). Although the smoking
prevalence in Chinese women in Singapore is low, at about 3%
(29), the incidence rate of lung cancer is comparable to other
communities with much higher incidence of smoking (1,28),
and a significant proportion of lung cancers occur among non-
smokers. We thus have a unique opportunity to investigate risk
factors specific to non-smoking-related lung cancer in an Asian
Chinese population. Differences in the type and variety of meat
consumed between our population and others may also offer
insights into risks associated with meat intake. In a hospital-
based case–control study of Chinese women, we examined the
association of fresh and processed meat consumption with lung
cancer risk in never smokers.
MATERIALS AND METHODS
We conducted a hospital-based case–control study from
February 2005 to January 2008 in the 5 major public-sector hos-
pitals in Singapore. Eligible cases were Chinese women with
a diagnosis of primary lung carcinoma (all histological types).
The methodology has been previously described (30).
A total of 497 lung cancer patients were identified in the 5
hospitals. We excluded 14 cases that did not satisfy the eligibility
criteria, and 9 others that were not contactable for a variety
of reasons (e.g., some were too ill), leaving 474 women. Of
these, 401 (84.6%) consented to the interview. Histological or
cytological reports were reviewed and confirmed the diagnosis
of primary lung carcinoma in 372 of these women; we excluded
2 patients who were subsequently confirmed to have metastatic
cancer to the lung. Twenty-nine cases were confirmed on the
basis of radiological investigations, in which metastatic cancer
to the lung from other sites was deemed to be unlikely on clinical
grounds. In total, we had 399 confirmed lung cancer cases in
this study. Two hundred and fifty-eight never smokers (65%)
were used for this analysis.
We selected controls from among Chinese female patients
admitted to the same hospitals, frequency-matched by 10-yr
age groups and admitted or seen in the hospital within 30 days
of the date of diagnosis of the corresponding case. Exclusion
criteria were the diagnosis or management of malignancy or
chronic respiratory disease (excluding tuberculosis). No more
than 10% of controls were recruited within a single diagnostic
category.
Of a total of 962 eligible controls identified, 821 (85.3%)
consented to be interviewed. One was reclassified as a case,
while 6 were subsequently excluded because their admission
was due to a malignancy, leaving 815 participants as controls.
Control patients had a wide range of conditions: 23% had dis-
eases of skin, bones, joints, and connective tissue; 11% were ad-
mitted for gastrointestinal or hepatobiliary system complaints;
10% were admitted for acute trauma; 8% each were admitted
for respiratory tract diseases and for neurological or psychiatric
conditions; 16% had diseases of the cardiovascular system; 7%
each had renal or urinary problems; and generalized infections
such as dengue and viral fever. Seven hundred and twelve never
smokers (87%) were included for this analysis.
All subjects (cases and controls) were interviewed using
a standardized questionnaire by trained research nurses inter-
viewing both cases and controls. Training and supervision was
conducted by the same investigator throughout. Interviewers
were not blind to case or control status, but interviews were
recorded, and a random sample was checked. None of the in-
terviews were conducted solely with the next-of-kin, although
relatives, if present, were allowed to give information that was
corroborated by the subject. The study protocol was approved
by the National University of Singapore Institutional Review
Board and the Ethics Committees of the participating health-
care institutions.
Our questionnaire elicited history of personal and passive
tobacco exposure, cooking, exposure to kitchen fumes and
inhalants such as incense and mosquito coils, family history
of cancer, childhood living conditions, occupational history,
past history of lung diseases and allergies, menstrual and
reproductive history, exogenous hormone use, and use of other
medications.
Information on usual dietary intake of commonly available
fruit (17 items), vegetables (21 items), soy products (10 items),
and meats (18 items) was obtained via a semiquantitative FFQ.
Consumption of the 6 common meat groups (fish, chicken, pork,
duck, squid and prawns, and beef) was elicited. For each meat
type, participants indicated their consumption frequency (num-
ber of times per wk) and portion size. Portion size was elicited
as multiples of a standard serving specific to each food item.
A standard serving was defined and weights of portion sizes
calculated from a pilot study among a group of middle-aged
and older Chinese women. Pictures of food portions were used
to aid participants. Food frequency and usual portion size were
multiplied to define the number of standard servings per wk.
Consumption of each food item was then categorized in tertiles
(based on the distribution among controls).
The questionnaire also elicited information on cooking meth-
ods for 9 selected meat-cooking method combinations (e.g.,
pan-fried fish, pan-fried chicken, roasted pork) and on the con-
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sausages, and Chinese sausages). The concentrations of 5
different HCAs had been previously determined in 25 com-
monly consumed and available meat items in Singapore (27).
Five food items were found to have relatively high HCA
concentrations and were commonly consumed in our popu-
lation (pan-fried fish, deep-fried chicken, pan-fried chicken,
grilled/roasted pork, and pan-fried pork). We used the es-
timates of HCA concentration for each food item obtained
from our previous study (27) to derive an estimate for the
usual weekly intake of HCAs (in nanograms) in our par-





Data analyses were performed using Stata v. 10 (StataCorp
2007; College Station, TX) software. Unconditional logistic re-
gression with the case–control status taken as the dependent
variable was performed, with adjustment for age, family history
of cancer, smoking status, country of origin, housing type, and
years of education [as proxies for socioeconomic status (SES)],
usual body mass index (BMI) in adulthood (defined as usual
body weight prior to current illness, in kilograms, divided by
the square of the height, in meters), and total fruit and total
vegetable consumption (measured in standard servings/wk, as a
continuous variable). The inclusion of variables for adjustment
in the multiple logistic regression model was based on biologic
considerations as well as stepwise backward regression. Tests
for linear trend were performed by treating the 3 tertiles for each
food group as a continuous variable.
RESULTS
Table 1 gives a summary of relevant characteristics among
the 258 cases and 712 controls who were never smokers. The
median age was 63.5 yr among cases, and 66 yr among con-
trols. Usual BMI, years of education, and housing type differed
significantly between cases and controls in bivariate analysis.
One-third (34.8%) of cases had a first-degree relative with a
history of cancer, compared to 23.6% in controls (P ≤ .001).
Table 2 describes the association between dietary factors and
lung cancer. High consumption of fruits was inversely associated
with lung cancer, with an odds ratio (OR) of 0.39 (Ptrend <
.001) in the highest tertile compared to the lowest. An inverse
association was also seen with consumption of vegetables, with
an OR of 0.57 (Ptrend = .003) in the highest tertile compared to
the lowest, and with cruciferous vegetables (ORs = 1.25, 0.66
in second and third tertiles, respectively, Ptrend = .046).
Overall, an inverse association with meat consumption was
seen in this study population, with an OR of 0.88 and 0.59 in the
second and third tertiles respectively, compared to the first tertile
(Ptrend = .012). Among controls, fish comprised 50% of the
meat consumed by servings, pork 19%, and chicken 24%. Duck,
prawns, and squid were not commonly consumed (with median
consumption of only 1 serving a wk). Beef was very rarely
consumed, with about 80% of the study population reporting no
consumption (data not shown).
We observed a strong inverse relationship between fish con-
sumption and risk of lung cancer in nonsmokers (ORs = 0.81,
0.47 for 2nd and 3rd tertiles of fish consumption, respectively,
Ptrend < .001). We further examined the effect of fish by quintiles
of intake. The inverse association was seen only in the fourth
and fifth quintiles of fish consumption (Fig. 1). These 2 quintiles
were equivalent to consumption at 7.5–15 servings of fish per
wk, and more than 15 servings per wk, respectively. Chicken
and pork consumption had no significant effect on risk of lung
cancer.
Overall, processed meats were not associated with lung
cancer risk (ORs = 1.04, 0.83, Ptrend = 0.37). Of the various
constituents comprising processed meats, bacon increased
lung cancer risk (OR = 1.51, 95% CI 1.06–2.17, compared to
participants who do not consume bacon). Ham, luncheon meat,
sausages, and Chinese sausages were not associated with lung
cancer (Table 3). None of the 3 HCAs examined (PhIP, MelQx,
and 4,8-DiMelQx) was associated with lung cancer risk nor
was total HCA (Table 4).
Further adjustment with self-reported exposure to meat cook-
ing fumes did not alter the results obtained for fresh meat, pro-
cessed meat, and dietary HCA consumption and the association
with lung cancer (data not shown).
DISCUSSION
In this study of never smokers, total meat intake (of mostly
white meat—fish and chicken) is associated with a lower risk
of lung cancer. Among meat components, fish consumption is
associated with a reduced risk of lung cancer. Processed meats
do not appear to be associated with lung cancer risk, although
bacon may increase lung cancer risk among never smokers.
Dietary HCAs arising from Chinese-style meat-cooking did not
increase lung cancer risk.
Recent research into the effect of meat on lung cancer
risk have focused on red and processed meat. Carcinogenic
compounds arising from the cooking of red meat such as
HCAs (17,23–25) and the polycyclic aromatic hydrocarbon
benzo(a)pyrene (17,24) have been implicated as the mechanism
conferring risk. In addition, processed meat products have also
been identified as a possible risk factor for lung cancer (17,24).
Nitrosamines are formed from nitrates and nitrites added to
processed meats (31), are carcinogenic (32), and may be the bi-
ological mechanism linking processed meats with lung cancer.
The association of processed meats was not convincing in our
study; most processed meats did not show a relationship with
lung cancer and, although bacon appeared to be associated with
lung cancer cases in our study, this increase was in the context
of a comparison between nonconsumers and ever-consumers.
Consumption levels of processed meats (with the exception of
Chinese sausages) were generally low in our population. It is
likely therefore that any risks associated with processed meats
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TABLE 1
Baseline characteristics of never-smoking female Chinese lung cancer patients and controls
Baseline Characteristic Cases (n = 258) Controls (n = 712) P
Age (yr)
Mean +/− SD 63.80 +/−12.02 64.86 +/−11.63 .22
Median 63.5 66
Usual body mass indexa
Mean +/− SD 22.45+/−3.81 24.21 +/−4.88 <0.01
Median (23.37) (22.07)
n % n %
Dialect group .41
Hokkien 92 35.8 303 42.7
Teochew 65 25.3 145 20.4
Cantonese 48 18.7 123 17.3
Hainanese 17 6.6 40 5.6
Hakka 26 10.1 69 9.7
Others 9 3.5 30 4.2
Country of birth .69
Singapore 178 69.8 497 69.8
Malaysia 38 14.7 117 16.4
China 30 11.6 74 10.4
Other 12 4.7 24 3.4
Education .01
Nil 81 31.4 266 37.4
6 yr or less 121 47.5 233 32.7
7 yr or more 58 22.8 213 29.9
Current housing .01
1–3 room public flat 76 29.8 234 33.1
4 room or larger public flat 121 47.5 373 52.8
Private apt or house 58 22.8 99 14.0
Marital status .42
Currently or previously married 241 93.4 654 91.9
Never married 17 6.6 58 8.2
Ever worked outside the home .87
Yes 210 81.4 582 81.9
No 48 18.6 129 18.1
Environmental tobacco smoke exposure at home .43
Less than daily 122 48.8 321 45.9
Every day 128 51.2 378 54.1
Family history of cancerb <.001
No 165 65.2 537 76.4
Yes, other cancers 60 23.7 131 18.6
Yes, lung cancer 28 11.1 35 5.0
Exposure to cooking fumesc 0.093
Cooked <1/mo 59 23.2 147 20.9
Cooked at least 1/mo; kitchen
filled with fumes <1/wk
156 61.4 405 57.5
Cooked at least 1/mo; kitchen
filled with fumes 1/wk or
more
39 15.4 153 21.7
aCalculated as usual body weight (in kilograms) divided by the square of the height (in meters).
bFirst-degree relative with history of cancer of any site.
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TABLE 2
Fruit, vegetable, and meat consumption and risk of lung cancer in Chinese women, Singapore 2005–2008
Cases Controls Odds Ratios
Servings/wk (n = 258) (n = 712) (95% Confidence Intervals)a
Fruitsb
1st tertile (<3.88) 97 (37.6) 226 (31.7) 1.0
2nd tertile (>3.87–11.02) 108 (41.9) 246 (34.6) 0.86 (0.60, 1.22)
3rd tertile (>11.02) 53 (20.5) 240 (33.7) 0.39 (0.26, 0.60)
Ptrend <.001
Vegetablesc
1st tertile (<11.88) 103 (39.9) 233 (32.7) 1.0
2nd tertile (>11.87–24.00) 88 (34.1) 236 (33.2) 0.81 (0.56, 1.16)
3rd tertile (>24.00) 67 (26.0) 243 (34.1) 0.57 (0.39, 0.83)
Ptrend .003
Cruciferous vegetablesd
1st tertile (<5.61) 83 (32.2) 232 (32.6) 1.0
2nd tertile (>5.60–12.00) 110 (42.6) 241 (33.9) 1.25 (0.88, 1.79)
3rd tertile (>12.00) 65 (25.2) 239 (33.6) 0.66 (0.44, 0.98)
Ptrend .046
Total meatsd
1st tertile (<9.70) 103 (40.1) 232 (32.9) 1.0
2nd tertile (9.70–19.60) 93 (36.2) 238 (33.7) 0.88 (0.61, 1.26)
3rd tertile (>19.60) 61 (23.7) 236 (33.4) 0.59 (0.39, 0.89)
Ptrend .012
Fish
1st tertile (<2.51) 112 (43.4) 231 (32.4) 1.0
2nd tertile (>2.50–10.00) 100 (38.8) 265 (37.2) 0.81 (0.57, 1.14)
3rd tertile (>10.00) 46 (17.8) 216 (30.3) 0.47 (0.31, 0.73)
Ptrend .001
Chicken
1st tertile (<1.01) 125 (48.5) 358 (50.3) 1.0
2nd tertile (>1.00–2.50) 49 (19.0) 132 (18.5) 1.08 (0.72, 1.63)
3rd tertile (>2.50) 84 (32.6) 222 (31.2) 1.00 (0.69, 1.45)
Ptrend .95
Pork
1st tertile (<1.01) 106 (41.1) 323 (45.5) 1.0
2nd tertile (>1.00–2.50) 68 (26.4) 176 (24.8) 1.09 (0.75, 1.60)
3rd tertile (>2.50) 84 (32.6) 211 (29.7) 1.15 (0.80, 1.64)
Ptrend .44
aAdjusted for age, history of cancer in first-degree relative, country of origin, dwelling type, yr of education, usual body mass index, and
fruit and vegetable intake (only for meat variables).
bSummed weekly consumption of banana; papaya; apple; orange or mandarin orange; pineapple; watermelon; mango; starfruit; jackfruit;
plum; cantaloupe/rock melon; dried prunes; fresh fruit juice; canned peaches; pear; Chinese pear; and grapes.
cSummed weekly consumption of wong-nga-pak; pak choy (Chinese cabbage); kai lan (Chinese kale); head cabbage; cauliflower; kai choy;
choy sum; sai yong choy (watercress); broccoli; kang kong (water convolvulus); por choy (spinach); sang choy (Chinese lettuce); tomatoes;
French beans; long beans; snow peas; ladies’ fingers (okra); red carrot; and sweet potato.
dSummed intakes of fish, chicken, pork, duck, prawns and squid, and beef.
We did not find a relationship with lung cancer of total HCA
or any of the 3 common HCAs. This is not unexpected, as
red meat consumption is relatively low in our population, and
the Chinese cooking methods employed by our population do
not generate significant quantities of HCAs as a by-product of
cooking (26). Indeed, the consumption levels of the 3 HCAs
studied in our population was about 6–8 times lower than that
reported in the Missouri study (23).
Studies that have differentiated white from red meat have
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FIG. 1. Odds ratios and the 95% confidence intervals of the association of fish consumption with lung cancer among Chinese female never smokers, by quintile
of consumption, adjusted for age, history of cancer in first-degree relative, country of origin, dwelling type, yr of education, usual body mass index, fruit intake,
and vegetable intake.
cancer (12,13). This may be because white meat in gen-
eral does not produce significant quantities of HCAs when
cooked.
In contrast to most other studies that have reported either a
direct or no association between meat consumption and lung
cancer, our study suggests an inverse association. This associ-
ation is completely driven by fish consumption, because fish is
the main source of meat in this population and the only type of
meat to have a significant inverse association with lung cancer
risk. The reasons for this are not clear. A substitution effect of
red meat by white meat (i.e., fish) intake is possible, although no
increased risks were seen with either pork or beef consumption.
Confounding by socio-economic status (SES) is unlikely, since
the relationship was significant in multivariate analyses, after
adjustment for SES using proxies of dwelling type and years
of education. An inverse association of BMI with lung cancer
risk, particularly in current smokers, has been proposed (33),
and it is possible that meat consumption is confounded by BMI
in our study. However, we adjusted for BMI based on usual
body weight before the development of illness in our analyses,
and residual confounding is unlikely to explain these findings.
Perhaps meat consumption may simply reflect better overall
nutritional status, with adequate intakes of trace minerals and
vitamins conferring protection.
Of the various meat types, the most striking relationship ob-
served in our study was the inverse association of fish intake
with lung cancer. The nature of the relationship between fish in-
take and lung cancer risk has not been clearly elucidated despite
many studies looking at diet in lung cancer. Some case–control
studies, especially those conducted in population with rela-
tively low rates of fish consumption, have reported that fish
consumption is positively associated with lung cancer
(16,34,35). Other case–control studies, however, report inverse
effects (12,36,37). In general, all these studies had a high pro-
portion of smokers among cases and did not look at effects sep-
arately in smokers and nonsmokers. Three case–control studies
that did look specifically at never smokers did not find an effect
of fish consumption (14,15,38). An ecological study concluded
that high fish consumption at the country level is associated
with a reduction in lung cancer mortality in men, but only in
countries with high levels of cigarette smoking or animal fat
consumption (39). A Japanese cohort study (40) reported an
inverse effect of fish intake on incidence of lung cancer, but no
association of fish consumption with lung cancer incidence was
found in two cohorts (11,41) in Norway, nor with lung cancer
mortality in one other cohort in Japan (42). Our data suggest that
an inverse association is seen in never smokers and at intakes
of more than 1 serving a day (Fig. 1), and we speculate that
the inconsistent findings between studies could be due to the
high proportion of smokers among cases in these studies and
to differences in the range of consumption of fish in the base
populations. [For example, the Galician study (16) that showed
a positive relationship compared <1 time per wk to >1 time
per wk, while the Japanese case–control study (36) showing an
inverse relationship compared <1 time per wk with 5 or more
times per wk in the highest consumption quartile.]
A protective effect of fish intake is biologically plausible.
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TABLE 3
Consumption of processed meats and risk of lung cancer in never-smoking Chinese women
Cases Controls Odds Ratios
Servings/wk (n = 258) (n = 712) (95% Confidence Intervals)a
Processed meatsb
1st tertile (<0.30) 73 (28.6) 192 (27.2) 1.0
2nd tertile (0.30–<0.70) 100 (39.2) 263 (37.3) 1.04 (0.71, 1.51)
3rd tertile (>0.69) 82 (32.2) 251 (35.6) 0.83 (0.55, 1.25)
Ptrend .37
Baconc
1st tertile (0) 173 (67.6) 548 (77.1) 1.0
2nd tertile (>0) 83 (32.4) 163 (22.9) 1.51 (1.06, 2.16)
Hamd
1st tertile (0) 148 (59.6) 424 (59.6) 1.0
2nd tertile (>0–0.10) 67 (26.0) 156 (21.9) 1.12 (0.77, 1.62)
3rd tertile (>0.10) 43 (16.7) 132 (18.5) 0.81 (0.52, 1.26)
Ptrend .52
Luncheon Meate
1st tertile (<5.61) 101 (39.3) 306 (43.2) 1.0
2nd tertile (>5.60–12.00) 84 (32.7) 182 (25.7) 1.53 (1.06, 2.22)
3rd tertile (>12.00) 72 (28.0) 221 (31.2) 1.20 (0.82, 1.74)
Ptrend .25
Sausages f
1st tertile (<9.70) 147 (57.0) 436 (61.3) 1.0
2nd tertile (9.70–19.60) 34 (13.2) 77 (10.8) 1.20 (0.74, 1.93)
3rd tertile (>19.60) 77 (29.8) 198 (27.9) 1.00 (0.69, 1.43)
Ptrend .93
Chinese sausages/waxed meatg
1st tertile (<2.51) 113 (43.8) 355 (49.9) 1.0
2nd tertile (>2.50–10.00) 58 (22.5) 123 (17.3) 1.54 (1.03, 2.31)
3rd tertile (>10.00) 87 (33.7) 233 (32.8) 1.23 (0.87, 1.74)
Ptrend .19
aAdjusted for age, history of cancer in first-degree relative, country of origin, dwelling type, yr of education, usual body mass index, and
fruit and vegetable intake.
bSum of serving portions consumed per wk of the following 5 processed meat types: ham, bacon, luncheon meat, sausages, and Chinese
sausages.
c1 serving defined as 1 slice of bacon.
d1 serving defined as 1 slice of ham.
e1 serving defined as 1 slice of luncheon meat.
f1 serving defined as 0.5 sausages.
g1 serving defined as 2–3 slices of Chinese sausages or waxed meat.
eicosapentaenoic acid (EPA) and docosahexoic acid (DHA),
both prominent constituents of fish oil, have antiinflammatory,
proapoptotic, and anticarcinogenic effects through their inter-
actions with Peroxisome Proliferator-Activated Receptor-γ ,
nuclear factor kappa B, cyclooxygenase-2, and integrin-linked
kinase (43–47). Some, but not all, epidemiologic studies
investigating lung cancer risk with fish oil consumption
support this (11,48). Singapore imports almost all fish for retail
consumption, of which 96–98% is consumed fresh (rather than
as processed fish) (26), and relatively fatty fish such as mackerel
and salmon represent a substantial proportion of fish consumed
in Singapore (Agri-Food and Veterinary Authority of Singapore,
unpublished data). The authors of a recent study of omega-3
content of local fish (49) estimated that consumption of about
50–60 g of local fish (equivalent to about 2 serving sizes in
this study) would provide about 350 mg of DHA/EPA per day.
It is also possible that the protective effect of fish is mediated
through other vitamin or mineral constituents of fish. Lastly, the
inverse association seen may be due to substitution of fish for red
meat.
A key strength of our study is the homogeneity of the study
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TABLE 4
Dietary heterocyclic amines (HCA) and risk of lung cancer in never-smoking Chinese women
Cases Controls Odds Ratios
Nanograms/wk (n = 258) (n = 712) (95% Confidence Intervals)a
Total HCA
1st tertile (<92.32) 83 (32.4) 237 (33.6) 1.0
2nd tertile (>92.32–275.90) 98 (38.3) 238 (33.7) 1.31 (0.91–1.89)
3rd tertile (>275.90) 75 (28.3) 231 (32.7) 0.98 (0.66–1.45)
Ptrend 0.96
PhIP
1st tertile (<55.70) 83 (32.4) 239 (33.9) 1.0
2nd tertile (>55.70–160.47) 97 (37.9) 233 (33.0) 1.28 (0.89–1.85)
3rd tertile (>160.47) 76 (29.7) 234 (33.1) 0.98 (0.66–1.46)
Ptrend 0.98
MelQx
1st tertile (<19.80) 90 (35.2) 238 (33.7) 1.0
2nd tertile (>19.79–62.90) 98 (38.3) 241 (34.1) 1.16 (0.81–1.66)
3rd tertile (>62.90) 68 (26.6) 228 (32.3) 0.81 (0.55–1.20)
Ptrend 0.34
4,8-DiMelQx
1st tertile (<11.22) 92 (35.9) 238 (33.7) 1.0
2nd tertile (>11.22–34.85) 100 (39.1) 241 (34.1) 1.20 (0.84–1.71)
3rd tertile (>34.85) 64 (25.0) 228 (32.3) 0.76 (0.51–1.13)
Ptrend 0.22
aAdjusted for age, history of cancer in first-degree relative, country of origin, dwelling type, yr of education, usual body mass index, and
fruit and vegetable intake.
number of nonsmokers in our study population. These fea-
tures allow us to elucidate weaker associations in this important
subgroup, which may be overshadowed by smoking-related ef-
fects in other populations. At the same time, we are mindful of
limitations of these data that are inherent to the retrospective na-
ture of the study. We used a semiquantitative FFQ, and reporting
errors associated with FFQs are well known. Such errors associ-
ated with the dietary instrument would likely be nondifferential
and would bias estimates toward the null. Other types of report-
ing errors are also possible. We cannot exclude the possibility
that dietary effects observed might have been due to dietary
changes as a consequence of symptoms or disease. Because we
used hospital controls, our control population’s dietary intake
may differ substantially from the general population because
of their disease status. However, we used controls who were
admitted to a wide variety of hospital departments and with dif-
ferent admitting diagnoses. In addition, excluding participants
who reported that they had changed their diet recently due to
illness or other factors (about 25% of controls and 31% of cases
reported that they had done so) did not alter the relationship seen
between meat and fish consumption and lung cancer risk in this
population (data not shown). Our questionnaire did not allow
us to control for total calorie intake; however, we adjusted for
usual BMI in our analyses. Moreover, if the main findings were
due to reduced overall consumption amongst cases compared
to controls, we would have expected to see inverse associations
across all food items.
In summary, within the range of consumption prevalent in this
Asian population, our findings support a protective role for white
meat intake and, specifically, fish intake in the development of
lung cancer in never smokers.
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